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Summary 
Triple negative breast cancer (TNBC) is an aggressive subtype of breast cancer that accounts 
for 15-20% of breast cancer incidences. Since it lacks estrogen receptor, progesterone 
receptor and HER2 overexpression, therapy options are limited to surgery, radiation and 
chemotherapy, which are curative only to a small fraction of TNBC patients. Accordingly, TNBC 
has the highest rates of metastatic disease and the poorest overall survival of all breast cancer 
subtypes. Recently, the sialoglycolipid stage-specific embryonic antigen 4 (SSEA-4) has been 
identified as an epitope whose overexpression in TNBC strongly correlates with metastasis 
and chemoresistance. As TNBC patients are typically exposed to multiple rounds of 
chemotherapy and SSEA-4-positive cells have been found to be enriched in residual tumors 
surviving this treatment, a sequential therapeutic approach using chemotherapy followed by 
SSEA-4-directed chimeric antigen receptor (CAR) T cell administration holds great promise to 
improve the therapeutic outcome of TNBC patients. Consequently, the aim of this study was 
to develop and evaluate an SSEA-4-directed CAR T cell-based treatment modality for TNBCs. 
In order to explore the optimal CAR configuration, five second generation chimeric receptors 
that differed in type and length of the spacer region were generated. All receptors contained a 
human/mouse cross-reactive single chain variable fragment which allowed a preclinical on 
target/off tumor toxicity profiling due to the correlated antigen expression between the mouse 
and the human organism. The three lead candidates, that showed good surface expression, 
activated T cells in an antigen-specific manner as characterized by T cell degranulation, 
secretion of inflammatory cytokines and effective killing of SSEA-4-expressing target cells in 
vitro. The efficacy of T cell activation was not uniform between the constructs and no direct 
correlation between CAR potency and CAR spacer length was observed. When the SSEA-4-
directed CAR T cells were adoptively transferred into mice with subcutaneous TNBC cell line 
xenografts (MDA-MB-231), only the CAR variant that showed the strongest in vitro bioactivity 
could control tumor growth. No anti-tumor effect was detectable in mice cohorts receiving the 
other CAR T cell variants. In parallel to the tumor burden control, mice receiving T cells 
incorporating the most potent CAR variant exhibited toxicity symptoms and cachexia. It was 
found that the administered CAR T cells proliferated primarily in the lungs and in bone marrow 
with the latter demonstrating hypocellularity and a strong decrease of the CD45+Sca-1bright 
population upon therapy. In bone marrow, hematopoietic multipotent progenitor cells were 
identified to express SSEA-4 which were likely co-targeted by the CAR T cells. In the lungs, 
the SSEA-4-positive subset was found to co-express CD44, CD81, CD98, and Prominin-1 
suggesting an epithelial pluripotent population. The severe side-effects observed in this study 
raise safety concerns for therapies targeting SSEA-4-positive tumor cells, as a high risk exists 
to collaterally damage vital pluripotent cells within the organism. Therefore, great care has to 
be invested in SSEA-4-directed immunotherapies to avoid life threatening side effects.  
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Zusammenfassung 
Das dreifach negative Mammakarzinom (engl. triple negative breast cancer, TNBC) ist ein 
aggressiver Brustkrebssubtyp, der in 15-20% der Brustkrebsfälle vorkommt. Da es weder eine 
Expression von Östrogen- oder Progesteronrezeptoren noch eine Überexpression von HER2 
aufweist, beschränken sich die therapeutische Maßnahmen auf Operation, Bestrahlung und 
Chemotherapie. Diese sind allerdings nur für einen kleinen Teil der TNBC Patienten kurativ, 
weshalb bei ihnen – im Vergleich zu anderen Brustkrebsformen – die höchste Metasta-
sierungsrate und die niedrigste Überlebenserwartung auftreten. Vor kurzem wurde das 
Sialoglykolipid Stadienspezifische embryonale Antigen-4 (SSEA-4) als Epitop identifiziert, 
dessen Überexpression stark mit den metastasierenden und chemoresistenten Eigenschaften 
im TNBC korreliert. Da Krebspatienten mehrere Chemotherapiezyklen durchlaufen und  
SSEA-4-positive Zellen in Tumoren angereichert werden, die diese Behandlung überstehen, 
verspricht ein sequentieller Therapieansatz aus Chemotherapie und einer darauffolgenden 
SSEA-4-gerichteten chimären Antigenrezeptor (CAR) T-Zelltherapie, das Behandlungs-
ergebnis zu verbessern und die Gesamtüberlebensdauer der Krebspatienten zu erhöhen. 
Demnach war das Ziel dieser Studie die Entwicklung und Evaluation einer SSEA-4-gerichteten 
Behandlungsmethode für TNBC, die auf einer CAR T-Zelltherapie basiert.  
Zur Untersuchung der optimalen CAR-Konfiguration wurden 5 Rezeptoren der zweiten 
Generation entwickelt, die sich in Typ und Länge der Distanzregion zwischen der 
antigenbindenden Domäne und der Transmembranregion unterschieden. Da die Antigen-
expression zwischen Maus und Mensch korreliert, wurde zur Antigenerkennung ein 
Einzelkettenfragment der variablen Region eines SSEA-4-spezifischen Antikörpers eingebaut, 
das kreuzreaktiv zum humanen und murinen Epitop ist und somit eine on target/off tumor 
Toxizitätsanalyse bei einem Mausmodel erlaubte. Die drei Kandidaten, welche die beste 
Oberflächenexpression zeigten, aktivierten T-Zellen auf eine antigenspezifische Weise, was 
sich in Form von Degranulation von T-Zellen, Sekretion von inflammatorischen Zytokinen und 
Abtötung von SSEA-4-positiven Zielzellen zeigte. Die Effizienz der T-Zellaktivierung war bei 
den Konstrukten nicht einheitlich und es ließ sich keine direkte Korrelation zwischen der CAR-
Wirksamkeit und der Distanzdomänenlänge der Rezeptoren beobachten.  
Nach adoptivem Transfer von SSEA-4-spezifischen CAR T-Zellen in Mäuse mit subkutanen 
Tumoren einer TNBC-Zelllinie (MDA-MB-231) konnte nur dasjenige CAR-Konstrukt das 
Tumorwachstum kontrollieren, welches zuvor die stärkste in vitro-Bioaktivität gezeigt hatte. Bei 
den Mauskohorten, die die anderen CAR T-Zellgruppen erhielten, trat kein Antitumoreffekt auf. 
Neben der Tumorkontrolle konnten bei den Mäusen auch Toxizitätssymptome und 
Kräfteverfall beobachtet werden. Die verabreichten CAR T-Zellen proliferierten vorrangig in 
Lunge und Knochenmark, wobei bei letzterem Hypozellularität sowie eine starke Abnahme der 
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CD45+Sca-1hell Population infolge der Therapie auftraten. Es stellte sich heraus, dass 
hämatopoetische multipotente Vorläuferzellen eine SSEA-4-Expression aufweisen, weshalb 
diese mit hoher Wahrscheinlichkeit von den CAR T-Zellen ebenfalls angegriffen werden. In 
der Lunge zeigte die antigenpositive Subpopulation eine Koexpression von CD44, CD81, 
CD98 und Prominin-1, was darauf hindeutet, dass es sich um epitheliale pluripotente Zellen 
handelte. Die gravierenden Nebeneffekte, die in dieser Studie beobachtet wurden, geben 
Anlass zu Sicherheitsbedenken für Therapien, die auf die Zerrstörung SSEA-4-positiver 
Tumorzellen abzielen, da hohes Risiko besteht, hierbei auch essenzielle pluripotente 
Stammzellen innerhalb des Organismus zu zerstören. Aufgrund dieser lebensbedrohlichen 
Kollateralschäden ist bei SSEA-4-bezogenen immuntherapeutischen Ansätzen große Vorsicht 
geboten.  
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1 Introduction 
1.1 Breast cancer  
Breast cancer represents the most common neoplasm in women worldwide and is the number 
one cause of cancer death in females (Anderson et al., 2006; Bray et al., 2004). Each year, 
more than 1.6 million new cases are diagnosed of which less than 1% affect men (Ferlay et 
al., 2015; Ghoncheh et al., 2016; Korde et al., 2010). Interestingly, while the incidence of breast 
cancer is on the rise, the mortality rates have dramatically declined since the 1980s. This 
decrease is attributed to technological advancements in screeninsg and increased use of 
targeted therapy directed against dysregulated hormone or growth factor receptor signaling 
(Berry et al., 2005). Nevertheless, breast cancer still imposes a considerable health and 
economic burden making it a major public health concern. There are more than twice as many 
new breast cancer cases diagnosed each year than new incidences of cancer at any other site 
(Stewart and Wild, 2014). Its etiology has been described to be multifactorial, although 
increased levels of estrogen are attributed to play a key role in the development of breast 
tumors. On the basis of epidemiological studies it was found that women with early menarche 
and late menopause exhibit an increased risk due to longer exposure to endogenous estrogen. 
In addition, late age of first pregnancy further augments the possibility for developing mammary 
tumors (Clemons and Goss, 2001).   
In terms of genetic factors, germline mutations in the two tumor suppressor genes breast 
cancer gene 1 (BRCA1) and/or breast cancer gene 2 (BRCA2) were shown to contribute up to 
80% increased lifetime risks of developing breast cancer until the age of 70. Alterations in 
these genes are associated with 15-20% of familial breast cancers and comprise 2-3% of all 
breast cancer incidences (Venkitaraman, 2002). Accordingly, somatic mutations are still 
perceived as the most common causes driving breast carcinogenesis (Nik-Zainal et al., 2016). 
The most prevalent somatic alterations were described to occur in tumor protein 53 (TP53), 
retinoblastoma 1 (RB1), GATA binding protein 3 (GATA3), phosphatase and tensin homolog 
(PTEN), phosphatidylinositol-4,5-bisphosphate 3-kinase subunit α (PI3CA), cyclin D1 (CCND1), 
fibroblast growth factor receptor 1 (FGFR1), mitogen-activated protein kinase kinase kinase 1 
(MAP3K1), and Erb-b2 receptor tyrosine kinase 2 (ERBB2) (Nik-Zainal et al., 2016). 
Around 522,000 women succumb to the disease per year (Ferlay et al., 2015). In this context, 
metastasis is a very important clinical challenge as it attributes to 90% of all breast cancer 
related deaths (Chaffer and Weinberg, 2011; Cummings et al., 2014). Although the majority of 
patients is diagnosed with localized disease, around 30-50% receiving therapy for early stage 
disease will develop metastatic lesions (Cardoso et al., 2012; Henderson, 2013). Solutions to 
improve metastatic disease prevention are therefore urgently needed and an active area of 
current research. 
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1.1.1 Breast cancer subtypes 
Breast cancer is a heterogeneous 
disease with different pathological 
features and different therapeutic 
response patterns. In clinical practice, 
it is therefore routinely categorized 
into 4 subtypes based on the 
immuno-histochemical staining levels 
for the expression of estrogen 
receptor (ER), progesterone receptor 
(PR), human epidermal growth factor 
receptor 2 (HER2) and the 
proliferation marker Ki67 (Figure 1). 
Classification into subtypes helps to stratify patients into groups with divergent prognosis and 
optimize therapeutic treatment (Hennigs et al., 2016; Perou et al., 2000). 
 
1.1.1.1 Luminal A breast cancer 
Luminal A is the most common subtype of breast cancers which accounts for 43-59% of all 
tumors diagnosed. These cancers are characterized by high expression of ER and/or PR but 
a lack of HER2 amplification (HER2-negative). They are relatively slow growing as seen by 
low levels of Ki67 expression, less likely to spread and respond well to anti-hormonal therapy. 
Therefore, patients with luminal A tumors have the most favorable prognosis with high survival 
and low recurrence rates (Peppercorn et al., 2008; Voduc et al., 2010).  
 
1.1.1.2 Luminal B breast cancer 
Luminal B type of breast cancer encompasses 6-19% of the total cases and is defined by a 
weaker expression of ER and/or PR compared to luminal A breast cancer and an over-
expression or amplification of the HER2 gene product (HER2-positive). Based on increased 
expression of Ki67, these tumors display a higher cell proliferation rate than luminal A cancers 
and have a slightly worse prognosis (Parise and Caggiano, 2014). Besides chemotherapy, 
first-line treatment options are anti-hormonal and HER2-directed therapies (Ades et al., 2014). 
 
1.1.1.3 HER2-enriched breast cancer 
The HER2-enriched subtype is characterized by absent expression of both hormonal receptors, 
but an amplified expression of the HER2 oncogene. It has a prevalence of about 7-12% and is 
Figure 1: Clinical classification of breast cancers based on 
receptor expression. Pie slice sizes represent fractions of breast 
cancer incidences. ER, estrogen receptor; PR, progesterone 
receptor; HER2, human epidermal growth factor receptor 2; TNBC, 
triple negative breast cancer. Figure modified from Kumar et al. 
(2012).  
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susceptible to early and frequent recurrence and metastasis (Blows et al., 2010). The use of 
targeted therapies directed against the HER2 gene product, however, has reversed much of 
the adverse prognostic impact of HER2 overexpression (Baselga, 2010).  
 
1.1.1.4 Triple negative breast cancer 
Approximately 15-20% of breast cancer patients develop lesions that are clinically described 
as “triple negative” due to their negativity for expression of ER and/or PR and lack of 
overexpression for HER2. This subtype of breast cancers differs from others in its predilection 
to primarily affect women below the age of 40 (Bauer et al., 2007) and a disproportionate 
number of metastatic cases and cancer deaths (Dent et al., 2007; Pal et al., 2011). Patients 
with triple negative breast cancer (TNBC) display a distinct pattern of metastasis with higher 
rates of distant recurrence to brain and lungs, but less likely to bones (Dent et al., 2007; Liedtke 
et al., 2008). The 5-year survival rate of TNBC patients (77%) is significantly lower compared 
to non-TNBC patients (93%) (Bauer et al., 2007).  
 
 
1.1.2  Treatment options for TNBC: current status and future trends 
TNBC is one of the most 
complicated types of breast cancer 
to treat. Compared to other breast 
cancers, triple negative tumors are 
more aggressive and display an 
increased likelihood of local and 
distant metastasis (Dent et al., 
2009; Fulford et al., 2007). Initially, 
TNBC patients respond well to 
standard care chemotherapy with 
anthracyclines, taxanes, and/or 
platinum compounds, however, only 
30-45% achieve a pathological complete response and survival rates similar to other breast 
cancer subtypes (Balko et al., 2014; Liedtke et al., 2008; Masuda et al., 2011). When residual 
disease remains, the prognosis is worse than for patients without pathological complete 
response from other subtypes of breast cancer (Liedtke et al., 2008) (Figure 2). This is largely 
due to the fact that no oncogenic alterations are known that could be therapeutically targeted 
across a significant fraction of triple negative tumors. Inhibition of epidermal growth factor 
Figure 2: Overall survival by tumor type and response status. 
TNBC, triple negative breast cancer; pCR, pathological complete 
response; RD, residual disease. Figure adapted from Liedtke et al. 
(2008). 
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receptor (EGFR), the only target that was found so far to be expressed in ~70% of TNBC, 
failed in a cetuximab-based targeting approach in clinical trials (ClinicalTrials.gov identifier: 
NCT00232505) (Carey et al., 2012). It was later discovered that EGFR inhibition rewires the 
cell to activate AKT and ERBB3 signaling pathways, which ultimately mediate resistance 
(Sergina et al., 2007). 
Taking into consideration that novel therapies for this type of breast cancer are essential and 
urgent, large scale genomic and proteomic analyses have identified at least four molecularly 
distinct subtypes of TNBC (Balko et al., 2014; Burstein et al., 2015; Cabezón et al., 2013; 
Lawrence et al., 2015; Lehmann et al., 2011). These findings in turn have enabled the 
identification of possible targets specific for each subtype. Currently, several therapies have 
entered clinical trials for the treatment of TNBC, including  
- poly-ADP ribose polymerase (PARP) inhibitors (e.g. olaparib (NCT026815562, 
NCT03205761), veliparib (NCT02849496), talazoparib (NCT02401347), and rucaparib 
(NCT01074970)), anti-androgen receptor agents (e.g. bicalutamide (NCT03055312, 
NCT03090165), CR1447 (NCT02067741), darolutamide (NCT03383679), 
enzalutamide (NCT01889238, NCT02457910, NCT02689427, NCT02750358), 
enobosarm (NCT02971761), seviteronel (NCT02580448), and ortelonel 
(NCT01990209)),  
- histone deacetylase (HDAC) inhibitors (e.g. entinostat (NCT01349959, NCT02708680, 
NCT03361800), panobinostat (NCT01105312, NCT01194908, NCT02890069), 
romidepsin (NCT02393794), and tinostamustine (NCT03345485)),  
- serine-threonine kinase mammalian target of rapamycin (mTOR) inhibitors (e.g. 
AZD2014 (NCT02583542, NCT02208375), PQR309 (NCT02723877), everolimus 
(NCT00499603), and PF-05212384 (NCT01920061)),  
- angiogenesis inhibitors (e.g. sunitinib (NCT00887575, NCT00246571), sorafenib 
(NCT02624700), and bevacizumab (NCT00528567, NCT00472693, NCT01201265 
and others)), as well as  
- drug combinations that target several signaling pathways (Pal and Mortimer, 2009).  
While most studies are still ongoing, initial results remain modest thus highlighting the 
challenges of intra- and intertumoral heterogeneity and the danger of therapy resistance 
development (Kalimutho et al., 2015).  
In recent years, studies of immune infiltration in breast tumors have shown that aggressive 
breast cancers such as HER2-enriched breast cancer and TNBC have the greatest incidence 
of patients with a robust immune infiltrate. Elevated levels of either intratumoral or stromal 
T cells were associated with improved disease-free and overall survival as well as pathologic 
complete response in the neoadjuvant setting (Adams et al., 2014; Ibrahim et al., 2014; Loi et 
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al., 2013, 2014). Interestingly, TNBC was more likely to have lymphocyte infiltration greater 
than 50% of the total tumor mass indicating that this subtype is more immunogenic than other 
breast cancers. These findings advocated the potential use of therapeutic immunomodulation 
and clinical trials have now been attempting to assess immune checkpoint inhibition as a new 
treatment modality for TNBC. Several options are currently being investigated, specifically  
- cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) inhibition by ipilimumab 
(NCT03326258) or tremelimumab (e.g. NCT02527434) as well as  
- the blockade of the programmed cell death 1 (PD-1)/PD-1 ligand 1 (PD-L1) axis by 
atezolizumab (e.g. NCT02425891), avelumab (e.g. NCT02926196), durvalumab (e.g. 
NCT02489448), nivolumab (NCT02393794), pembrolizumab (e.g. NCT02447003), 
and PDR001 (NCT02404441).  
Preliminary results indicate a tolerable safety profile of this treatment modality and a response-
rate of 10-19% (Bianchini et al., 2016; Kwa and Adams, 2018).  
In parallel to these activities, a phase I clinical trial study is evaluating antibody targeting of 
CD73 as an alternative treatment option to TNBC (NCT03454451). CD73 is a membrane-
associated enzyme that converts adenosine monophosphate (AMP) into adenosine with the 
latter being an immuno-suppressive metabolite that protects tissues against excessive 
inflammation (Eltzschig, 2013). In the tumor microenvironment, adenosine suppresses 
antitumor immunity essentially through A2a (Sitkovsky et al., 2014) and A2b (Mittal et al., 2016) 
adenosine receptors. Overexpression of CD73 was shown mainly in metastatic TNBC and is 
linked to worse prognosis and resistance to chemotherapy (Loi et al., 2013).  
Additional immune targets such as the cancer/testis antigens melanoma associated antigens 
(MAGE-A) A3 and A4 as well as New York esophageal squamous cell carcinoma 1 (NY-ESO-
1) are currently being evaluated in preclinical studies as their expression was shown in a 
substantial proportion of TNBC cells (Badovinac Črnjević et al., 2012; Curigliano et al., 2011; 
Turner et al., 2010). Other attractive immunotherapeutic targets in preclinical evaluation for 
TNBC treatment are the glycosylated form of mucin 1 (MUC-1) and mesothelin. Consequently, 
while still work in progress, the future therapeutic approaches to TNBC are expected to 
implement immune modulatory strategies to achieve successful treatment results.  
 
 
1.1.3 Expression of SSEA-4 by a chemoresistant subpopulation in TNBC 
First-line treatment of TNBC is predominantly a combination chemotherapy with several 
genotoxic drugs (Davis et al., 2014). TNBC patients who present residual disease after such a 
treatment have in general very poor outcome and alternative treatment options with a favorable 
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efficacy and safety profile are 
urgently needed. In an attempt to 
identify novel targetable biomarkers 
of chemoresistant cells in TNBC, 
Aloia et al. performed a flow 
cytometry-based cell surface marker 
screening with patient-derived TNBC 
tumor xenografts treated in mice with 
standard care chemotherapy of 
doxorubicin and cyclophosphamide. 
The authors found that upon 
chemotherapy treatment, a 
subpopulation of tumor cells 
becomes enriched with an 
overexpression of a 
glycosphingolipid, commonly known 
as stage-specific embryonic antigen-
4 (SSEA-4) (Aloia et al., 2015) 
(Figure 3A). The molecule is part of the globoseries family and is composed of a hexameric 
carbohydrate structure that is linked to a ceramide moiety (Figure 3B). Currently, it is widely 
used as a marker to identify pluripotent embryonic and mesenchymal stem cells that rapidly 
disappears upon cell differentiation (Breimer et al., 2017; Gang et al., 2007; Pittenger, 1999; 
Riekstina et al., 2009; Shinohara et al., 2015). In their work, Aloia et al. identified a fraction of 
~10-30% of SSEA-4-positive cells in TNBC tumors, whose frequency increased by 2-3-fold 
upon genotoxic treatment. More important, the overall number of SSEA-4-positive cells was 
not augmented upon therapy, rather these cells showed more resistance to drug toxicity. 
Besides doxorubicin and cyclophosphamide, these observations were also made with other 
commonly used chemo-therapeutic drugs such as cicplatine, mafosfamide, and 5-flurouracil. 
Interestingly, when the tumors were allowed to regrow after chemotherapy, some tumor 
xenografts retained a high frequency of SSEA-4-positive cells, while in other tumors this 
subpopulation returned to pretreatment levels indicating that these cells do not have a general 
growth advantage. Gene expression analysis and functional assays linked antigen positivity to 
a mesenchymal phenotype of the cancerous cells, a state which is broadly accepted to be 
associated with increased resistance to a variety of cell death-inducing signals and strong 
metastatic potential (Creighton et al., 2009; O’Reilly et al., 2015; Thiery, 2002). The 
mesenchymal characteristics along with an increased migratory potential of SSEA-4-positive 
tumor cells were further confirmed by an independent study of Sivasubramaniyan et al. 
Figure 3: Expression of SSEA-4 in TNBC. (A) Immunohisto-
chemical analysis of SSEA-4 expression in untreated and 
chemotherapy-treated TNBC tumor (red, SSEA4; blue, 4 ′ ,6-
diamidino-2-phenylindole). Figure modified from Aloia et al. (2015). 
(B) Structure of SSEA-4. Glc, glucose; Gal, galactose; GalNac, N-
acetyl-galactosamin, NeuNac, N-acetyl-neuraminic acid. 
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(Sivasubramaniyan et al., 2015). Using a different clone and an antibody of the Immunoglobulin 
(Ig) M class (instead of IgG as by Aloia et al.), the authors found SSEA-4-positive 
subpopulations in an array of solid tumor cell lines but not leukemic blasts. Upon further 
characterization, they identified SSEA-4-positive cells to be enriched for additional pluripotent 
embryonic stem cell markers such as SSEA-3, Tra-1-60, and Tra-1-81 suggesting their low 
differentiation status. Furthermore, imaging approaches revealed that the glycolipid 
predominantly accumulates in filopodia and invadopodia, cellular protrusions that are 
associated with degradation of the cellular matrix in cancer invasiveness and metastasis. 
These findings suggest a role of SSEA-4 in the metastatic cascade of neoplastic cells. 
Collectively, the data sets of two independently working groups using two different antibodies 
compliantly identified SSEA-4 as a marker for intratumoral heterogeneity and the acquisition 
of a mesenchymal state by antigen-positive cells. The high metastatic potential along with 
chemoresistant properties of cells expressing the glycolipid suggest an essential role of this 
molecule in cancer progression making it an attractive target for immunotherapeutic 
approaches in TNBC treatment. Moreover, the fact that the expression of SSEA-4 is limited in 
healthy tissue showing only restricted antigen positivity by subpopulations in placenta, testis, 
skin, and small intestine (internal data, not shown) further supports a therapeutic targeting 
strategy. 
 
 
1.2 Targeted immunotherapy of cancer with chimeric antigen 
receptor-expressing T cells 
Immunotherapeutic treatment of cancer using chimeric antigen receptor (CAR)-expressing T 
cells is a relatively new approach in adoptive cell therapy. The strategy is based on genetically 
equipping T cells with novel synthetic receptors that consist extracellularly of an antibody-type 
recognition domain and intracellularly of T cell signaling modules (Figure 4). The direct 
identification of intact antigens that is provided by the antibody-derived binding domain of the 
receptor enables T cells to bypass restrictions of the major histocompatibility complex (MHC)-
mediated antigen recognition, so that a given CAR can be used in any patient regardless of its 
MHC haplotype. Furthermore, the MHC independence endows the CAR T cells with a 
fundamental anti-tumor advantage, as some tumor cells downregulate MHC expression to 
escape the T cell receptor (TCR)-mediated immune response (Garrido et al., 1993). T cells 
that are engineered to express the CAR of interest, on the other hand, are still able to recognize 
and eradicate these escaping tumor cells. Moreover, by using CAR T cells, the range of 
potential tumor targets can be broadened to epitopes that are beyond the scope of TCR-based 
recognition, e.g. it is possible to include not only proteins but also carbohydrates 
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(Mezzanzanica et al., 1998) and glycolipids (Yvon et al., 2009) for tumor targeting. One 
limitation of the current CAR T cell strategies, however, is that they are restricted to 
extracellular antigens on the cancer cells and are unable to target the intracellular proteome. 
 
 
1.2.1 Historical overview of CAR T cell therapy development 
The development of CAR T cell therapy has been a multistep process with a series of ups and 
downs and the significant historical events are summarized in Figure 5. Originally, the concept  
of providing T cells with antibody-type specificity was described by Eshhar and colleagues at 
the Weizmann Institute of Science in Israel in 1989 (Gross et al., 1989). In an endeavor to 
overcome the MHC restriction for T cell activation, they replaced the Vα and Vβ extracellular 
domains of the TCR chains with their homologs of immunoglobulin variable light chain (VL) and 
variable heavy chain (VH) this way giving rise to two chimeric TCR chains (CαVH:CβVL or 
CαVL:CβVH) that functioned independently of their natural ligand partners (Figure 4). When 
stimulated with an antigen, the fusion proteins induced T cell effector function which provided 
evidence that stimuli through the TCR:CD3 complex can activate T cells in an MHC-
independent manner (Goverman et al., 1990; Gross et al., 1989). As the practicability of this 
approach suffered from laborious gene engineering as well as inefficient surface expression 
of the chimeras, the scientists pioneered in 1993 a one-polypeptide-chain design that 
incorporated a single-chain variable fragment (scFv) of a given antibody as the antigen 
recognition unit, an extracellular spacer and a transmembrane region as structural features, 
and a cytoplasmic CD3ζ or FcRγ domain for T cell activation (Eshhar et al., 1993). This linear 
arrangement has been termed ‘first generation’ CAR (Figure 4) and showed antigen-
dependent activation of T cell signaling events that eventually resulted in the induction of the 
cytolytic machinery and Interleukin(IL)-2 production (Eshhar et al., 1993; Eshhar, 2008). Since 
then, efforts have been made to improve the quality, strength, and duration of the signals 
delivered by the CAR through incorporation of co-stimulatory domains into the design. The first 
successful attempt in generating a dual signaling domain containing chimeric receptor was 
described by Finney et al. from Celltech Therapeutics, Ltd. in 1998. By engineering the single 
chain variable fragment (scFv) in line to the hinge, transmembrane, and intracellular domains 
of CD28 followed distally by the CD3ζ, they were able to show increased antigen-stimulated 
IL-2 production compared to first generation CAR T cells (Finney et al., 1998). This finding was 
further supported by Maher et al. in 2002 who reported that CD28 co-stimulation confers both 
enhanced IL-2 secretion and robust expansion of the gene-modified immune cells in vitro 
(Maher et al., 2002). Of note, both studies demonstrated that the orientation of the signaling 
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domains is important and positioning the CD28 co-stimulus downstream of CD3ζ abrogates 
the superior function of the CAR (Finney et al., 1998; Maher et al., 2002).  
In parallel to activities with CD28 co-stimulation, reports testing 4-1BB as a co-stimulatory 
domain in CAR design described that increased antigen-triggered IL-2 secretion was also 
observed for this alternative co-signaling moiety and – additionally – 4-1BB introduction 
equipped T cells with superior cytolytic ability when compared to first generation CAR T cells 
(Imai et al., 2004). Intriguingly, 4-1BB incorporating CAR T cells showed lower levels of IL-4 
and IL-10 production and conferred the longest leukemia-free survival in a pre-B cell acute 
lymphoblastic leukemia (pre-B-ALL) mouse model when compared side-by-side to CD28 co-
stimulated CAR T cells (Carpenito et al., 2009; Milone et al., 2009). In these years, CAR 
constructs harboring a co-stimulatory signaling domain in tandem with CD3ζ became known 
as ‘second generation’ CARs (Figure 4). 
Besides intracellular signaling units, the extracellular CAR spacer region was also subjected 
to extensive research. Initially, it was introduced into the receptor’s single-chain architecture 
as a structural element that allowed the scFv to extend beyond the dense glycocalyx of the 
T cell thus ensuring better antigen accessibility (Moritz and Groner, 1995). For this purpose, a 
variety of spacer regions was simultaneously designed which were primarily based on the 
immunoglobulin domains of the crystallizable fragments (Fc) of antibodies (Cooper et al., 2003; 
Hombach et al., 1998; Weijtens et al., 1998). This repertoire was quickly expanded by 
immunoglobulin-like domains derived from the extracellular portions of CD8α, CD28, TCRβ 
chain, or NKG2D (Barber et al., 2008; Darcy et al., 1998; Eshhar et al., 2001; Morgenroth et 
al., 2007; Niederman et al., 2002; Zhang et al., 2005; Zhang et al., 2007), but without 
comparative analyses. However, the fact, that the spacer domain can have an impact on CAR 
function had been previously shown by Patel et al. in 1999. In their work they demonstrated 
that varying the spacer region within otherwise identical CAR framework resulted in significant 
changes of receptor stability and ligand affinity leading to differences in cytokine secretion and 
killing efficacy of the modified T cells (Patel et al., 1999). Moreover, in recent years it was found 
that efficient antigen recognition by CAR-expressing T cells not only depends on the nature of 
the spacer region, but also on the epitope position of the antigen. Membrane-distal epitopes 
are well engaged by CARs with short spacer elements, whereas effective recognition of 
membrane-proximal epitopes requires receptors with a long spacer region (Guest et al., 2005; 
James et al., 2008; Krenciute et al., 2016; Haso et al., 2013; Hudecek et al., 2013) suggesting 
the biological requirements of optimal T cell:target cell distance for accurate effector cell 
activation. More recently, studies have found out that the commonly used immunoglobulin G 
(IgG) Fc spacer domains engage with Fcγ receptors (FcγR) expressed by myeloid cells 
resulting in activation which induced death of T cells and limited persistence in vivo. To block 
the undesired interactions, deletions and mutations have been engineered into the receptors’ 
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IgG Fc spacer domains leading to increased anti-tumor activity and CAR T cell persistence 
(Hombach et al., 2010; Hudecek et al., 2015; Jonnalagadda et al., 2015). 
In 2006, while second generation CARs were at the preclinical stage, two first generation CAR 
T cell therapies have gone through clinical trials – with disappointing results. Treatment of 
ovarian carcinoma with folate receptor-redirected CAR T cells led to no tumor burden reduction 
in any of the patients receiving the therapy. It was found that the administered CAR T cells 
failed to home to the tumor site and quickly declined to undetectable levels within the first 30 
days after adoptive transfer (Kershaw et al., 2006). A separate center targeted carbonic 
anhydrase IX (CAIX) for the treatment of metastatic renal cell carcinoma (RCC). The antigen 
had been shown to be highly expressed in RCC with a limited presence in healthy kidneys or 
other tissues. Moreover, the antibody from which the CAR scFv was derived was previously 
proven to be safe in RCC patients (Bleumer et al., 2004). The initial 4 to 5 CAR T cell infusions 
were well tolerated by the patients, however, afterwards grade 2-4 hepatotoxicity and a mild 
anti-scFv-directed antibody response became apparent, leading to termination of treatment in 
2 out of 3 patients. Later on, biopsies revealed low level CAIX expression in bile duct epithelial 
cells with infiltration of CAR T cells suggesting that CAIX-targeted destruction of these cells 
resulted in the hepatotoxicity (Lamers et al., 2006, 2007, 2013, 2016). This incidence was the 
first documented clinical evidence of on target/off tumor toxicity elicited by CAR T cells. In an 
attempt to circumvent the observed hepatotoxicity, the protocol was adjusted to include pre-
treatment with low dose of CAIX blocking antibody in subsequent cohorts which abrogated the 
on target/off tumor toxicity. However, with regard to tumor burden, no clinical responses were 
detected (Lamers et al., 2013).  
The lack of persistence of first generation CAR T cells observed in the clinical trials as well as 
the demonstration of improved functional efficacy of second generation CAR T cells were 
directed development efforts to integrate two co-stimulatory domains into the CAR design. In 
2007, Wang et al. described a ‘third generation’ CAR (Figure 4) with three tandem intracellular 
signaling domains, one derived from CD3ζ and the other two from CD28 and 4-1BB (Wang et 
al., 2007). Compared to first and second generation CAR T cells, T lymphocytes incorporating 
the third generation CAR demonstrated superior cytotoxicity, cytokine secretion, and 
proliferation ability in vitro. This observation was further confirmed by the June group in 2009. 
Using also CD28 and 4-1BB as co-stimuli, they demonstrated an improved activity of this CAR 
architecture among all tested constructs, but were unable to show that this enhanced potency 
translated into a statistically significant survival benefit in a mouse model when compared with 
a 4-1BB-based second generation CAR (Carpenito et al., 2009; Milone et al., 2009). Additional 
work on third generation CARs was contradictory. While Kochenderfer et al. showed that 
second generation, CD28-costimulated CAR T cells targeting CD19 produced more cytokines 
than their third generation, CD28 and 4-1BB co-stimulated counterpart (Kochenderfer et al., 
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2009), Tammana et al. demonstrated a superior functionality of umbilical cord blood cells 
containing a third generation anti-CD19 CAR incorporating signaling domains of CD28, 4-1BB, 
and CD3ζ compared with second generation CARs containing CD3ζ with CD28 or 4-1BB 
(Tammana et al., 2010). Using in vivo models, the group showed further that its third generation 
CAR T cells conferred prolonged survival in both intraperitoneal and systematic models of 
xenografted B cell tumors (Tammana et al., 2010). The discrepancies in these results may be 
attributed to experimental differences such as the choice of scFv fragments, the detailed 
architecture of the receptors, method of transgene delivery into cells, and inconsistencies in 
the materials and methods applied by the different investigators. 
 
 
As preclinical work was further focused on improving the efficacy of CAR technology, the first 
third generation CAR entered the clinical trial setting only three years after its initial description. 
One female patient with metastatic colon cancer was treated with a HER2-directed CAR 
incorporating CD28, 4-1BB, and CD3ζ as signaling moieties. The antigen-binding domain was 
derived from the therapeutically approved monoclonal antibody trastuzumab, which had 
previously shown a favorable safety profile in HER2-positive breast cancer patients. Without 
conservative dose-escalation strategies, the patient received a single high-dose infusion of 
Figure 4: Evolution of chimeric antigen receptors (CARs). CARs are fusion proteins that combine antigen 
recognizing regions from antibodies with intracellular T cell signaling domains. In the original CAR design, the VH 
and VL chains of immunoglobulins were engineered to the constant regions of the TCR α- or β-chains, giving rise 
to double chain chimeric receptors. Over time, a one-single-chain approach was introduced that combined the 
targeting and signaling motifs into one polypeptide. First generation CARs contain CD3ζ for T cell stimulation, 
whereas second generation CARs additionally possess a co-stimulatory domain, e.g. CD28 or 4-1BB. Third 
generation CARs consist of two co-stimulatory domains linked to CD3ζ. Co-stimulation enhances the overall 
survival as well as proliferation, cytokine production, and persistence of activated T cells. mAb, monoclonal 
antibody; scFv, single-chain variable fragment; TCR, T cell receptor; TM, transmembrane domain. 
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1010 CAR T cells, upon which she developed respiratory distress within 15 min and multiple 
cardiac arrests over the course of 5 days eventually resulting in mortality. CAR T cell infiltration 
was found in the lung, abdominal and mediastinal lymph nodes, and at low levels in the heart, 
but not in tumor metastases. Serum cytokine profiling starting 4 hours after CAR T cell 
administration revealed strong increases in granulocyte-macrophage colony-stimulating factor 
(GM-CSF), Interferon γ (IFNγ), IL-6, IL-10, and Tumor necrosis factor α (TNFα). It is believed 
that the observed toxicity was due to HER2 recognition in lung epithelium leading to 
inflammatory cytokine release syndrome (CRS), which in turn caused lethal multi-organ failure 
(Morgan et al., 2010).  
While the initial attempts in treating solid tumors with CAR T cells were doomed to failure, 
treatment of B cell hematological malignancies experienced a therapeutic breakthrough using 
this technology. Emily Whitehead, in 2011 a 6 year old pre-B-ALL patient who stopped 
responding to conventional treatment, was the first child to receive a CD19-targeted CAR T 
cell therapy using a second generation construct with 4-1BB and CD3ζ signaling domains. 
CD19 is a transmembrane glycoprotein that is found exclusively on cells of the B lineage and 
on most B cell-derived leukemias or lymphomas thus representing a suitable target. Upon 
receiving the third CAR T cell dose, the patient developed high fever and respiratory failure 
induced by CRS as a result of intensive CAR T cell activation. Her clinical status did not 
improve, despite administration of high-dose steroids and TNFα-directed therapy. It was then 
noted that the serum levels of IL-6 were also elevated and tocilizumab, an IL-6 receptor 
blocking antibody, was administered leading to rapid improvement in her clinical status. B cell 
aplasia, which developed as a result of on target/off tumor recognition, was mitigated with 
regular immunoglobulin infusions. The patient has been now in remission for 7 years.  
Following this initial CAR T cell therapeutic success, treatments of pediatric and adult relapsed 
or refractory B-ALL, chronic lymphocytic leukemia (CLL), and B-cell non-Hodgkin lymphoma 
(NHL) using CD19-directed CAR T cell therapy have consistently demonstrated high anti-
tumor efficacy with complete remissions ranging from 70-94% in different clinical trials 
(Brentjens et al., 2013; Davila et al., 2014; Grupp et al., 2013; Lee et al., 2015; Maude et al., 
2014; Maher, 2013). Based on these results, the Food and Drug Administration (FDA) 
approved two immunotherapies with CD19-directed CAR T cells, Kimriah™ (tisagenlecleucel; 
containing 4-1BB and CD3ζ signaling domains; approved in August 2017) as a second-line 
treatment for patients up to 25 years of age with ALL and Yescarta™ (axicabtagene ciloleucel, 
containing CD28 and CD3ζ signaling domains; approved in October 2017) for the treatment of 
adult patients with relapsed or refractory B cell lymphoma. These advancements have 
reinforced the scientific interest to transfer the CAR technology beyond B cell malignancies. In 
fact, currently, 727 trials are testing or are due to open CAR T cell and natural killer (NK) cell 
therapies worldwide, of which 549 trials target non-hematological malignancies (according to 
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ClinicalTrials.gov, accessed April 1, 2018). Hotspots for clinical CAR research are the United 
States and China (Hartmann et al., 2017).  
 
 
1.2.1 Generation of CAR T cells for clinical applications 
As CAR T cell therapy is mostly an autologous treatment, generation of the medicinal product 
begins with the collection of leukocytes from the patient’s blood via leukapheresis. The cell 
product is subsequently further processed by density gradient centrifugation to obtain 
peripheral blood mononuclear cells (PBMCs). In the most simplistic approach, CAR T cells are 
generated from the bulk PBMC population, while more elaborated protocols include a selection 
step for T cell subsets prior to gene modification, e.g. by enrichment of CD4+ and CD8+ 
(Gardner et al., 2017; Turtle et al., 2016), virus-specific (Ahmed et al., 2017), or CD62L+ (Wang 
et al., 2012) populations using fluorescence or magnetic activated cell sorting. To achieve 
efficient subsequent transgene delivery and ex vivo expansion, the cellular product is 
stimulated through T cell-specific signaling pathways. In this context, primarily monoclonal 
CD3- and CD28-directed antibodies, either in soluble state or immobilized to a colloidal matrix 
Figure 5: Timeline of the preclinical and clinical development of CAR T cell therapy. Milestones and 
throwbacks in the history of CAR development are listed. Figure modified from Gilham et al. (2012). Key references: 
1989: Gross et al.; 1991: Irving and Weiss, Romeo and Seed, Letourneur and Klausner; 1993: Eshhar et al.; 1998: 
Finney et al.; 2006: Kershaw et al., Lamers et al.; 2007: Wang et al.; 2010: Morgan et al.; 2011: Kalos et al.; 
Brentjens et al.; Porter et al,; 2017: Approval letter for Kymriah™: https://www.fda.gov/downloads/Biologics 
BloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM574106.pdf; Approval letter for Yescarta™: 
https://www.fda.gov/downloads/biologicsbloodvaccines/cellulargenetherapyproducts/approvedproducts/ucm58125
9.pdf. 
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or artificial antigen presenting cells (aAPCs), are used. Alternatively, cell-based aAPCs are 
applied that express a manifold of T cell stimulatory ligands (Huls et al., 2013). 
During the activation process, T cells are genetically modified with either a γ-retroviral or 
lentiviral vector encoding the CAR. Both viral systems are structurally similar but biologically 
different in that lentiviral vectors are more efficient in transducing non-dividing cells. Moreover, 
γ-retroviral vectors generally use the native virus promoter for CAR expression, while 
lentiviruses depend on an internal promoter (Geldres et al., 2016). Though very efficient in 
transgene delivery, one limitation of these systems is their relatively costly production, which 
is why non-viral gene modification approaches such as sleeping beauty (Maiti et al., 2013) and 
piggyBac (Saha et al., 2012) transposon/transposases are being further investigated. These 
are plasmid-based expression systems that transfer the CAR gene encoded on a vector to the 
host’s genome via an enzymatic cut-and-paste mechanism (Hackett et al., 2010). The 
relatively simple manufacturing procedure of these methods renders them economically 
advantageous, however, they suffer from low efficiency of deoxyribonucleic acid (DNA) 
integration requiring more time for T cell expansion to reach sufficient therapeutic cell numbers. 
In addition to the above mentioned systems, messenger ribonucleic acid (mRNA) 
electroporation has been used to permit transient expression of the CAR molecule where 
desired (Maus et al., 2013).  
Following effective transgene introduction, T cells are subjected to an expansion phase to 
achieve significant numbers of cells for treatment. The most widely used growth factor to 
support T cell propagation is IL-2, however, it is increasingly replaced by a combination of  
IL-7 and IL-15. Culture conditions with the latter two cytokines have been shown to increase 
the frequencies and expansion of T cells with various memory phenotypes, while IL-2 drives 
effector T cell differentiation. Memory T cells have greater in vivo anti-tumor effect due to 
increased proliferation and persistence ability thus holding promise to improve the treatment 
efficacy in the clinic (Cieri et al., 2013; Xu et al., 2014). Moreover, novel expansion protocols 
also employ IL-21 as a growth factor because IL-21-exposed CAR T cells have shown the 
greatest in vivo persistence in animal models (Singh et al., 2011; Xu et al., 2016). More recently, 
pharmacological immune modulators, that interfere with differentiation pathways of T cells, are 
under investigation, including inhibition of glycolysis (Sukumar et al., 2013) or AKT signaling 
(Crompton et al., 2015), induction of WNT/β-catenin signaling pathways (Gattinoni et al., 2009), 
and combinations thereof (Litterman et al., 2014). Independent of the growth stimulus used, 
most protocols aim at keeping CAR T cells less than 3 weeks in culture to limit aging and loss 
of proliferative potential.  
Once the therapeutic cell dose is reached, the gene-modified T cells are reinfused back into 
the patient’s circulation. As the CAR T cell manufacturing facility is usually separated from the 
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healthcare center, a cryopreservation step of the medicinal product often precedes shipment. 
However, such a freeze-thaw cycle is usually associated with a reduction in quality of the 
cellular product, which is why current endeavors are focusing on decentralizing the 
manufacturing procedure and bringing it closer to the bedside. In this context, the CliniMACS 
Prodigy® is gaining increased attention, a single device that accomplishes T cell preparation, 
enrichment, activation, transduction, and expansion in an automated and good manufacturing 
practice (GMP)-compliant fashion. Since all preparation steps are performed in a closed 
system, the clean room requirements are lower than for personnel-prepared cell products 
making them easier to realize in hospitals (Kaiser et al., 2015). 
Prior to adoptive CAR T cell transfer, patients usually undergo preconditioning chemotherapy 
to both reduce the tumor burden and induce lymphopenia. In fact, it has been shown that 
lymphodepleting regimen greatly increase the therapeutic potential of CAR T cells by 
facilitating engraftment and expansion of the gene-modified immune cells (Brentjens et al., 
2011; Heczey et al., 2017). The individual steps of CAR T cell generation with a cumulative 
consideration of the key variables in the protocols applied by different centers are summarized 
in Figure 6. 
 
 
 
 
Figure 6: A step-by-step breakdown of the CAR T cell manufacturing procedure. For CAR T cell production, 
patients first undergo leukapheresis upon which the cellular product is further processed to obtain PBMCs. Prior to 
T cell activation and transgene integration, specific T cell subsets may be further enriched. Following T cell 
stimulation, the lymphocytes are genetically modified to express a transgene encoding a tumor antigen-directed 
CAR and expanded ex vivo under optimized T cell culture conditions. The cellular biomedicinal product can be 
cryopreserved for later administration or is infused directly into the patient. For better in vivo engraftment of the 
gene-modified T cells, patients are commonly preconditioned with lymphodepleting chemotherapy. Divergent 
variables in the protocols applied by different investigators are listed. Dashed lines represent optional steps in 
product preparation. 
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1.2.2 CAR T cell therapy in the solid tumor setting 
Compared to hematological malignancies, the clinical experience of CAR T cell therapy for 
solid tumors has been less encouraging. Several challenges have hampered the therapeutic 
success with the lack of truly tumor-specific antigens being the predominant obstacle. In fact, 
the vast majority of CARs recognize tumor cells in a tumor-associated manner meaning that 
their targets are highly expressed by tumor cells, but are also present at low levels on healthy 
cells. Recognition of the non-malignant tissue by CAR T cells poses not only a potential 
concern, but has already occurred in the clinical setting – with partially lethal outcome (Morgan 
et al., 2010). Nevertheless, continuous optimization of the clinical protocols as well as in the 
CAR design led to the emergence of clinical incidences in which neuroblastoma, glioblastoma, 
prostate cancer, and sarcoma patients have benefitted from CAR T cell treatment (targets: 
GD2 (Louis et al., 2011), interleukin 13 receptor subunit α-2 (IL13Rα2) (Brown et al., 2016), 
prostate-specific membrane antigen (PSMA) (Slovin et al., 2013), and HER2 (Ahmed et al., 
2015)), suggesting that this strategy is still worthwhile pursuing. Presently, 29 solid tumor 
antigens are being evaluated preclinically and clinically for CAR T cell therapy against solid 
tumors (Table 1). Among them, only one, variant III mutation of EGFR (EGFRvIII), can be 
described as tumor-specific. The splice variant is the result of an in-frame deletion in the 
amplified EGFR gene, which lacks the antigen binding domain and constitutively delivers 
prosurvival signals (Villa and Mischel, 2016). Its expression has been strictly identified on 
tumorous cells (Wikstrand et al., 1995) and EGFRvIII-directed CAR T cell therapy for the 
treatment of glioblastoma is currently being evaluated by several centers (US: NCT02209376, 
NCT01454596, NCT02664363; China: NCT02844062). Preliminary phase I clinical data 
indicate tumor infiltration with both CAR-engineered and non-modified T cells as well as 
EGFRvIII target antigen loss suggesting CAR-mediated anti-tumor activity. No antigen 
recognition outside the tumorous tissue was reported so far (O’Rourke et al., 2017).  
Despite the presence of targetable antigens in certain cancers, a high risk of therapeutic failure 
remains. Compared to hematological malignancies, solid tumors are characterized by stronger 
genetic heterogeneity with non-clonal antigen expression profiles (Sun and Yu, 2015) so that 
one-single-target therapy approaches may lead to selective expansion of target antigen-null 
tumor cells. To circumvent this hurdle, studies have reported the targeting of the immuno-
suppressive tumor microenvironment as a means to inhibit tumor growth and augment host 
immunity. In this context, fibroblast activating protein (FAP)-directed CAR T cell therapies have 
been controversially discussed in the literature. FAP is selectively expressed by cancer-
associated stromal cells which form a significant component of the solid tumor stroma (Kakarla 
et al., 2013; Schuberth et al., 2013; Tran et al., 2013; Wang et al., 2014) and promote tumor 
growth, metastasis, and angiogenesis through secretion of growth factors, cytokines, and 
chemokines (Pure and Lo, 2016). By using a mouse specific scFv, Tran et al. tested a FAP-
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directed CAR T cell therapy in several syngeneic mouse tumor models and described 
treatment-related lethal bone marrow toxicities with limited anti-tumor efficacy (Tran et al., 
2013). By contrast, Kakarla et al. and Wang et al. developed FAP-directed CARs derived from 
human/mouse cross-reactive antibodies and demonstrated anti-tumor efficacy in the absence 
of toxicity symptoms of FAP-directed CAR T cell therapies in mice (Kakarla et al., 2013; Wang 
et al., 2014). The discrepancies in these findings are being attributed to the epitope specificity 
and affinity of the different scFvs which may confer the discrimination of highly FAP-expressing 
cancer-associated stromal cells and low level FAP-expressing normal tissue (Magee and 
Snook, 2014). One clinical trial is currently recruiting patients for the treatment of malignant 
pleural mesothelioma by FAP-directed CAR T cell therapy (NCT01722149). 
Beyond FAP, targeting of vascular endothelial growth factor 2 (VEGFR-2) for the disruption of 
tumor blood vessels was investigated. In one completed phase I/II clinical study 
(NCT01218867), 24 patients received VEGFR-2-directed CAR T cell therapy, of which one 
patient achieved stable disease, one patient reached partial response and 22 showed 
progressive disease (Li and Zhao, 2017). This result was clearly disappointing but re-
emphasized that additional factors are in play and their consideration is essential for a 
successful therapeutic outcome. One of these factors is the suboptimal trafficking of the T cells 
to the tumor site. Efficient tumor homing is a complex multi-step process which requires the 
appropriate expression of adhesion receptors on both T cells and tumor endothelium and a 
compatible expression profile of chemokine receptors on the CAR T cells and the chemokines 
secreted by the tumors. As this is rare in a biological setting, regional delivery of CAR T cells 
is being explored by several clinical trials (NCT00730613, NCT01373047, NCT01818323, 
NCT02208362, NCT02414269, NCT02498912) – primarily for the treatment of glioblastoma 
and metastatic colorectal cancer. While some studies are still ongoing, completed trials report 
good tolerance by this administration route and therapeutic efficacy in selected instances 
(Adusumilli et al., 2014; Brown et al., 2015; Brown et al., 2016; Katz et al., 2015; van Schalkwyk 
et al., 2013; Yaghoubi et al., 2009). Though very promising, it is unlikely that this approach will 
be universally applicable as some tumor sites are less well accessible for site-specific 
injections. Another potential limitation is that locally administered CAR T cells may not be able 
to traffic to other tumor sites in metastatic cancer patients. In such instances inefficient tumor 
homing may be overcome by CAR T cells engineered to co-express chemokine receptors that 
recognize tumor-secreted chemokines. Although this approach has only been tested 
preclinically as yet (Craddock et al., 2010; Moon et al., 2011; Peng et al., 2010), existing data 
is encouraging and clinical trials are awaited.  
Additional factors that may hinder the therapeutic potential of CAR T cell therapy in solid 
tumors are the limited persistence of the gene-modified immune cells as well as the multiple 
immunosuppressive mechanisms of the tumor microenvironment, e.g. physical and 
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metabolical barriers, tumor-derived soluble factors and cytokines, and immunosuppressive 
immune cells. Their intervention points for improved therapeutic outcomes are still subject of 
preclinical research (Newick et al., 2016). 
In summary, while the development of CAR T cell therapies for the treatment of solid tumors 
is still in its infancy and is facing several challenges at once, various approaches have been 
undertaken to circumvent these obstacles. Expanded clinical experience and therapeutic 
optimization will help maximizing clinical benefit and permit a widespread adoption of this 
treatment modality to the solid tumor setting. 
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1.2.3 CAR T cell therapy-mediated toxicity 
To date, the majority of preclinical CAR T cell research has primarily focused on establishing 
target specificity and anti-tumor potency of the gene-modified cells. Potential side effects 
associated with this treatment modality have not been addressed in the therapeutic evaluation. 
This is largely due to the incompatibility of the mouse models that are used for therapy 
assessment. Regulatory authorities generally require information on the in vivo effectivity of 
the CAR T cell product to approve clinical translation and standard laboratory practice has 
become to use immunocompromised mice for these purposes as they allow engraftment of 
human T cells. The experimental design of these studies involves systemically administered 
human CAR T cells targeting human antigens whose expression is restricted to the 
xenografted tumor cells. Consequently, the interplay of the transgenic cells with other immune 
cells as well as the on target/off tumor reactivity remain unassessable. As illustrated in Figure 
7, despite a rising interest in CAR research with more and more therapies being evaluated in 
animal models, there are very few studies that document toxicity – even where toxicity has 
been observed in the clinic. This highlights the poor predictive nature of current models for a 
complete therapeutic evaluation. As an inevitable consequence of this trend, most CAR T cell-
based clinical trials have been initiated without proper toxicity profiling and many adverse 
events associated with this therapy were primarily learnt “the hard way” in the clinical setting. 
In some instances, the unpredictability and intensity of the side-effects led to patient mortality. 
With increasing clinical experience, the mechanisms of regularly occurring adverse events are 
starting to be better understood and allow for better preparation and toxicity management. It is 
now widely established, that there are several potential routes to be considered by which CAR 
T cells may contribute to toxicity. 
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1.2.3.1 Anaphylaxis 
The vast majority of CARs used in clinical trials incorporate a murine scFv which renders the 
receptors immunogenic. Both cellular and humoral anti-scFv responses have been described 
that not only lead to rejection of CAR T cells (Jensen et al., 2010; Kershaw et al., 2006; Turtle 
et al., 2016), but can also induce acute anaphylaxis in patients receiving multiple rounds of 
CAR T cell infusions. In a phase I clinical trial aimed to evaluate the on target/off tumor toxicity 
of mesothelin-directed CAR T cells, mesothelioma and pancreatic cancer patients received 
repetitive doses of T cells transiently expressing mesothelin-directed CAR. The transgene was 
introduced temporarily into T cells by mRNA electroporation to limit potential adverse effects 
due to low level mesothelin expression by a variety of normal tissue. One minute following the 
completion of the third CAR T cell infusion, one patient experienced an anaphylactic shock and 
cardiac arrest as a result of a human anti-mouse antibody (HAMA) response directed against 
the mouse scFv. He received cardiopulmonary resuscitation and recovered (Maus et al., 2013). 
To avoid such drastic immune reactions against the therapeutic drug, humanized scFvs or 
scFvs derived from fully human antibodies should be used in the future.  
 
Figure 7: In vivo application of CARs. Timeline shows the number of publications 
citing chimeric antigen receptors analyzed in animal models as well as the proportion 
that reports therapy-associated toxicity between 2005 and 2017. For in vivo CAR 
studies, search terms ’“chimeric antigen receptor”[TIAB] AND mice’ and ‘”chimeric 
antigen receptor”[TIAB] AND “in vivo”’ were applied. To select in vivo CAR studies that 
report toxicities the search terms ’“chimeric antigen receptor”[TIAB] AND mice AND 
toxicity’ and ‘”chimeric antigen receptor”[TIAB] AND “in vivo” AND toxicity’ were used.  
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1.2.3.2 Cytokine release syndrome 
CRS is the most commonly observed toxicity in CAR T cell treated patients and occurs within 
1-14 days of CAR T cell infusion. It is a systemic inflammatory response that results from a 
strong antigen-specific activation of CAR T cells which in turn activates other immune cells. 
Patients with CRS show elevated circulating levels of C-reactive protein (CRP), ferritin,  
GM-CSF, IL-1β, IL-2, IL-8, IFNγ, TNFα, but also IL-6 and IL-10, the latter two cytokines 
traditionally associated with macrophage activation syndrome. As a rule of thumb, the amount 
of inflammation produced correlates with disease burden and the input CAR T cell dose. Of 
note, CRS induced by CAR T cells is usually more severe than that by tumor-infiltrating 
lymphocytes (TILs) or TCR-based therapies (Kalos et al., 2011) and its resolution typically 
takes 2-3 weeks (Frey and Porter, 2016). 
Clinical signs of CRS are initially fever and malaise but can progress to life-threatening 
vasodilatory shock and capillary leakage with hypoxic respiratory failure. Intervention occurs 
when patients develop severe signs of CRS as early immunosuppression bears the possibility 
to limit the therapeutic efficacy. Front-line treatment of CRS is the blockade of the IL-6/IL-6 
receptor axis by the monoclonal antibody (mAb) tocilizumab alone or in combination with 
corticosteroids. Where possible, corticosteroids are excluded as their prolonged treatment 
leads to ablation of the therapeutic cells (Davila et al., 2014; Frey and Porter, 2016). 
 
1.2.3.3 Insertional mutagenesis 
To facilitate the stable expression of CARs on T cell surface, integrating vectors of retroviral 
and lentiviral background are commonly used. In this context, malignant transformation of 
T cells, caused by the integration of vector DNA into host cells near an oncogene, is a potential 
concern. In practice, no cases of T cell transformation have been reported – despite a decade-
long experience. Although insertional oncogenesis has been reported in gene therapy of 
hematopoietic stem cells for X-linked severe combined immunodeficiency (SCID) due to 
retroviral insertion near the LIM domain only 2 (LMO-2) oncogene (Hacein-Bey-Abina et al., 
2003; Howe et al., 2008; Kohn et al., 2003), in T cells LMO-2 is silent making it an unlikely 
target for retroviral integration (Scholler et al., 2012). Nevertheless, as CAR T cells are able to 
persist in treated patients for months or years, insertional mutagenesis is an important 
consideration in the future.  
 
1.2.3.4 Neurological toxicity 
Neurological complications – mainly observed in CD19-directed CAR T cell therapies – were 
largely unforeseen adverse events and manifest as confusion, delirium, tremor, aphasia, and 
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ataxia. They may occur at different time points than CRS with incidences ranging between 0-
50% of affected patients (Brudno and Kochenderfer, 2016; Davila et al., 2014; Kochenderfer 
et al., 2015; Maude et al., 2014; Porter et al., 2015; Turtle et al., 2016). Although in the majority 
of cases neurological toxicities are reversible, treatment-related mortalities due to cerebral 
edema have been reported in two clinical trials (one sponsored by Juno Therapeutics, Inc.; 
another one by Kite Pharma, Inc.). In one of these trials, 133 adults with refractory B-ALL, NHL, 
or CLL were treated with CD19-directed CAR T cells upon which five patients experienced 
lethal cerebral swelling. Autopsies of two of the deceased patients revealed that elevated blood 
cytokine levels induced endothelial cell activation leading to bleeding disorder, capillary 
leakage, and blood-brain-barrier disruption. The latter allowed CAR T cells and high 
concentrations of systemic cytokines to enter the cerebrospinal fluid inducing continuous 
activation of endothelial cells and pericytes in the central nervous system (CNS) which 
ultimately led to deadly brain edema. A more detailed pathophysiology of these neurologic side 
effects is necessary to allow intervention or prophylaxis in future CAR T cell treatments (Gust 
et al., 2017).  
 
1.2.3.5 On target/off tumor recognition 
Due to a lack of truly tumor-specific antigens, on target/off tumor toxicity is inevitable and 
occurs through recognition of the target antigen on healthy tissue. In B cell malignancies, CD19 
is co-expressed by malignant B cells and normal cells of the B cell lineage from pro-B cells to 
mature B cells. Therefore, therapeutic intervention with CD19-directed CAR T cells leads not 
only to tumor eradication but also to on target/off tumor aplasia of healthy B cells – a side effect 
that is clinically managed by repetitive infusions of immunoglobulins to avoid susceptibility to 
infections. 
In the solid tumor setting, the target antigen is generally overexpressed by tumor cells but may 
be present at low levels on healthy tissue. If such tissue resides in an essential organ, life-
threatening consequences may occur. In fact, in the past, on target/off tumor recognition was 
the main cause hampering the application of CAR T cell therapies to solid tumors (as illustrated 
by several clinical examples in preceding chapters). Consequently, target antigen selection is 
probably the most critical factor for a successful CAR therapy. 
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1.3 Aims of the study 
TNBC is a particularly aggressive form of breast cancer with high propensity for metastatic 
spread and poor survival rates. Currently, cytotoxic chemotherapy is the only treatment 
available for TNBC patients, but its efficacy is often challenged by the chemoresistant nature 
of the disease. Therefore, there is an unmet clinical need for a second-line therapy for patients 
with refractory or relapsed TNBC. Due to the immunogenic properties of this cancer type, 
immunotherapeutic approaches are particularly promising as an alternative treatment modality. 
In this context, targeting SSEA-4, a recently identified plasma membrane epitope of a TNBC 
subpopulation that survives chemotherapy and has high metastatic potential, represents a 
complementary therapeutic strategy that can be applied to chemotherapy-pretreated patients. 
It allows to specifically target those tumor cells that escape chemotherapy this way giving hope 
to accomplish improved therapeutic efficacy and increased overall survival of TNBC patients. 
The objective of this study was therefore to develop and evaluate a CAR T cell-based targeting 
approach to SSEA-4. As CARs are synthetic receptors whose efficacy can vary tremendously 
depending on the spatial topologic structure of their epitope as well as on the CAR architecture 
itself, an array of different chimeric receptors was to be empirically designed, tested, and 
compared using different in vitro functionality assays. The most bioactive receptors were then 
to be evaluated in an in vivo mouse model for both anti-tumor efficacy and toxic potential to 
identify the CAR variant with the best efficacy-to-toxicity profile. In the presence of 
on target/off tumor reactivity, the collaterally damaged non-cancerous cells were to be 
identified to assess the risks and side effects of an SSEA-4 CAR T cell therapy in the clinical 
setting.  
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2 Material and Methods 
2.1 Materials 
 
2.1.1 Animals and animal facility products 
 
NOD.Cg-Prkdcscid Il2rgtm1WjI/SzJ    Charles River, Ecully, France 
SmartFlow       Tecniplast, Buggugiate, Italy 
Single use mouse cage (SUMC) composed of  Tecniplast, Buggugiate, Italy 
- IVC rack adaptor  
- card holder 
- food hopper 
- cage body 
- static filter top 
- top adaptor 
SUM water bottle pre-filled irradiated   Tecniplast, Buggugiate, Italy 
2919 Teklad 19% protein extruded rodent diets  Envigo, Madison, USA 
 
 
2.1.2 Antibodies 
 
2.1.2.1 Biotinylated antibodies 
 
Table 2: Biotin-conjugated primary antibodies used within the scope of this study. 
Specificity Clone Species  
(Isotype) 
Dilution 
factor 
source 
anti-mouse IgG  
(Fab-specific) 
polyclonal goat (n/a) 
 
1:100 Sigma Aldrich 
LNGFR, h ME20.4-1.H4 mouse 
(IgG1κ) 
1:10 Miltenyi Biotec 
GmbH 
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2.1.2.2 Fluorescence-labeled antibodies 
 
Table 3: Fluorochrome-conjugated antibodies used within the scope of this study. 
Specificity Coupled 
fluorophore 
Clone Species 
(Isotype) 
Dilution 
factor 
source 
CD3, h FITC BW264/56 mouse 
(IgG2aκ) 
1:10 Miltenyi Biotec 
GmbH 
CD4, h APC, 
VioBlue, 
VioGreen 
VIT4 mouse 
(IgG2aκ) 
1:10 Miltenyi Biotec 
GmbH 
CD8, h FITC, 
VioBlue, 
VioGreen  
BW135/80 mouse 
(IgG2aκ) 
1:10 Miltenyi Biotec 
GmbH 
CD24, m FITC M1/69 rat  
(IgG2bκ) 
1:10 Miltenyi Biotec 
GmbH 
CD31, m FITC 390 rat  
(IgG2aκ) 
1:10 Miltenyi Biotec 
GmbH 
CD34, m FITC REA383 rec. human 
(IgG1) 
1:10 Miltenyi Biotec 
GmbH 
CD34, h APC AC136 mouse 
(IgG2aκ) 
1:10 Miltenyi Biotec 
GmbH 
CD38, h FITC IB6 mouse 
(IgG2aκ) 
1:10 Miltenyi Biotec 
GmbH 
CD38, m APC 90.4 rat  
(IgG2aκ) 
1:10 Miltenyi Biotec 
GmbH 
CD41, m FITC MWReg30 rat  
(IgG1κ) 
1:10 Miltenyi Biotec 
GmbH 
CD43 Glyco APC REA364 rec. human 
(IgG1) 
1:10 Miltenyi Biotec 
GmbH 
CD44, m FITC IM7.8.1 rat  
(IgG2bκ) 
1:10 Miltenyi Biotec 
GmbH 
CD45, h FITC 5B1 mouse 
(IgG2aκ) 
1:10 Miltenyi Biotec 
GmbH 
CD45, m FITC 30F11 rat  
(IgG2bκ) 
1:10 Miltenyi Biotec 
GmbH 
      
     (continued) 
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Figure 3: continued.     
CD48, m FITC, PE HM48-1 hamster 
IgG1λ 
1:10 Miltenyi Biotec 
GmbH 
CD49a, m&r PE REA493 rec. human 
(IgG1) 
1:10 Miltenyi Biotec 
GmbH 
CD49f, h&m PE REA518 rec. human 
(IgG1) 
1:10 Miltenyi Biotec 
GmbH 
CD68, m FITC FA-11 rat  
(IgG2a) 
1:10 Miltenyi Biotec 
GmbH 
CD71, m APC REA627 rec. human 
(IgG1) 
1:10 Miltenyi Biotec 
GmbH 
CD81, m&r FITC EAT2 hamster 
IgGκ 
1:10 Miltenyi Biotec 
GmbH 
CD98, m FITC REA861 rec. human 
(IgG1) 
1:10 Miltenyi Biotec 
GmbH 
CD102, m APC REA745 rec. human 
(IgG1) 
1:10 Miltenyi Biotec 
GmbH 
CD105, m FITC MJ7/18 rat  
(IgG2aκ) 
1:10 Miltenyi Biotec 
GmbH 
CD106, m APC 429 rat  
(IgG2aκ) 
1:10 Miltenyi Biotec 
GmbH 
CD107a, h VioBlue H4A3 mouse 
(IgG1κ) 
1:10 Miltenyi Biotec 
GmbH 
CD115, m PE AFS98 rat  
(IgG2aκ) 
1:10 Miltenyi Biotec 
GmbH 
CD117, m PE 3C11 rat  
(IgG2bκ) 
1:10 Miltenyi Biotec 
GmbH 
CD119, m APC REA189 rec. human 
(IgG1) 
1:10 Miltenyi Biotec 
GmbH 
CD135, m APC A2F10 rat  
(IgG2aκ) 
1:10 Miltenyi Biotec 
GmbH 
CD138, m PE REA104 rec. human 
(IgG1) 
1:10 Miltenyi Biotec 
GmbH 
CD140b, m APC APB5 rat  
(IgG2aκ) 
1:10 Miltenyi Biotec 
GmbH 
      
     (continued) 
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Figure 3: continued.    
CD146, m FITC ME-9F1 rat  
(IgG2aκ) 
1:10 Miltenyi Biotec 
GmbH 
CD150, m APC REA299 rec. human 
(IgG1) 
1:10 Miltenyi Biotec 
GmbH 
α-Biotin APC Bio3-18E7 mouse 
(IgG1) 
1:10 Miltenyi Biotec 
GmbH 
Embigin, m PE REA501 rec. human 
(IgG1) 
1:10 Miltenyi Biotec 
GmbH 
ESAM, m PE REA722 rec. human 
(IgG1) 
1:10 Miltenyi Biotec 
GmbH 
Gr-1, m FITC RB6-8C5 rat  
(IgG2bκ) 
1:10 Miltenyi Biotec 
GmbH 
Hapten NP 
acetyl 
(isotype ctrl) 
APC, FITC, 
VioBlue, 
VioGreen 
S43.10 mouse 
(IgG2aκ) 
1:10 Miltenyi Biotec 
GmbH 
IFNγ APC-Vio770 45-15 mouse 
(IgG1κ) 
1:10 Miltenyi Biotec 
GmbH 
Keyhole 
limpet 
hemocyanin 
(isotype ctrl) 
APC, FITC, 
PE, VioBlue 
IS5-21F5 mouse 
(IgG1κ) 
1:10 Miltenyi Biotec 
GmbH 
Keyhole 
limpet 
hemocyanin 
(isotype ctrl) 
PE-Vio770 IS6-11E5.11 mouse 
(IgG2bκ) 
1:10 Miltenyi Biotec 
GmbH 
Keyhole 
limpet 
hemocyanin 
(isotype ctrl) 
APC, FITC, 
PE, PE-
Vio770, 
VioBlue 
REA293 rec. human 
(IgG1κ) 
1:10 Miltenyi Biotec 
GmbH 
LNGFR, h APC, FITC, 
PE 
ME20.4-
1.H4 
mouse 
(IgG1κ) 
1:10 Miltenyi Biotec 
GmbH 
PD-1, h PE-Vio770 PD1.3.1.3 mouse 
(IgG2bκ) 
1:10 Miltenyi Biotec 
GmbH 
PD-L1, h APC MIH1 mouse 
(IgG1κ) 
1:10 Miltenyi Biotec 
GmbH 
     (continued) 
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Figure 3: continued.    
PD-L2, h APC MIH18 mouse 
(IgG1κ) 
1:10 Miltenyi Biotec 
GmbH 
Prominin-1, 
m 
APC MB9-3G8 rat (IgG1) 1:10 Miltenyi Biotec 
GmbH 
RAMP-2 APC REA703 rec. human 
(IgG1) 
1:10 Miltenyi Biotec 
GmbH 
Sca-1, m APC,  
PE-Vio770 
REA422 rec. human 
(IgG1) 
1:10 Miltenyi Biotec 
GmbH 
SSEA-4, 
h&m 
APC, PE, 
VioBlue 
REA101 rec. human 
(IgG1) 
1:10 Miltenyi Biotec 
GmbH 
TNFα PE-Vio770 cA2 human 
(IgG1κ) 
1:10 Miltenyi Biotec 
GmbH 
 
 
2.1.3 Buffer and solutions 
 
2.1.3.1 Ready-to-use buffers and solutions 
 
CliniMACS® PBS/EDTA Buffer, pH7.2   Miltenyi Biotec GmbH, Bergisch  
        Gladbach, Germany 
InsideFix       Miltenyi Biotec GmbH, Bergisch  
        Gladbach, Germany 
InsidePerm       Miltenyi Biotec GmbH, Bergisch  
        Gladbach, Germany 
MACS® Bleach Solution     Miltenyi Biotec GmbH, Bergisch  
        Gladbach, Germany 
MACS® BSA Stock Solution      Miltenyi Biotec GmbH, Bergisch  
        Gladbach, Germany 
MACS® Tissue Dissociation Solution   Miltenyi Biotec GmbH, Bergisch  
        Gladbach, Germany 
MACS® Tissue Storage Solution    Miltenyi Biotec GmbH, Bergisch  
        Gladbach, Germany 
MACSQuant® Running Buffer    Miltenyi Biotec GmbH, Bergisch  
        Gladbach, Germany 
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MACSQuant® Storage Solution    Miltenyi Biotec GmbH, Bergisch  
        Gladbach, Germany 
MACSQuant® Washing Solution    Miltenyi Biotec GmbH, Bergisch  
        Gladbach, Germany 
Gibco™ PBS, pH7.2      Thermo Fisher Scientific,  
        Schwerte, Germany 
 
2.1.3.2 Self-prepared buffers and solutions 
 
PEB buffer       CliniMACS® PBS/EDTA Buffer 
        0.5% MACS® BSA Stock Solution 
 
TAE running buffer (50x), pH8.4    242 g Tris base 
57,1 mL acetic acid 
100 mL 0.5 M EDTA 
ad 1 L ddH2O 
 
Sodium butyrate stock solution, 500 mM   5.5 g sodium butyrate 
        ad 100 mL ddH2O 
 
D-luciferin solution, 30 mg/mL    1 g D-luciferin 
        ad 33 mL ddH20 
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2.1.4 Cell lines 
 
2.1.4.1 Prokaryotic cells 
 
Table 4: Prokaryotic cells used for cloning. 
Denotation Description Source 
DH5-alpha Chemically competent cells that can 
be transformed with high efficiency 
New England BioLabs GmbH, 
Frankfurt am Main, Germany 
 
 
2.1.4.2 Eukaryotic cells 
 
Table 5: Eukaryotic cell lines used within the scope of this study. 
Cell line Characterization source 
HEK293T Human embryonic kidney cell line genetically 
engineered to express the large T antigen 
ATCC, Wesel, 
Germany 
HT1080 Human fibrosarcoma cell line ATCC, Wesel, 
Germany 
MCF-7 Human breast cancer cell line that is 
oestrogen and progesterone receptor positive 
ATCC, Wesel, 
Germany 
MCF-7_eGFP_Luc MCF-7 cell line engineered in-house to stably 
express eGFP and luciferase 
- 
MDA-MB-231 Human breast cancer cell line that lacks 
oestrogen receptor and progesterone 
receptor expression, as well as HER2 
amplification 
ATCC, Wesel, 
Germany 
MDA-MB-
231_eGFP_Luc 
MDA-MB-231 cell line engineered in-house to 
stably express eGFP and luciferase 
- 
SK_BR_3 Human breast cancer cell line that over-
expresses the Her2 (Neu/ErbB-2) gene 
product 
ATCC, Wesel, 
Germany 
BT-474 Human breast cancer cell line that over-
expresses the Her2 (Neu/ErbB-2) gene 
product 
ATCC, Wesel, 
Germany 
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2.1.5 Cell culture media and supplements 
2.1.5.1 Media and supplements for prokaryotic cell cultures 
LB agar       Carl Roth, Karlsruhe, Germany 
LB medium       Carl Roth, Karlsruhe, Germany 
SOC medium       New England BioLabs GmbH,  
        Frankfurt am Main, Germany 
 
2.1.5.2 Media and supplements for eukaryotic cell cultures 
DMEM high glucose w/ L-glutamine w/o sodium pyruvate Biowest, Nuaillé, France 
Fetal calf serum (FCS)     Biochrom GmbH, Berlin, Germany 
L-Glutamine, 200 mM     Lonza, Basel, Switzerland 
TexMACS™ medium, research grade   Miltenyi Biotec GmbH, Bergisch  
        Gladbach, Germany 
T cell TransAct™, research grade    Miltenyi Biotec GmbH, Bergisch  
        Gladbach, Germany 
IL-2, improved sequence (IS), research grade  Miltenyi Biotec GmbH, Bergisch  
        Gladbach, Germany 
 
 
2.1.6 Enzymes and enzyme reaction buffers 
 
2.1.6.1 Enzymes 
BamHI        New England BioLabs GmbH,  
        Frankfurt am Main, Germany 
NheI        New England BioLabs GmbH,  
        Frankfurt am Main, Germany 
NdeI        New England BioLabs GmbH,  
        Frankfurt am Main, Germany 
NotI        New England BioLabs GmbH,  
        Frankfurt am Main, Germany 
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SacI        New England BioLabs GmbH,  
        Frankfurt am Main, Germany 
SalI        New England BioLabs GmbH,  
        Frankfurt am Main, Germany 
XmaI        New England BioLabs GmbH,  
        Frankfurt am Main, Germany 
 
2.1.6.2 Enzyme reaction buffers 
CutSmart® Buffer, 10x     New England BioLabs GmbH,  
        Frankfurt am Main, Germany 
NEBuffer 3.1, 10x      New England BioLabs GmbH,  
        Frankfurt am Main, Germany 
NEBuffer 1.1, 10x      New England BioLabs GmbH,  
        Frankfurt am Main, Germany 
 
 
2.1.7 Disposables 
 
Blood lancets Solofix®     B. Braun Melsungen AG,  
        Melsungen, Germany 
Cell culture flasks (T25, T75, T175)    Corning Inc., Durham, USA 
Cell culture plates (6 well, 24 well, 48 well, 96 well) Corning Inc., Durham, USA 
C-Chip Neubauer counting chamber   Science Services GmbH,  
        München, Germany 
Nalgene® system 100™ cryogenic vials  
(1 mL, 2 mL)       Thermo Fisher Scientific, New  
        York, USA 
Falcon® tubes (15, 50 mL)     Corning Inc., Durham, USA 
Filter tips (10 µL, 100 µL, 200 µL, 1000 µL)   Kisker Biotech GmbH & Co. KG,  
        Steinfurt, Germany 
Flat cap microcentrifuge tubes (0.5, 1.5, 2.0 mL)  StarLab, Hamburg, Germany 
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gentleMACS® C tubes     Miltenyi Biotec GmbH, Bergisch  
        Gladbach, Germany 
MACS® Columns (MS, LS)     Miltenyi Biotec GmbH, Bergisch  
        Gladbach, Germany 
MACS® SmartStrainer (30 µm, 70 µm)   Miltenyi Biotec GmbH, Bergisch  
        Gladbach, Germany 
Needles (Microlance: 23G, 26G, 27G)   BD Biosciences, New Jersey, USA 
Reagent reservoir (25 mL)     VWR, Darmstadt, Germany 
Serological pipettes (5, 10, 25, 50 mL) Sarsted AG & Co. KG, Nümbrecht, 
Germany 
Surgical disposabel scalpels B. Braun Melsungen AG,  
Melsungen, Germany 
Storage Bottle (250 mL, 500 mL, 500 mL)   Corning Inc., Durham, USA 
Syringes (1, 2, 5, 10 mL)     B. Braun Melsungen AG,  
        Melsungen, Germany 
Microtube K3 EDTA (1.3 mL)    Sarsted AG & Co. KG, Nümbrecht,  
        Germany 
 
 
2.1.8 Laboratory equipment 
 
Table 6: Laboratory equipment used within the scope of this study. 
Denotation Type Supplier 
Agarose gel electrophoresis 
chamber 
Wide Mini-Sub Cell 
GT cell 
Bio-Rad Laboratories, Inc., 
Hercules, USA 
Agarose gel electrophoresis 
imaging system 
cool SamBa HR-
830 
LTF Labortechnik GmbH, 
Wasserburg, Germany 
Autoclave VX-150 Systec GmbH, Linden, Germany 
Centrifuge Centrifuge 4515R Eppendorf AG, Hamburg, 
Germany 
   
  (continued) 
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Table 6: continued.   
 Multifuge 4KR Thermo Fisher Scientific, 
Waltham, USA 
 Eppendorf 5415D Eppendorf AG, Hamburg, 
Germany 
 Multifuge X3R Heraeus Instruments, Hanau, 
Germany 
Digital Electronic Caliper  Fine Science Tools GmbH, 
Heidelberg, Germany 
Gas anesthesia system XGl-8 Perkin Elmer, Inc., Waltham, USA 
gentleMACS® Dissociator Octo Miltenyi Biotec GmbH, Bergisch 
Gladbach, Germany 
In vivo Bioluminescent imaging 
system 
Lumina Series III Perkin Elmer, Inc., Waltham, USA 
Incubation shaker (bacteria) CERTOMAT® BS-1 B. Braun Biotech International 
GmbH, Melsungen, Germany 
CO2 Incubator (eukaryotic cells) HERAcell™ 240i Thermo Fisher Scientific, New 
York, USA 
Cryobox Mr. Frosty Thermo Fisher Scientific, New 
York, USA 
Incubator (bacteria) ED 53 Binder GmbH, Tuttlingen, 
Germany 
Live cell imaging system IncuCyte® S3 Essen BioScience, Inc., Ann 
Arbor, USA 
Light microscope Axiovert 25 Zeiss, Oberkochen, Germany 
Multi pipette Transferpette®  
S-12 
BRAND GmbH & CO KG, 
Wertheim, Germany 
Spectrophotometer NanoDrop™ 1000 Thermo Fisher Scientific,  
New York, USA 
pipetting aid Thermo 
Scientific™ S1 
Pipet Filler 
Thermo Fisher Scientific,  
New York, USA 
pH meter InLab730 Mettler Toledo AG, 
Schwerzenbach, Switzerland 
   
   
  (continued) 
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Table 6: continued.   
pipets Research Plus 
(10 µL, 100 µL, 
1,000 µL) 
Eppendorf AG, Hamburg, 
Germany 
refrigerator LKV3910 MediLine Liebherr, Bulle, Switzerland 
scale Kern ABT 220-4M KERN & SOHN GmbH, 
Barlingen, Germany 
 Kern PES 2200-2M KERN & SOHN GmbH, 
Barlingen, Germany 
tabletop centrifuge Biofuge Pico Kendro Laboratory Products 
GmbH, Hanau, Germany 
Thermo shaker/mixer ThermoMixer C Eppendorf AG, Hamburg, 
Germany 
Flow cytometer MACSQuant™ 
Analyzer 10 
Miltenyi Biotec GmbH, Bergisch 
Gladbach, Germany 
Laminar airflow workstation HERAsafe™ K12 Thermo Fisher Scientific, New 
York, USA 
Freezer (-20°C) G4013 Comfort Liebherr, Bulle, Switzerland 
Freezer (-80°C) HERAfreeze 
HCF286 
Thermo Fisher Scientific, New 
York, USA 
UV transilluminator SM-20 Single LTF Labortechnik GmbH, 
Wasserburg, Germany 
Vortex mixer Vortex-Genie 2 Scientific Industries, Inc., New 
York, USA 
Water bath GFL-1083 GFL GmbH, Burgwedel, Germany 
Water purification system Professional 
G7895 
Miele & Cie. KG, Gütersloh, 
Germany 
 
 
 
2.1.9 Plasmids 
pMDG2 (VSV-G)      generated in-house (R&D version) 
pCMVdR8.74 (gag/pol)      generated in-house (R&D version) 
pSEW-GFP       generated in-house (R&D version) 
various CAR transfer plasmids    generated in-house (R&D version) 
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2.1.10 Ready-to-use kits 
 
Lineage cell depletion kit, mouse    Miltenyi Biotec GmbH,  
        Bergisch Gladbach, Germany 
Pan T cell isolation kit, human    Miltenyi Biotec GmbH,  
        Bergisch Gladbach, Germany 
NucleoSpin       Machery-Nagel GmbH & Co. KG,  
        Düren; Germany 
EndoFree® Plasmid Maxi Kit     Qiagen, Hilden, Germany 
MACSPlex Cytokine 12 Kit, human    Miltenyi Biotec GmbH, Bergisch  
        Gladbach, Germany 
QIAquick Gel Extraction Kit     Qiagen, Hilden, Germany 
Rapid DNA Ligation Kit Roche Diagnostics GmbH, 
Mannheim, Germany 
 
 
2.1.11 Reagents and chemicals 
 
1 kb Plus DNA Ladder     ThermoFisher Scientific,  
        Schwerte, Germany 
17β-estradiol powder      Sigma-Aldrich, Schnelldorf,  
        Germany 
17β-estradiol pellet, 0.18 mg/pellet    Innovative Research of America,  
        Sarasota, USA 
Acetic acid       Merck KGaA, Darmstadt,  
        Germany 
Baytril™ 10%       Bayer Vital GmbH,   
        Leverkusen, Germany 
BD GolgiPlug™ (Brefeldin A)    BD Biosciences, New Jersey, USA 
BD GolgiStop™ (Monensin)      BD Biosciences, New Jersey, USA 
Capillary tubes      Roche Diagnostics GmbH,  
        Mannheim, Germany 
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Cell Stimulation Cocktail (500x)    Thermo Fisher Scientific,  
        Schwerte, Germany 
COBAS® capillary tubes     Roche Diagnostics GmbH,  
        Mannheim, Germany 
D-luciferin, potassium salt     Gold Biotechnology, Inc., Missouri,  
        USA 
Dimethyl sulfoxide (DMSO)     Sigma-Aldrich, Schnelldorf,  
        Germany 
Ethanol       Merck KGaA, Darmstadt,  
        Germany 
Ethidium bromide      Miltenyi Biotec GmbH, Bergisch  
        Gladbach, Germany 
Erythrosine B       Merck KGaA, Darmstadt,  
        Germany 
FcR blocking reagent, human Miltenyi Biotec GmbH, Bergisch  
Gladbach, Germany 
FcR blocking reagent, mouse Miltenyi Biotec GmbH, Bergisch  
Gladbach, Germany 
Gel loading dye (DNA), 6x New England BioLabs GmbH, 
Frankfurt am Main, Germany 
Isoflurane       Zoetis Schweiz GmbH, Zurich,  
        Switzerland 
Isopropanol       Carl Roth, Karlsruhe, Germany 
Kanamycin sulfate      Carl Roth, Karlsruhe, Germany 
LB Agar (Luria/Miller)      Carl Roth, Karlsruhe, Germany 
LB medium (Luria/Miller)     Carl Roth, Karlsruhe, Germany 
MACSfectin™ reagent     Miltenyi Biotec GmbH, Bergisch  
        Gladbach, Germany 
MACSQuant® calibration beads    Miltenyi Biotec GmbH, Bergisch  
        Gladbach, Germany 
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MACSelect LNGFR MicroBeads    Miltenyi Biotec GmbH, Bergisch  
        Gladbach, Germany 
Pancoll       Pan-Biotech GmbH, Aidenbach,  
        Germany 
Propidium iodide      Miltenyi Biotec GmbH, Bergisch  
        Gladbach, Germany 
Protein L-biotin      GenScript, New Jersey, USA 
Red blood cell lysis buffer, 10x    Miltenyi Biotec GmbH, Bergisch  
        Gladbach, Germany 
Sodium butyrate      Merck KGaA, Darmstadt,  
        Germany 
Tris base       Sigma-Aldrich, Schnelldorf,  
        Germany 
UltraPure™ Agarose       Thermo Fisher Scientific,  
        Schwerte, Germany 
 
 
2.1.12 Software 
 
Table 7: Softwares used within the scope of this study. 
Software Application Source 
MACSQuantify™ 2.11 Analysis of flow cytometric data Miltenyi Biotec GmbH, 
Bergisch Gladbach, Germany 
Microsoft Office 
Professional 2016 
Word, Excel, PowerPoint, 
Outlook 
Microsoft Coorporation, 
Redmond, USA 
Mendeley Desktop 
1.16.3 
Reference management Elsevier, Amsterdam, 
Netherlands 
GraphPad Prism 7.03 Graphical data evaluation GraphPad Software Inc, La 
Jolla (USA) 
Living Image 4.5.2 Analysis of in vivo imaging data Perkin Elmer, Inc., Waltham, 
USA 
   
  (continued) 
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Table 7: continued.   
Clone Manager 9 
Professional Edition 
In silico cloning tool Scientific & Educational 
Software, Denver; USA 
IncuCyte® S3 Control 
Software 
Data analysis of cellular growth 
assays 
Essen BioScience, Inc., Ann 
Arbor, USA 
Image Lab™ Analysis of agarose gels and 
Western blots 
Bio-Rad Laboratories, Inc., 
Hercules, USA 
NanoDrop™ 1000 
Software 
DNA quantification Thermo Fisher Scientific, 
New York, USA 
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2.2 Methods 
2.2.1 Molecular biology methods 
2.2.1.1 Plasmid transformation and amplification 
To amplify plasmid DNA via bacterial cellular replication, chemically competent NEB5-alpha 
were transformed with the plasmid of interest according to manufacturer’s instructions. A 
certain proportion of the mixture was then plated on LB plates containing the desired antibiotic 
for selection and incubated at 37°C overnight. Subsequently, single colonies were picked and 
inoculated into 5 mL LB medium containing the appropriate antibiotic. Upon overnight culture 
at 37°C and vigorous agitation (200 rpm), the samples were either processed using the 
NucleoSpin® Plasmid Kit (small scale plasmid preparation) or the culture was diluted in 
200 mL LB medium and bacteria were grown further at 37°C and 200 rpm overnight. DNA was 
then purified in large scale using the EndoFree® Plasmid Maxi Kit (2.2.1.2).  
 
2.2.1.2 Plasmid preparation 
Preparation of plasmid DNA from transformed NEB5-alpha was performed in small-scale using 
the NucleoSpin® Plasmid Kit or in large-scale using the EndoFree® Plasmid Maxi Kit following 
manufacturers’ instructions. The principle of both kits is based on alkaline lysis of the bacterial 
membrane after which the extracted plasmids are bound to silica membranes in the presence 
of high concentrations of chaotropic salts (NucleoSpin® Plasmid Kit) or to anion exchange 
columns (EndoFree® Plasmid Maxi Kit). Cellular contaminations such as proteins and 
metabolites are then washed away, while the DNA is retained within the columns. Eventually, 
pure and concentrated plasmid DNA is eluted using water or appropriate buffers.  
Small scale plasmid preparations were performed after amplification of newly received plasmid 
gene sequences (all ordered from ATUM; https://www.atum.bio/) or from colonies containing 
recombinant plasmids for subsequent confirmation of proper cloning. The DNA yield was 
typically in the range of 10-20 µg. For DNA applications in transfection experiments, large scale 
plasmid purification was conducted. The utilized kit contained an endotoxin removal step thus 
minimizing agonists in the final DNA product that may decrease viability of mammalian cell 
cultures and inhibit transfection efficiencies. Generally, a total of 400-700 µg DNA was 
obtained using the EndoFree® Plasmid Maxi Kit. After quantitation (2.2.1.5), the DNA was 
aliquoted and stored at -20°C.  
 
2.2.1.3 Restriction of plasmid DNA 
To verify sequence integrity of recombinant plasmids or to isolate a subfragment of interest, 
plasmid DNA was subjected to enzymatic restriction reactions. Restriction enzymes are 
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bacterial endonucleases that catalyze the cleavage of duplex DNA at specific palindromic 
sequences generating characteristic fragments. These DNA fragments are then 
electrophoretically separated and – when necessary – extracted from the gel (2.2.1.4). 
Generally, a restriction reaction was set up as listed in Table . For restriction reaction with two 
enzymes, the buffer ensuring the maximal activity for both nucleases was selected using the 
NEB double digest finder (https://nebcloner.neb.com/#!/redigest). In an analytical setting, the 
reaction mixture was incubated for 1 hour at the temperature recommended by the 
manufacturer. Preparative restrictions were performed for 3 hours at the temperature optimum 
of the utilized restriction enzymes.  
 
Table 8: Composition of analytical and preparative restriction reactions 
Chemical Analytical restriction enzyme 
reaction 
Preparative restriction enzyme 
reaction 
DNA 1 µg 20 µg 
10x buffer 2 µL 5 µL 
Enzymes  
(each in case of a 
double digest) 
5 U  10 U 
ddH20 ad 20 µL ad 50 µL 
 
 
2.2.1.4 Agarose gel electrophoresis and isolation of DNA 
For the separation and analysis of DNA fragments exclusively on the basis of their size, 
agarose gel electrophoresis was used as the method of choice. Agarose is a seaweed-derived 
polysaccharide that, once hydrated and polymerized, functions as a sieve through which DNA 
molecules can migrate. When an electric field is applied across it, DNA fragments travel to the 
anode due to their negatively charged phosphate backbone. Shorter strands move through the 
gel more quickly than larger strands whereby the gel pore size affects the migration rate and 
the separation resolution. For the separation of DNA fragments >1,000 bp, 0.8-1% (w/v) 
agarose gels were used, whereas 1.5-2% (w/v) agarose gels were prepared for smaller 
fragments. For this purpose, the appropriate amount of agarose was emulsified in 250 mL TBE 
buffer and then dissolved by heating the suspension in a microwave oven. After cooling down 
to 60°C, the solution was supplied with ethidium bromide (EtBr) to a final concentration of 
50 µg/mL and subsequently transferred into a cartridge for polymerization. Before the gel 
solidified, a well-forming comb was inserted to generate pockets for subsequent sample 
loading. DNA samples and 1 kb Plus DNA ladder as a size standard were mixed with 6x DNA 
loading dye and applied into the wells of the polymerized agarose gel. Following 
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electrophoresis at 100 V for 45 min in TBE buffer, the DNA was visualized by fluorescence of 
DNA-intercalating EtBr excited by UV light. Analytical gels performed to verify correct cloning 
were investigated at 254 nm whereas preparative gels were analyzed at a longer wavelength 
(302 nm) to reduce the induction of double strand breaks in the DNA molecules. In the latter 
instances, the desired DNA was subsequently isolated by excising the respective gel 
fragments with a scalpel and extracting the DNA using the Gel Extraction Kit following 
manufacturer’s instructions.  
 
2.2.1.5 Quantitation of DNA 
DNA was quantitated spectrophotometrically by measuring the absorbance at 260 nm (A260) 
using the NanoDrop™ 1000. The absorbance maximum of nucleic acids at 260 nm originates 
from the delocalized π-electron system of purine and pyrimidine rings in nucleotides and thus 
correlates with the DNA or RNA concentration of a given solution. Thereby, an A260 of one 
equals 50 μg/ml double-stranded DNA or 40 μg/ml RNA, respectively. To assess the purity of 
the DNA, A280 was additionally determined as aromatic amino acids derived from protein 
contaminations have an absorbance maximum at 280 nm. A ratio of the absorbance at 260 nm 
and 280 nm (A260/280) of 1.8 is indicative for pure DNA, while A260/280 < 1.8 corresponds to 
protein impurities and A260/280 > 1.8 points to RNA contamination. 
 
2.2.1.6 Ligation  
The ligation of vector and insert fragments derived from gel extractions of preparative 
restrictions was performed using the Rapid DNA Ligation Kit from Roche Diagnostics GmbH 
as instructed by the manufacturer. The linearized insert was added in a molar ratio of 5:1 to 
the vector backbone and ligation was performed for 5-10 min at room temperature. To assess 
the frequency of backbone religation, a ligation reaction containing only the vector but no insert 
was set up as a control. Finally, 2 μl of the ligation reaction or the religation control were used 
to transform chemically competent NEB5-alpha (2.2.1.1). 
 
2.2.1.7 Sequencing of DNA 
DNA sequencing was performed at GATC Biotech GmbH. For this purpose, plasmid DNA from 
large scale preparations was diluted with ddH2O to a concentration of 50-100 ng/µL and a total 
volume of 50 µL and sent to the company. Suitable primers were designed using the Clone 
Manager software and ordered along with sequencing orders. The obtained sequences were 
analyzed by comparison with an in silico reference sequence.   
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2.2.2 Cell biology methods 
Cell preparation and handling was exclusively performed under laminar flow and strict aseptic 
conditions. All cell cultures and assays were conducted in appropriate culture medium (for 
adherent cells see 2.2.2.1; for T cells 2.2.2.11) at 37°C in a 5% CO2 atmosphere and 95% 
humidity. Functionality assays with T cells were performed in TexMACS™ medium without 
additives.  
 
2.2.2.1 Cultivation of adherent cell lines 
All cell lines utilized in this study were maintained in DMEM supplemented with 2 mM glutamine 
and 10% FCS. To further support the growth of MCF-7, 17β-estradiol was supplied to the 
culture medium at a final concentration of 10 nmol/L. Cell confluency ranged typically between 
20-80% during the culture maintenance phase.  
 
2.2.2.2 Passaging of adherent cells 
Adherent cells were subcultured or used for downstream applications when they had reached 
a confluency of 70-80%. For detachment, the medium was aspirated and the cultures were 
washed briefly with pre-warmed PBS (5 mL for T75 flask; 8 mL for T175 flask). Following a 
2 min incubation with Trypsin/EDTA (1.5 mL for T75 flask; 3 mL for T175 flask), 5-7 mL culture 
medium containing 10% FCS was added and the cells were gently dissociated from the plastic 
culture surface using light pipetting. The detached cells were pelleted by centrifugation at 
300xg for 5 min at 21°C, resuspended in 10 mL culture medium, and then seeded into T75 or 
T175 flasks at the desired density. Alternatively, the cells were used as antigen expressing 
target cells for in vitro or in vivo CAR T cell functionality studies.  
 
2.2.2.3 Cryopreservation of cells 
PBMCs and T cells were cryopreserved at a maximal cell concentration of 2∙107 cells/mL while 
adherent cancer cell lines were frozen at a density of 3∙106 cells/mL. For this, the cell sediment 
was resuspended in an appropriate volume of freezing medium composed of 9 parts FCS and 
1 part DMSO and transferred to cryovials placed in a cryocontainer. The isopropanol within the 
cryocontainer allowed the cooling of cells by approximately 1°C per minute when put at  
-80°C. After a 24 hour storage period at -80°C, the cell aliquots were transferred to liquid 
nitrogen for long-term storage at -196°C.  
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2.2.2.4 Thawing of cells 
Cryovials containing the cells of interest were thawed at 37°C for a few minutes until only a 
small amount of ice remained, after which the cells were transferred into an appropriate, 37°C 
prewarmed culture medium. After centrifugation at 21°C and 300xg for 5 min, the cells were 
resuspended in fresh culture medium, counted (2.2.2.5) and seeded at the desired density.  
 
2.2.2.5 Cell quantitation 
Cell number determination was performed either automatically via MACSQuant® Analyzer or 
manually using the Neubauer chamber. For MACSQuant®-based cell quantitation, the cell 
suspension was supplied with propidiumiodide (PI) at a dilution factor of 100 and immediately 
thereafter, a volume of at least 50 µL of the cell suspension was measured. PI is a membrane 
impermeable dye that only penetrates into dead cells with compromised plasma membrane. 
Due to its DNA intercalating properties and an emission peak shift upon DNA binding, PI allows 
for exclusion of dead cells in a flow cytometric setting and was therefore also applied to assess 
the viability of the cell suspensions.    
For cell density determination via the Neubauer chamber, 30 µL of the cell suspension were 
diluted with erythrosine B, which selectively stains dead cells with compromised membrane 
integrity. Routinely, a dilution ratio of 1:2 was used. Upon transfer of the cell solution into the 
Neubauer chamber, the non-stained cells in all four major quadrants were counted, including 
those placed on two of the four borderlines. The cell number was calculated according to the 
formula: 
 
∑ 𝑐𝑒𝑙𝑙 𝑐𝑜𝑢𝑛𝑡 𝑖𝑛 4 𝑞𝑢𝑎𝑑𝑟𝑎𝑛𝑡𝑠
4
∙ 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 ∙
10
𝑚𝐿
4
=
𝑐𝑒𝑙𝑙 𝑛𝑢𝑚𝑏𝑒𝑟
𝑚𝐿
 
 
 
2.2.2.6 Transfection of HEK293T cells for CAR expression 
The expression of generated chimeric receptors was first assessed in HEK293T cells by 
transient transfection of the transgene-encoding transfer vectors. To introduce the plasmid 
DNA into cells, MACSfectin™ reagent was used, a composition of cationic lipopolyamines that 
facilitates nucleic acid condensation and cellular uptake. One day prior to transfection, 3∙105 
HEK293T cells were plated per cavity of a 6 well-plate and were allowed to adhere overnight 
in standard culture medium. The next day, the transfection solution was prepared with a 
DNA:MACSfectin™ ratio of 1:2. For this, 3 µg of plasmid DNA were diluted in additive-free 
DMEM to give a final volume of 100 µL. In a second tube, another 100 µL were prepared 
containing 6 µL MACSfectin™ reagent in additive-free DMEM. After transfer of the 
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MACSfectin™ solution to the DNA mix and careful mixing by inversion 3-4 times, the mixture 
was incubated for 20 min at room temperature to allow complex formation between the 
plasmids and MACSfectin™. Eventually, the transfection solution was added dropwise to the 
cells and the plate was rocked gently for uniform distribution. Transfection efficiency was 
assessed by transfecting a separate well with a plasmid encoding GFP, e.g. pSEW-GFP. 
Transgene expression was analyzed flow cytometrically 48 hours after transfection when peak 
expression was expected. For this purpose, cells were detached with 1 mL of pre-warmed 
PBS/EDTA per well and careful trituration followed by fluorescent labeling of the CAR as 
described in 2.2.2.16. 
 
2.2.2.7 Transfection of HEK293T cells for lentiviral vector production 
To achieve stable and efficient gene transfer into primary T cells, lentiviral transduction was 
the method of choice. Lentiviral vectors are a subgroup of retroviral vectors that display two 
key advantages over other retroviral systems: (1) they are able to integrate their genetic cargo 
into chromosomes of both dividing and non-dividing cells, thus improving transduction 
efficiencies and (2) they are less likely to integrate in proto-oncogenic regions of the genome, 
which may lead to insertional mutagenesis (Biffi et al., 2013). Hence, lentiviral-based gene 
delivery offers a superior safety profile in the gene therapeutic setting compared to other 
retroviral vectors. 
Second generation self-inactivating VSV-G-pseudotyped lentiviral vectors were produced by 
transient transfection into adherent HEK293T cells. One day before transfection, 1.6∙107 
HEK293T cells were seeded per T175 flask to reach a confluency of 70-90% on the following 
day. Each T175 flask was then transfected with a total of 35 µg plasmid DNA composed of 
3.14 µg pMDG2 (encoding VSV-G), 19.34 µg pCMVdR8.74 (encoding gag/pol), and 12.52 µg 
transfer vector (encoding the transgene) using MACSfectin™ reagent. When titer analyses of 
different transfer vectors were performed, the transfer vectors were used in equimolar amounts. 
All transfection reactions were performed with a DNA:MACSfectin™ ratio of 1:2. In a first step, 
the different DNA plasmids were mixed with additive-free DMEM to yield a final volume of 
3.5 mL while in another reaction tube, MACSfectin™ reagent was diluted in additive-free 
DMEM to 3.5 mL. Both tubes were mixed by inverting 3-4 times and afterwards the 
MACSfectin™ solution was transferred to the DNA mix. Upon careful mixing by inverting 3-4 
times, the transfection solution was incubated for 20 min at room temperature. In the meantime, 
the culture medium of the cells was replaced by 18 mL of fresh additive-free DMEM and then, 
the transfection solution was added to the cells. Following an incubation period of 6 hours, the 
cells were supplied with 2.5 mL FCS and after an additional 10 hours, sodium butyrate was 
given at a final concentration of 10 mM. Sodium butyrate is an inhibitor of histone deacetylases 
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and has been shown to prevent DNA compaction. In this way, promoter regions remain 
accessible which in turn improves RNA transcription and consequently vector production 
(Jaalouk et al., 2006). At 48 hours after DNA introduction into the cells, the medium was 
collected, cleared by centrifugation at 300xg and 4°C for 5 min and filtered through 0.45 µm-
pore-size PVDF filters. Concentration of the viral stock was performed by centrifugation at 4°C 
and 4,000xg for 24 hours. Pellets containing lentivirus were air-dried and resuspended at a 
100-fold concentration with 4°C cold PBS by trituration. Storage of the lentiviral aliquots 
occurred at -80°C.  
 
2.2.2.8 Titration of lentiviral vectors 
Lentiviral titers were determined by transduction of HT1080 cells with serially diluted viral 
vector preparations and subsequent flow cytometric analysis for transgene expression. One 
day prior to titration, HT1080 cells were plated at a concentration of 1.1∙105 cells/well of a 48-
well plate and incubated overnight. The following day, the culture medium was removed and 
each well was washed with 1 mL DMEM without additives. To determine the number of 
adherent cells at the time point of transduction, the cells of one well were detached with 
CliniMACS® buffer and quantitated. Subsequent transduction was performed by covering the 
cells with 250 µL of the serially diluted vector preparations in the presence of 8 µg/mL 
polybrene. The highest vector concentration used for titration was 2.5 µL per 250 µL DMEM 
and was diluted 2-fold in 4 steps yielding 0.156 µL per 250 µL DMEM as the lowest vector 
concentration. Addition of polybrene to the transduction mix helped to enhance transduction 
efficiency by neutralizing the charge repulsion between the vector particles and the cell surface 
(Davis et al., 2004).   
After an incubation period of 3 hours at 37°C, the transduction reaction mix was replaced by 
1 mL of fresh DMEM supplemented with 10% FCS and the cells were allowed to express the 
transgene for 3 days. Then, the transduction efficiency was analyzed flow cytometrically and 
the amount of transducing units (TU) per mL was calculated according to the formula below. 
Only dilutions that resulted in 1-20% of transduced cells were considered for titer determination 
as these most likely represent only one viral integration per cell.  
 
𝑇𝑈
𝑚𝐿
=
𝑐𝑒𝑙𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑎𝑡 𝑡𝑖𝑚𝑒 𝑜𝑓 𝑣𝑖𝑟𝑎𝑙 𝑣𝑒𝑐𝑡𝑜𝑟 𝑎𝑑𝑑𝑖𝑡𝑖𝑜𝑛 ∙ (
% 𝑓𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑡 𝑐𝑒𝑙𝑙𝑠
100 ) ∙ 1000
𝑥 µ𝐿 𝑜𝑓 𝑣𝑖𝑟𝑎𝑙 𝑣𝑒𝑐𝑡𝑜𝑟 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑒
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2.2.2.9 Isolation of human PBMCs 
Peripheral blood mononuclear cells (PBMCs) were isolated either from erythrocyte-depleted, 
heparinized peripheral blood, so-called buffy coats, or from leukapheresis obtained from the 
University Hospitals in Cologne and Dortmund. All cellular products were derived from healthy 
donors after informed consent.   
Isolation of PBMCs was conducted by density gradient centrifugation. Therefore, the blood 
products were diluted with CliniMACS® buffer in a ratio of 1:2 and 30 mL were carefully layered 
onto a 15 mL cushion of Pancoll. Generally, between 4 (buffy coats) and 12 (leukapheresis) 
50 mL Falcon tubes were prepared per donor. The tubes were then centrifuged for 30 min at 
21°C and 450xg in swing-out buckets with the brake switched off. During this procedure, 
erythrocytes and granulocytes penetrate the 1.077 g/mL dense Pancoll medium due to their 
higher density, while the low density mononuclear cells and platelets are retained at the 
interface between Pancoll and the sample layer. After centrifugation, the cells at the interface 
were carefully sucked off, pooled, and washed three times with 50 mL CliniMACS® buffer each 
in order to remove platelets and residual Pancoll. The washing steps were performed for 5 min 
at 21°C and descending g-force (400xg, 300xg, 200xg). Finally, the PBMCs were either directly 
processed for Pan T cell isolation (2.2.2.10) or cryopreserved for long-term storage (2.2.2.3). 
 
2.2.2.10 Pan T cell isolation 
Pan T cells were negatively selected from PBMCs by magnetic cell sorting (MACS®) using the 
Pan T Cell Isolation Kit from Miltenyi Biotec GmbH. In a first step, PBMCs were pelleted for 
5 min at 4°C and 300xg and the sediment was resuspended in 40 µL PEB buffer per 107 total 
cells. Subsequently, 10 µL of Pan T Cell Biotin-Conjugated Antibody Cocktail against non-
target cells (specifically against CD14, CD15, CD16, CD19, CD34, CD36, CD56, CD123, and 
CD235a) were added for each 107 cells. Following a 5 min incubation at 4°C, 30 µL of PEB 
buffer as well as 20 µL of Naïve Pan T cell MicroBead Cocktail per 107 total cells were given 
to the cell suspension, mixed and anti-biotin-directed MicroBead labelling was allowed for 
10 min at 4°C. The volume was adjusted to a minimum of 500 µL using PEB buffer and the 
cell suspension was allowed to pass through a PEB-equilibrated separation column placed in 
a magnetic field bead separator. During this step, the magnetically labeled non-target cells are 
depleted by being retained within the separation column in the magnetic field, while the 
unlabeled cells run through the column. The column was then washed twice with PEB buffer 
and the flow-through cell population representing the enriched pan T cell fraction was collected. 
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2.2.2.11 T cell activation, transduction and expansion 
Enriched pan T cells were resuspended at a density of 1∙106 cells/mL in TexMACS medium 
containing IL-2 at 40 IU/mL and T cell TransAct™ at a dilution of 1:17.5. As a colloidal 
polymetric nanomatrix incorporating CD3- and CD28-directed antibodies, TransAct™ allows 
efficient activation of resting T cells which in turn results in upregulated surface expression of 
the low density lipoprotein receptor (LDL-R). Since LDL-R serves as the major entry port for 
VSV-G-pseudotyped lentiviral vectors, transduction efficiencies of T cells can thus be 
dramatically increased (Finkelshtein et al., 2013; Amirache et al., 2017).  
The applied T cell seeding conditions for each culture vessel type are summarized in Table . 
Twenty-four hours after TransAct™ activation, lentiviral gene transfer into T cells was induced 
by adding the viral vector concentrate to the cell cultures at a multiplicity of infection (MOI) of 
1.5. Following proper resuspension, the cells were incubated for an additional 2 days, after 
which excessive TransAct™ was removed by replacing the culture supernatant with fresh T 
cell expansion medium (TexMACS™ medium supplemented with 40 IU/mL IL-2). By this day, 
the lymphocytes had usually reached a density of ≥2.5∙106 cells/mL and the cells were 
transferred to a T25, T75 or T175 flask in order to adjust the cell density to 1∙106 cells/mL. 
From this day onward, cell numbers were determined every 2-3 days and fresh T cell 
expansion media was added to maintain a cell concentration of 1∙106 cells/mL until enrichment 
for ΔLNGFR-positive cells (2.2.2.12) or day 12. Flow cytometric analysis for CD4, CD8, 
ΔLNGFR and CAR expression was performed before activation, on day 6 and day 11 of 
expansion.  
 
            Table 9: Cell numbers and volumes for different cell culture vessels 
 area/well  
[cm2] 
Seeded T 
cells/well 
Volume of 
medium/well 
[mL] 
96 well plate 0,32 2-3∙105 0.2 
48 well plate 1 1∙106 1 
24 well plate 2 2∙106 2 
12 well plate 4 4∙106 3 
6 well plate 10 10∙106 5 
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2.2.2.12 Selection of ΔLNGFR-expressing cells 
Transgene-encoded expression of ΔLNGFR was employed as a selection marker for the 
enrichment of transduced T cells by positive MACS® sorting. Using LNGFR MicroBeads, 
MACS® selection was performed in accordance with manufacturer’s instructions on day 6 of T 
cell culture and day 5 after transduction, respectively. Afterwards, cells were resuspended to 
a cell density of 1∙106 cells/mL in TexMACS™ medium containing 40 IU/mL IL-2 and expanded 
until downstream processing. In 2-3 day intervals, fresh TexMACS™ medium with 40 IU/mL 
IL-2 was supplied to adjust the cell concentration to 1∙106 cells/mL. 
 
2.2.2.13 Bead-based cytokine detection 
Quantitative analysis of cytokine secretion by CAR T 
cells upon antigen recognition was performed using 
the MACSPlex Cytokine 12 Kit for human analytes. 
MACSPlex is a bead-based assay technology that 
relies on the same principle as a sandwich ELISA with 
the minor modification that the capture antibody is 
bound to soluble beads instead of being immobilized 
on a plate. The colloidal beads distribute evenly in 
solution thus enabling a more efficient antigen 
capturing than the static surface of ELISA well 
bottoms. To allow determination of multiple cytokines 
simultaneously, the MACSPlex assay consists of a 
mixture of 12 bead populations, each coupled to a 
different capture antibody directed against one of the 
following cytokines: GM-CSF, IFNα, IFNγ, IL-2, IL-4, 
IL-5, IL-6, IL-9, IL-10, IL-12p70, IL-17A, and TNFα. For identification and discrimination 
purposes using flow cytometry, each bead population is color-coded with a unique mixture of 
two fluorochromes that emit in the FITC and PE channels (Figure 8). Upon binding to the 
beads-bound detection antibodies, the cytokines are detected by use of antibodies labeled 
with APC. The fluorescence intensity measured with APC is proportional to the cytokine 
concentration in the sample and is quantified from a calibration curve.  
For quantitative cytokine release analysis, CAR T cells were stimulated with target cells at a 
ratio 1:2 and incubated for 24 hours. Routinely, co-cultures were set up in U-bottomed 96 well 
plates with 5∙104 CAR-positive effector cells and a total volume of 200 µL. Harvested 
supernatants were either stored at -20°C until further processing or analyzed directly using the 
Figure 8: Detection of MACSPlex cytokine 
capture bead populations. Depicted FITC-
PE scatter plot shows the fluorescence 
distribution of the 12 bead populations in 
samples. Each population is defined in an 
elliptic gate region. Figure modified from 
https://www.miltenyibiotec.com/~/media/Imag
es/Products/Import/0009700/IM0009780.ashx  
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protocol provided with the kit. Flow cytometric measurements and subsequent data analysis 
were performed automatically using the MACSQuant® Express Mode for MACSPlex. 
 
2.2.2.14 Live cell imaging-based kinetic cell lysis assay 
Measurement of CAR T cell-mediated cytotoxicity by target cell death was performed by real-
time monitoring using the IncuCyte® S3 system. IncuCyte® is a live-cell imaging platform that 
enables automated analysis of cell behavior over time by automatically gathering and 
processing images in defined time intervals. This way, it provides information about cell 
behavior over an extended period of time, thus enaling more insight into the biological 
processes than standard end-point killing assays such as the chromium release assay (CRA).  
Cytotoxicity assays were set up by seeding 15,000 GFP-transgenic target cells per well of flat 
bottomed 96 well plates and – following overnight incubation – adding equivalent numbers of 
CAR T cells to the cultures. A ratio of 1 between target and effector cells was used as it reflects 
the physiological conditions within a tumor. Cultures of target cells only and target cells with 
mock-transduced T cells were taken along as controls. Phase contrast and green fluorescence 
images were captured with 10x magnification every hour for 3-6 days. Analysis of images was 
performed using the software provided by the manufacturer and the following settings for GFP: 
Top-hat (100 µm and 2.0 GCU) with edge sensitivity of -38 and filters of 2,000 µm2 area, 70.0 
mean intensity and 2E5 integrated intensity.  
 
2.2.2.15 Concurrent detection of degranulation and production of IFNγ and TNFα 
To assess the degranulative capacity of CAR T cells in a quantitative manner, the surface 
expression of lysosome associated membrane protein 1 (LAMP-1, also known as CD107a) 
was analyzed following antigen engagement. In resting T cells, CD107a is predominantly 
located intracellularly in the membrane of secretory granules. Upon activation, when lytic 
granules are exocytosed, their lipid layer fuses with the T cell plasma membrane thus exposing 
CD107a to the cell surface. Consequently, labeling responding T cells with an antibody to 
CD107a and measuring its surface expression by flow cytometry can directly identify 
degranulating CAR T cells. In this work, the measurement of CD107a expression on the cell 
surface was combined with intracellular cytokine staining for IFNγ and TNFα in order to provide 
a more complete assessment of the functionality of CAR T cells and identify polyfunctional T 
cells.  
For stimulation, 2∙105 CAR T cells were co-cultured with an equal number of target cells per 
well of a round bottomed 96 well plate. As CD107a is only transiently expressed on the cell 
surface and rapidly re-internalized via the endocytic pathway, VioBlue-labeled mAb directed 
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against CD107a was added directly after setting up the co-cultures. Following an incubation 
period of 1 hour, the cultures were further supplemented with 10 µg/mL monensin to prevent 
acidification and subsequent degradation of endocytosed CD107a antibody complexes. 
Moreover, to improve the readout of cytokine expression, Brefeldin A was given to the cultures 
at a final concentration of 10 µg/mL. The chemical inhibits the cytokine transport between the 
endoplasmic reticulum and the Golgi, in this way enabling accumulation of cytokines within the 
cell and increasing the sensitivity of cytokine detection. After an additional 4 hours of incubation, 
the cultivation was stopped and surface staining for CD4, CD8, and ΔLNGFR was performed. 
Therefore, the culture supernatant was removed after a centrifugation step at 300xg and 4°C 
for 5 min and the cells were resuspended in 110 µL per well of the respective antibody cocktail. 
Following incubation at 4°C for 10 min, the cultures were washed twice with cold PBS and the 
cells were fixed for intracellular staining by resuspending the pellet of each well in 100 µL PBS 
and 100 µL InsideFix. Cells were then incubated for 20 min at 4°C in the dark, after which they 
were washed with 200 µL InsidePerm per well. Antibodies directed against IFNγ and TNFα 
were diluted in InsidePerm and following cell sedimentation at 500xg and 4°C for 5 min, the 
cells were resuspended in 110 µL antibody mix per well. Upon incubation for 15 min at 4°C in 
the dark, cells were washed twice with PEB buffer (400xg, 4°C, 5 min), resuspended in 200 µL 
PEB buffer and analyzed flow cytometrically. 
 
2.2.2.16 Flow Cytometry 
Analyses of cellular properties on single cell level were performed by multicolor flow cytometry 
with the MACSQuant® Analyzer 10. The flow cytometer is equipped with a violet (405 nm), a 
blue (488 nm) and a red (638 nm) laser and allows the detection of 8 different fluorochromes 
simultaneously. Before each multi-parametric measurement, channel voltage settings were 
optimized using MACSQuant®  calibration beads and compensation was performed with single 
fluorochrome stained cells in combination with the MACSQuant® multicolor compensation 
modus. For cell immuno-phenotyping, antibodies were applied according to manufacturers’ 
recommendations and appropriate isotype-matched antibodies were used as controls. Surface 
expression of CARs was analyzed either by Protein L or by polyclonal antibody-based anti-
mouse IgG (Fab-specific) staining. To exclude dead cells from the analysis, PI was added to 
each sample right before the measurement using the MACSQuant® auto-labeling modus.  
Analysis of acquired flow cytometry data was carried out using the MACSQuantify™ software. 
The general gating strategy for each FACS experiment was based on the following three 
parameters: identification of target cells by appropriate forward scatter (FSC) and side scatter 
(SSC) setting, exclusion of cell aggregates by FSC-A and FSC-H blot and of dead cells by 
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gating on PI negative cells. Only these pre-gated cells were finally analyzed for expression of 
specific antigens. 
Protein L labeling 
Protein L is a bacterial protein that 
interacts with the framework regions in 
the variable domain of immunoglobulin 
κ light chains, in particular those of κ1, 
κ3, and κ4 (Graille et al., 2001). Its 
ability to also bind mammalian scFvs of 
CARs has recently been described by 
Zheng et al. suggesting its application 
as a general CAR detection reagent 
(Zheng et al., 2012). In initial validation 
experiments, in which the cells were 
processed according to the published 
protocol, strong unspecific staining was 
regularly observed. Therefore, the 
labeling procedure was optimized and 
from this point on, cells were stained adhering to the following protocol: On day 6 or 11 after 
TransAct™ activation, T cells were harvested and subjected to efficient washing. Generally, 
1∙106 cells were washed twice with 5 mL CliniMACS® buffer each (300xg, 5 min, 4°C) to 
remove possible carry-over immunoglobulins in culture media. Subsequent cell labeling was 
performed in 200 µL CliniMACS® buffer containing 0.5 µg/µL of biotinylated Protein L for 
45 min at 4°C. Afterwards, cells were washed 3x with 5 mL CliniMACS® buffer (300xg, 5 min, 
4°C) and then incubated with APC-conjugated α-biotin monoclonal antibody (mAb) following 
manufacturer’s recommendations. Following a washing step with 200 µL PEB buffer (300xg, 
5 min, 4°C), cells were resuspended in 200 µL of fresh PEB buffer and analyzed by flow 
cytometry. Importantly, no combinatorial labeling with immunophenotypic antibodies was 
possible as one Protein L molecule contains two antigen binding sites that can concurrently 
interact with two κ light chains (Graille et al., 2001; Figure 9B). Simultaneous interactions of 
Protein L with a CAR molecule on the one hand and a κ light chain-containing antibody on the 
other hand, raise the possibility of false-positive signals and data misinterpretation. To exclude 
this, CAR expression analyses by Protein L labeling were strictly performed as single-stainings. 
 
 
Figure 9: Illustration of the binding sites of Protein L. (A) 
Schematic representation of Protein L binding to the κ light chain 
of a single chain variable fragment of a CAR. VL, variable light 
chain; VH, variable heavy chain; PpL, Peptostreptococcus 
magnus-derived Protein L. (B) Ribbon representation of a 2 
Fab:1 Protein L complex. The two Fab molecules sandwich a 
single Protein L molecule which contacts similar VL framework 
regions of two light chains via independent interfaces. Light 
colors represent the light chain, while dark colors the heavy 
chain. Magenta highlights the complementarity determining 
regions (CDR). CH, constant heavy chain; CL, constant light 
chain. Figure adopted from Graille et al. (2001).  
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Anti-mouse IgG (Fab-specific) labeling 
Polyclonal antibody stainings directed against the scFv region of the CAR molecule are 
currently most widely used to determine the surface expression of CARs by flow cytometry. 
The limitation here is that the polyclonal nature of the antibodies does not provide information 
on whether the detected CARs are properly folded as some antibodies can recognize linear 
epitopes of the CAR amino acid sequence that reaches the cell surface. The ease of the 
staining procedure, however, makes it a quick and thus convenient detection method for 
artificial chimeric receptors. To evaluate the cell surface expression of CARs by anti-mouse 
IgG (Fab-specific) labeling, harvested cells were resuspended in 200 µL PEB buffer containing 
the biotinylated goat anti-mouse IgG (Fab-specific) antibody at a dilution of 1:100. Following 
an incubation period of 10 min at 4°C, cells were washed once with 200 µL of PEB (300xg, 
5 min, 4°C) and then subjected to α-biotin labeling using an APC-conjugated mAb as instructed 
by the manufacturer. Afterwards, cells were washed once with 200 µL PEB buffer (300xg, 
5 min, 4°C) and resuspended in fresh 200 µL of PEB buffer for subsequent flow cytometric 
analysis.  
 
 
2.2.3 In vivo study methods 
2.2.3.1 Animal model and housing conditions 
To study the in vivo activity of human SSEA-4-directed CAR T cells, the NOD/scid/IL2rγ-/- 
(NSG™) mouse model was selected. The NOD genetic background of this mouse strain 
confers an intrinsic reduction of innate immunity due to an absent complement system, 
defective dendritic cells and macrophages as well as lowered NK cell activity. On the other 
hand, the loss-of-function mutation in the PRKDC gene, which is commonly known as SCID, 
eliminates the adaptive immune system. The underlying mechanism here is that the mutational 
silencing of PRKDC abrogates the expression of the catalytic subunit of a protein kinase 
complex that is crucial for the repair of DNA double-strand breaks during V(D)J recombination. 
In the absence of V(D)J recombination, B and T cells fail to express their cell specific receptors 
and cannot mature. Moreover, the knockout of the IL-2-receptor common γ chain gene (IL2rγ) 
further abolishes the adaptive and innate immune system by eliminating high affinity signaling 
through IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21 receptors. The major consequence of this genetic 
deletion is the prevention of NK cell differentiation, because its development is strongly 
dependent on IL-15 signaling. As an ultimate result, neutrophils and monocytes constitute most 
of the remaining mouse immune cells which renders the NSG™ strain highly immunodeficient 
and this way amendable to engraftment of human cells (Shultz et al., 2005; Shultz et al., 2014).  
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All experimental procedures conducted within this study were in compliance with European 
and German guidelines for the care and use of laboratory animals and were approved by the 
ethical committee on animal care and use in Nordrhein-Westfalen (approval number:  
84-02.04.2016.A177). Mice were purchased at an age of six weeks and were allowed to adapt 
to the housing conditions for at least two weeks before starting the experiments. Maximum 
occupancy was 5 animals per cage. At all times, the animals were maintained under specific 
pathogen-free (SPF) conditions using individually ventilated cages (IVC), sterile chow and 
antibiotic-supplemented drinking water provided ad libitum. A 12 hour day and night cycle was 
sustained.  
 
2.2.3.2 Tumor inoculation 
To establish subcutaneous (s.c.) tumors from cancer cell lines, female NSG™ mice of 8 to 10 
weeks of age were injected subcutaneously with 5-10∙106 cells resuspended in 150 µL PBS in 
the flank. Mice were shaved at site of injection beforehand and injections were performed using 
a 1 mL syringe equipped with 27G needle. In the context of the MCF-7 tumor model, mice were 
additionally supplied with slow-release 17β-estradiol pellets directly before tumor cell injection. 
Through s.c. implantation of the pellets in the neck region, a continuous release of the hormone 
was ensured over 60 days, which was meant to support the growth of the estrogen-dependent 
tumor cell line (Dall et al., 2015).   
After tumor inoculation, the growth rate of the tumors was monitored by both measuring the 
size using a caliper and by bioluminescent imaging. 
 
2.2.3.3 T cell injections 
Adoptive transfer of CAR or mock T cells into NSG™ mice occurred via the intravenous route 
and was kindly performed by Janina Brauner and Dr. Wa’el Al Rawashdeh. Doses between  
2-10∙106 CAR T cells in 100 µL PBS per mouse were administered while the untransduced T 
cell control was adjusted to the total T cell number injected in the CAR T cell groups.  
 
2.2.3.4 Physical tumor measurements 
Measurements of tumor size were performed 2–3 times weekly by determining the greatest 
longitudinal diameter (length) and the greatest transverse diameter (width) using an electronic 
caliper. Tumor volume was then calculated using the formula (Euhus et al., 1986; Tomayko 
and Reynolds, 1989):  
𝑇𝑢𝑚𝑜𝑟 𝑣𝑜𝑙𝑢𝑚𝑒 =  
1
2
(𝑙𝑒𝑛𝑔𝑡ℎ ∙ 𝑤𝑖𝑑𝑡ℎ2) 
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2.2.3.5 Bioluminescent imaging of mice 
For bioluminescent imaging of luciferase-expressing tumor or T cells, mice received 
intraperitoneal (i.p.) injections of 3 mg D-luciferin dissolved in 100 µL PBS and 10 min after 
injection, anesthesized mice were imaged using an IVIS Lumina III imaging system. General 
anesthesia was induced by inhalation of 1.5% (v/v) isoflurane in oxygen and continued during 
the measurement procedures with 0.5% (v/v) introduced via a nose cone (flow rate: 1 L/min). 
Image acquisition was conducted in auto-exposure mode, binning 8, field of view E, and  
F-stop 1.2. Using Living Image software, regions of interest (ROIs) were manually drawn 
around the luminescent signal and luciferase activity for each mouse was quantitatively 
analyzed as total flux.  
 
2.2.3.6 Preparation of blood plasma 
Blood samples were collected by puncture of vena facialis using a lancet and immediately 
transferred to EDTA-coated microtubes to avoid agglutination. After centrifugation at 
4,000 rpm for 20 min at 4°C the supernatant blood plasma was harvested and stored at -20°C 
until further processing. Routinely, 80 µL of whole blood were used for blood plasma 
preparation.  
 
2.2.3.7 Preparation of single cell suspensions for flow cytometry 
For organ harvest, mice were euthanized by cervical dislocation and rinsed with 80% ethanol 
prior to excision of the respective organs. The organs were stored in MACS® tissue storage 
solution until downstream processing.  
 
2.2.3.7.1 Blood  
Peripheral blood with a maximum volume of 80 µL was collected from vena facialis after 
puncturing it with a lancet. To prevent agglutination, sample takes were directly transferred to 
EDTA-coated tubes, after which equal blood volumes of each mouse were withdrawn and red 
blood cell lyzed. Routinely, 50 µL of whole blood were lyzed in 1 mL 1x RBC lysis buffer for 
5 min at room temperature. After centrifugation at 300xg and room temperature for 5 min, the 
specimens were processed for flow cytometric analysis as described in 2.2.3.8.  
 
2.2.3.7.2 Bone marrow 
Bone marrow was extracted from the femurs and tibias of mice by cutting off the heads of the 
bones and rinsing the inner fragments with RPMI 1640 using a 21G needle. Upon thorough 
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trituration to break up the tissue, the cell suspension was passed through a MACS® 
SmartStrainer with 70 µm pore size and centrifuged at 300xg for 5 min at 21°C. Subsequent 
RBC lysis was performed by resuspending the cell pellet in 1 mL of 1x RBC lysis buffer and 
incubating the cells at room temperature for 2 min. Addition of 5 mL PBS then stopped the 
reaction, after which the cells were pelleted at 300xg for 5 min at 21°C. Following resuspension 
of the cell sediment in 2 mL of PBS, the cell number per mL was determined using 
MACSQuant® Analyzer and 2∙106 cells were extracted for flow cytometric analysis (2.2.3.8).  
 
2.2.3.7.3 Liver and lung 
Liver and lung were mechanically disaggregated with scalpels and transferred to 37°C pre-
warmed gentleMACS™ C Tubes containing MACS® tissue dissociation solution. For lung 
2.5 mL and for liver 5 mL of dissociation solution per organ were used. Upon manual 
disaggregation, automated tissue homogenization was started by transferring the 
gentleMACS™ C Tubes onto a gentleMACS™ Octo Dissociator and selecting the appropriate 
program settings (program for lung: m_LDK_37; program for liver: m_LIDK_37). Routinely, the 
viability of the dissociated specimens was in the range of 80-90% for lung and 85-95% for liver. 
After dissociation, the homogenized tissues were filtered through MACS® SmartStrainers with 
70 µm pore size and sedimented at 300xg and 4°C for 5 min. To lyze red blood cells, the pellet 
was resuspended in 2 mL of 1x RBC lysis buffer and after a 2 min incubation at room 
temperature, 5 mL PEB buffer were added. Upon centrifugation at 300xg and 4°C for 5 min, 
the cellular sediment was resuspended in 3-5 mL of PEB buffer and cell numbers per mL were 
determined by MACSQuant® Analyzer. Two million cells of each specimen were then used for 
flow cytometric phenotyping as detailed in 2.2.3.8. 
 
2.2.3.7.4 Spleen 
Spleen cell suspensions were prepared by gently mashing the organs with the plunger end of 
a 5 mL syringe in a Petri dish. Following transfer of the splenocyte suspensions through a 
70 µm pore-size MACS® SmartStrainer, the cells were centrifuged at 300xg and 21°C for 5 
min and subsequently depleted from red blood cells by resuspending the sediment in 2 mL of 
1x RBC lysis buffer. After an incubation period of 2 min at room temperature, the reaction was 
stopped by addition of 5 mL PEB and the cells were re-pelleted at 300xg and 21°C for 5 min 
before being resuspended in 1 mL PBS. Ensuing cell counting was performed with 
MACSQuant® Analyzer and 2∙106 cells were routinely used for downstream flow cytometric 
application (2.2.3.8).  
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2.2.3.8 Flow cytometric analysis of ex vivo organ preparations 
To minimize non-specific binding of fluorochrome-conjugated antibodies during labeling 
procedures, all specimens obtained from ex vivo organ preparations were first pre-incubated 
with anti-human and anti-mouse FcR blocking reagent following manufacturer’s instructions. 
Labeling of cells was then performed by adding the respective antibody or antibody cocktail to 
the cell suspension as recommended by the supplier. Following an incubation period of 15 min 
at 4°C, unbound antibodies were removed by washing the cells twice with PEB buffer, after 
which the cell pellets were resuspended in 300 μL PEB buffer and subjected to flow cytometric 
analysis. An effort was made to acquire a total of 1∙106 viable cells per specimen at rates not 
exceeding 3,000 events per second.  
 
 
2.2.4 Statistics 
Unless otherwise specified, all graphical error bars represent standard deviation of the mean. 
Statistical comparisons between two groups were conducted by paired two-tailed Student’s t-
tests using GraphPad Prism 7.03. To facilitate overview, the significance analyses were 
organized in a pairwise significance matrix where each box represents a comparison between 
two groups. The order, in which the groups were compared, is illustrated in Figure 1. Significant 
differences between two comparing groups are defined by a white box, while insignificant 
differences by a black box. Moreover, asterisks within a white box denote the degree of 
significance where *, p<0.05; **, p<0.01; ***, p<0.001. 
 
Figure 10: Organization of the pairwise significant matrix 
for group comparison. 
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3 Results 
3.1 Construction of SSEA-4-specific chimeric antigen receptors 
Several studies have demonstrated that the spacer region can have a significant impact on 
CAR T cell function and needs to be customized for each epitope (Guest et al., 2005; Hudecek 
et al., 2016; Haso et al., 2013). Hence, a panel of SSEA-4-reactive second generation CARs 
was generated by using an in-house generated CAR spacer library. Within this library, each 
CAR-encoding transfer vector contained the following active transgene elements (Figure 11A):  
- Phosphoglycerate kinase (PGK) promoter to drive the expression of the transgene 
- 5’-3’ CAR open reading frame (ORF) consisting of 
• β-galactosidase (lacZ) reporter gene for blue/white selection 
• spacer region 
• CD8α transmembrane domain 
• CD137 (4-1BB) endodomain 
• CD3ζ endodomain  
- Porcine teschovirus-1 2A (P2A) ribosome skip sequence 
- A truncated low affinity nerve growth factor receptor (ΔLNGFR) that lacks the 
cytoplasmic signaling endodomain and serves both as a transduction marker as well 
as for enrichment purposes of transduced cells 
Depending on the transfer vector, the spacer region encompassed either the domain for IgG4  
CH1-hinge-CH2CH3 (extra large (XL) spacer), IgG4 hinge-CH2CH3 (large (L) spacer), IgG4 
hinge-CH3 (medium (M) spacer), CD8α hinge (small (S) spacer) or IgG4 hinge (extra small 
(XS) spacer) (Figure 11B). To abrogate potential interactions of the L and XL spacer CARs 
with FcR-expressing cells, the first six amino acids of the CH2 domain (APEFLG) were 
replaced with the corresponding five amino acids of IgG2 (APPVA) and an NQ mutation at 
the glycosylation site at position 297 was introduced (Hudecek et al., 2016). 
The backbone of the transfer vectors consisted of bacterial plasmid portions to allow selective 
plasmid amplification in bacteria, and standard lentiviral vector elements to enable the 
production of transgene-encoding lentiviral vectors in mammalian cells based on a three 
plasmid system (2.2.2.7).  
Specificity for SSEA-4 was introduced into the chimeric receptors by replacing the LacZ 
reporter gene with a codon-optimized VL-(G4S)3-VH-oriented scFv derived from the SSEA-4-
reactive monoclonal antibody REA101 into each CAR plasmid. To facilitate receptor trafficking 
to the plasma membrane, a mouse κ light chain leader sequence was added N-terminally to 
the scFv sequence (Figure 11C).  
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Figure 11: Schematic representation of the lentiviral transfer vectors used in this study and construction 
of SSEA-4-specific CARs. (A) Organization of the CAR expression vectors. (B) Overview of the spacer members 
comprised in the CAR spacer library. (C) Cloning strategy for introducing SSEA-4 specificity into a CAR backbone. 
aa, amino acid; cPPT, central polypurine tract; env, envelope protein; ΔLNGFR, truncated low affinity growth factor 
receptor; HIV, human immunodeficiency virus; Kanamycin-r, Kanamycin resistance gene; LacZ_α, α monomer of 
β-galactosidase; LTR, long terminal repeats; Ori_pUC, origin of replication derived from Escherichia coli plasmid 
pBR322; P2A, porcine teschovirus-1 2A peptide; pAmp, promoter of the Ampicillin resistance gene; PGK, human 
Results 
 
    63 
phosphoglycerate kinase; RBS, ribosome binding site; RRE, rev responsive element; rrnBT1, transcriptional 
terminator T1 of ribosomal RNA operon B (rrnB); RSV, Rous sarcoma virus promoter; RU5 (HIV1), R and U5 
components of HIV-1 LTR; SV40 pA, simian virus 40 polyadenylation sequence; SV40 Ori, simian virus 40 origin 
of replication; Term_bla, terminator operon of β-lactamase; Term_rpoC, terminator operon of RNA polymerase β’ 
subunit; 5’UTR, 5’ untranslated region; VH, variable heavy chain; VL, variable light chain; WPRE, woodchuck 
hepatitis virus regulatory element. Italic typefaces indicate restriction sites for the respective endonucleases. 
 
 
3.2 Expression analysis of SSEA-4-directed CAR variants in 
HEK293T cells 
Before characterizing the generated CAR constructs in-depth in primary T cells, their cell 
surface expression along with proper folding was first assessed in HEK293T cells. Contrary to 
suspension cells, HEK293T cells can be easily transfected by most transfection reagents thus 
enabling quick and efficient delivery of exogenous DNA and uncomplicated expression 
analyses.   
Equimolar amounts of CAR-encoding transfer vectors were introduced into HEK293T cells by 
lipofection (2.2.2.6) and surface expression was evaluated 48 hours later, when the level of 
transiently expressed proteins is expected to peak. For the determination of the transfection 
efficiency of each set-up, cells were labeled with a mAb directed against ΔLNGFR, which is 
encoded downstream of the CAR-P2A sequence in the transfer vectors (Figure 11A). In this 
configuration, CAR and ΔLNGFR are transcribed as a single mRNA, but translated into two 
separate proteins allowing a direct measurement of CAR expression efficiency when 
compared to the marker protein. No irregularities in ΔLNGFR expression were expected as the 
marker protein is (1) a naturally occurring protein with an evolutionary established amino acid 
sequence and (2) its efficient expression has already been verified in various mammalian 
systems within Miltenyi Biotec GmbH, among others in HEK293T cells and in connection with 
a P2A element (data not shown). To probe directly the expression of CARs, Protein L was 
employed – a bacterial agent that binds to variable κ light chains present in immunoglobulins, 
Fab, scFvs and consequently also CARs (2.2.2.16). An overview of the resultant expression 
data is illustrated in Figure 12. For all transfer vectors tested, the frequency of ΔLNGFR-
positive cells was higher than that of Protein L-positive cells. In general, 95-99% of cells 
expressed the reporter protein, indicating a uniform and high degree of transfection had 
occurred. By contrast, strong variabilities in CAR surface expression were observed depending 
on the nature of the spacer region. The following expression hierarchy was determined in 
descending order: L spacer CAR > S spacer CAR > XS spacer CAR > XL spacer CAR > M 
spacer CAR.  
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3.3 Generation of lentiviral vectors encoding SSEA-4 CAR variants 
and T cell engineering 
Self-inactivating (SIN) HIV-1-based lentiviral vectors encoding the CAR of interest were 
produced based on the three plasmid system and an effort was made to transduce T cells 
under standardized conditions for a maximum degree of reproducibility. The rationale was 
based on the assumption that strong differences in the transgene copy number in the T cell 
genome can lead to differential intensity of transgene expression on the cell surface in this way 
impacting the amplitude and kinetics of CAR T cell responses. On the other hand, as indicated 
by the CAR surface expression data on HEK293T cells in Figure 12, the inequality of surface 
expression of the CAR variants had to be taken into consideration. Therefore, for comparison 
purposes, a congruent surface expression of ΔLNGFR intra- and interexperimentally was 
aimed for, so that each lentiviral batch was first titrated on HT1080 and the amount of 
transduction-competent virions was determined based on surface ΔLNGFR expression. As 
exemplified in Table  and in accordance with published literature, functional viral titers 
decreased as the size of the cargo increased. In fact, the rough tendency was observed that 
addition of 100 bp to the transgenic cargo reduced the vector concentration of approximately 
10%.  
 
Figure 12: Expression of ΔLNGFR and second generation XS, S, M, L, and XL 
spacer CAR variants on HEK293T cell surface. Transfer vector DNA was introduced 
transiently into HEK293T cells by lipofection and flow cytometric analysis was 
performed 48 hours later. Expression of ΔLNGFR was detected by mAb staining, while 
that of CARs by Protein L staining. Both detection reagents were used in biotinylated 
form and fluorescence tagging was performed by secondary α-Biotin-APC mAb 
labeling. A GFP-encoding vector served as control. Results are the average of 3 
independent experiments. 
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Table 10: Overview of cargo length and obtained titers for lentiviral vectors encoding XS, S, M, L, and XL 
spacer CAR variants. Transduction experiments were performed with lentiviral vector suspensions received after 
100-fold concentration. Each vector batch was subjected to serial dilution and then used to transduce HT1080 cells 
in the presence of polybrene (8 µg/mL). Following 72 hours of incubation, ΔLNGFR expression was assayed flow 
cytometrically. Only samples displaying transduction efficiencies ≤20% were considered for concentration 
calculations of transduction-competent virions. Data represents the average of 3 independently produced batches 
for each construct. 
 CAR payload [bp] 
CAR-P2A-ΔLNGFR 
payload [bp] 
Average titer 
[TUHT1080/mL] 
XS spacer CAR 1,358 2,267 7.2∙108 
S spacer CAR 1,457 2,366 6.6∙108 
M spacer CAR 1,679 2,588 5.4∙108 
L spacer CAR 2,006 2,915 3.0∙108 
XL spacer CAR 2,294 3,203 1.4∙108 
 
In a first T cell transduction experiment, all spacer CAR variants were tested for surface 
expression on the immune cells. T cells were transduced with a MOIHT1080 of 1.5 of the 
respective lentiviral vector and transgene surface expression was assayed 5 days later. As 
depicted in Figure 13, the rates of surface ΔLNGFR ranged between 40 and 55%, whereas 
surface CAR expression was in general lower than that of the reporter protein and ranged 
between 13 and 38% as determined by Protein L staining.  
Figure 13: Expression of ΔLNGFR and second generation XS, S, M, L, and XL 
spacer CAR variants on T cell surface. Naïve Pan T cells were isolated from PBMCs 
and cultured in the presence of IL-2 and the T cell stimulating matrix TransAct™. For 
permanent receptor expression, the lymphocytes were transduced lentivirally with an 
MOI of 1.5 and expanded in IL-2. Surface transgene expression was determined by 
flow cytometry 5 days after transduction and 4 days after TransAct™ removal, 
respectively. Expression of ΔLNGFR was analyzed by mAb-based staining, while 
Protein L staining was applied to analyze CAR expression. Both detection reagents 
were used as biotin-conjugates and fluorescence marking was achieved by secondary 
labeling with α-biotin-APC mAb. The results of one experiment are displayed. UnTd, 
untransduced. 
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Notably, normalization of CAR expression based on ΔLNGFR-positive cells revealed that the 
immune cells displayed an equivalent efficiency trend in expressing the individual chimeric 
receptors when compared with HEK293T expression data (Table 11). In both cell types, the 
highest frequency of CAR-positive cells was observed in cell populations that received the 
genetic element for the L spacer CAR, followed by the S and then XS spacer CAR. The lowest 
frequency of CAR-positive cells was detected in the M spacer CAR-engineered populations 
and the second lowest in the XL spacer CAR groups. At this stage, a percentual CAR:ΔLNGFR 
ratio below 50% was defined as an inefficient CAR expression and the M and XL spacer CAR 
constructs were eliminated from progression into the next series of experiments. 
 
Table 11: Expression efficiency of XS, S, M, L, and XL spacer CAR on the T cell surface normalized to 
ΔLNGFR. Calculations are based on the assumption that Protein L+ cells are within the ΔLNGFR+ population.  
 XS spacer 
CAR 
S spacer 
CAR 
M spacer 
CAR 
L spacer 
CAR 
XL spacer 
CAR 
Protein L+ cells/ 
ΔLNGFR+ cells 
65% 79% 23% 85% 42% 
 
Extended T cell transduction experiments with the three lead CAR candidates reproducibly 
confirmed the similar transduction efficiencies for each transfer vector by ΔLNGFR-specific 
staining. Frequencies of transgenic cells routinely ranged between 35-60% for XS and S 
spacer CAR encoding vectors and between 20-55% for L spacer CAR encoding vectors. 
Notably, for all donors and viral vectors, CD4+ T cells demonstrated a slight but significantly 
higher percent transduction than the CD8+ population (Figure 14).  
 
 
Figure 14: Expression of ΔLNGFR on CD4+ and CD8+ T cells after transduction of Pan T cells with XS, S, 
and L spacer CAR encoding lentiviral vectors. Pan T cells isolated from PBMCs were stimulated for 24 hours 
with TransAct™ and IL-2 and subsequently exposed to the respective vector at an MOIHT1080 of 1.5. One day after 
transduction, the medium was replaced and the cells were expanded in the presence of IL-2. Expression of 
ΔLNGFR was analyzed by flow cytometry 5 days after transgene transfer. The results are a summary of 4 
independent experiments.  
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3.4 Comparison of different flow cytometric CAR detection 
methods before and after ΔLNGFR enrichment 
Due to the unavailability of fluorochrome-conjugated SSEA-4, up to this point of the study, 
Protein L staining was employed for the direct identification of surface expressed CARs. This 
detection method, however, suffers from the disadvantages that it often gives high background 
in stainings and – more importantly – cannot be combined with antibodies to achieve 
multifactorial characterization of CAR T cells. The two binding sites per Protein L molecule can 
bind concurrently to a CAR receptor and an antibody resulting in false-positive double or multi 
labeling of cells. Sequential staining approaches of CAR T cells with Protein L labeling followed 
by a blocking step with fluorochrome-free antibodies and subsequent cell phenotyping by 
fluorochrome-conjugated antibodies were hindered by the low antigen affinity of Protein L 
which induced the protein to “fall off” of the cells (data not shown). For these reasons, a second 
direct CAR detection method was tested by staining the mouse-derived scFv domain of the 
receptors. Pan T cells transduced with lentiviral vectors that direct the co-expression of either 
XS, S, or L spacer CAR and ΔLNGFR were expanded for 5 days following transgene 
integration and one fraction of cells was subjected to transgene surface expression analysis. 
CAR expression was validated by both Protein L and anti-mouse IgG (Fab-specific) polyclonal 
antibody staining and compared to the expression of ΔLNGFR as determined by mAb labeling. 
All stainings were performed separately, but in parallel. Using the remaining cell fraction, the 
applicability of these staining methods after positive MACS® sorting was verified. In the setting 
of positive selection, target cells are labelled by antibody-bead conjugates which remain on 
the cell surface following the enrichment procedure. Subsequent CAR staining approaches 
bear the risk to result in false-positive signals due to binding of the detection reagents to the 
α-LNGFR mAb. To exclude this possibility, an expansion period of 6 days between ΔLNGFR 
enrichment and CAR expression analysis was introduced, in this way allowing the antibody-
bead conjugates to be degraded and/or diluted on the T cell surface. A representation of 
repeatedly obtained staining patterns for the different spacer CARs is shown in Figure 15. 
Based on ΔLNGFR expression, less than 50% of the T cells showed genetic modification 
before enrichment. With a regular compromise of roughly 3-5%, the frequency for transgene-
positive cells corresponded to that obtained by ΔLNGFR staining when the anti-mouse IgG 
Fab-directed antibody was used for CAR expression identification. This was indicative that a 
correlated expression of both transgenes was taking place. Strikingly, for the XS spacer CAR, 
a peak-shift towards lower MFI was observed, indicating that the receptor is either present in 
lower numbers on the cell surface than the marker protein or the antibody binding is affected 
by inefficient epitope accessibility due to the very short spacer region (12 amino acids in length). 
When using Protein L staining, a CAR spacer-dependent staining pattern was observed: with 
decreasing spacer length the discrepancy in the staining efficiencies of transgene-positive cells 
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with ΔLNGFR and Protein L reagents increased. Consequently, there was no compatibility in 
the staining pattern of the S and XS spacer CARs among the two CAR detection methods. 
This became more apparent when working with enriched populations. Reproducibly, MACS® 
sorting for ΔLNGFR yielded enriched transgene-positive cell populations with purities ranging 
between 78-96% and homogeneous levels of ΔLNGFR expression as determined by flow 
cytometry. In the context of the anti-mouse IgG Fab-staining approach, the staining patterns 
of ΔLNGFR were again reproducible for the L and S spacer CAR. However, similar to the non-
enriched population, for the XS spacer CAR a left-shift of the histogram’s peak was observed 
compared to the flow cytometric data of the marker protein. Nevertheless, the percentage of 
CAR-positive cells remained comparable. In strong disagreement with this, Protein L staining 
for the detection of XS spacer CAR displayed a reduction of > 50% in the frequency of 
transgene-positive cells when compared to the ΔLNGFR signal. In addition, the staining 
pattern adopted a shoulder type shape. A similar, although less drastic, trend was observed 
for the S spacer CAR staining. In comparison to the ΔLNGFR staining, labeling of the same 
population with Protein L showed a 20% lower frequency of transgene-positive cells and a 
broader peak with lower MFI. In contrast to these observations, staining of the L spacer CAR 
corresponded to that of ΔLNGFR. In summary, these data demonstrate that although the 
identification of transgene expression is not hampered after positive MACS® sorting, for some 
CAR variants, different CAR detection methods can give rise to contradictory results and have 
to be interpreted with caution. 
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Figure 15: Comparison of different flow cytometric methods for the detection of CAR expression on the T 
cell surface before ΔLNGFR enrichment (pre) and after ΔLNGFR enrichment and expansion (post). Five days 
after transduction of pan T cells with lentiviral vectors encoding the XS, S, or L spacer CAR variant, engineered T 
cells were enriched for ΔLNGFR by positive MACS® selection and expanded for an additional 6 days in the presence 
of IL-2. Transgene expression was analyzed directly before and 6 days after enrichment using different labeling 
methods. To detect the frequency of genetically modified T lymphocytes, cells were stained for ΔLNGFR using 
antigen-specific biotin-coupled mAb, while CAR expression was analyzed either by a biotinylated polyclonal goat 
anti-mouse IgG Fab-specific antibody or by staining with biotinylated Protein L. Detection of the biotin conjugates 
was performed using α-biotin-APC secondary mAb labeling. Percentage of positive staining is indicated in each 
histogram. Results are representative for 4 independent experiments. Fab, fragment antigen binding. 
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3.5 Surface expression of SSEA-4 on breast cancer cell lines 
As a prerequisite for the evaluation of CAR functionality, the surface expression of SSEA-4 by 
established breast cancer cell lines was first investigated. Flow cytometric analysis was 
performed on MCF-7, MDA-MB-231, SK_BR_3, and BT-474, as their use has already been 
described in in vivo models, thus confirming their engraftment ability in mice and their suitability 
for potential upcoming animal experiments. For SSEA-4 expression screening, fluorochrome-
labeled REA101 was used, the clone from which the scFv sequence of the CARs was derived, 
and controls were treated with an irrelevant isotype matched antibody. While no SSEA-4 signal 
was detectable for the two HER2-overexpressing cell lines SK_BR_3 and BT-474, a high 
percentage of MCF-7 and MDA-MB-231 cells displayed expression of the glycolipid (Figure 
16). In case of MDA-MB-231, which is known as a highly aggressive triple negative breast 
cancer cell line, 95±4% of the cells were SSEA-4-positive and surface antigen density was 
relatively high with a median fluorescence intensity for FITC (MFIFITC) of 24.9±0.8. Moreover, 
the intercellular surface expression of the antigen was rather homogeneous as indicated by 
the narrow width of the histogram’s peak. Contrary to that, the luminal A breast cancer cell line 
MCF-7, which is characterized by a low aggressive phenotype, showed antigen-positivity in 
80±3.2% of the cells with a low overall antigen density represented by a MFIFITC of 7.6±0.5. 
However, as suggested by the histogram’s broad peak width the intercellular antigen variation 
was broad. In summary, two breast cancer cell lines with differential SSEA-4 expression 
characteristics were identified and selected for following functionality screenings of SSEA-4-
redirected CAR T cells.  
 
 
 
 
Figure 16: Surface expression of SSEA-4 on the breast cancer cell lines MCF-7, MDA-MB-231, 
SK_BR_3, and BT-474. Antigen expression was determined by flow cytometry using FITC-labeled SSEA-4 
specific mAb REA101. Black line is isotype control and red line points out SSEA-4 labeling. Data is 
representative for 3 independent experiments.  
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3.6 Functional in vitro characterization of SSEA-4-directed XS, S, 
and L spacer CAR T cells 
To assess the bioactivity of the XS, S and L spacer CARs, T cells incorporating the respective 
receptors were analyzed for their effector function following antigen stimulation. All functionality 
assays were performed with ΔLNGFR-enriched populations and on day 12-14 following 
TransAct™ activation. Cytotoxicity was evaluated based on CD107a expression on the T cells 
surface and target cell death, whilst the ability for cytokine production and secretion was 
investigated using intracellular cytokine staining and MACSPlex. To exclude potentially 
confounding effects imparted by different levels of transduction, it was strived to achieve 
comparable ΔLNGFR expression levels in all T cell groups intra- and interexperimentally. The 
frequency of CAR-expressing T cells was equalized before all functional assays and 
untransduced T cells served as a control for allogeneic reactivity. Following activation with  
MDA-MB-231 and MCF-7, T cells engineered to express SSEA-4-directed CARs showed 
degranulation but not untransduced control T cells (Figure 17), demonstrating that the 
genetically modified T cells acquired specific lytic activity against SSEA-4-positive tumor cells. 
Intriguingly, despite the difference in the antigenic load between MDA-MB-231 and MCF-7, the 
frequency of degranulating T cells incorporating the same CAR variant was comparable. Also, 
T cell groups incorporating the S and L spacer CARs showed near-identical degranulative 
capacity, although the spacer of both receptors vary by 183 amino acids in length (for 
comparison: an Immunoglobulin domain is ~70-110 amino acids in length). The XS spacer 
CAR, however, which is 216 amino acids shorter than the L spacer receptor and 33 amino 
acids shorter than the S spacer receptor, induced a significantly lower degree of degranulation 
in T cells compared to the other CAR variants. Consequently, while all 3 chimeric receptors 
were able to activate degranulation of T cells following SSEA-4 engagement, no direct 
correlation of receptor potency and spacer length was detectable. 
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Since degranulation assays investigate intrinsic T cell properties and allow only analysis of the 
initial events after T cell stimulation, a live cell imaging-based cell lysis assay was performed 
to study the cytolytic activity of CAR T cells based on target cell death and for an extended 
period of time. Dynamic monitoring of CAR T cell cytotoxicity was performed using the 
IncuCyte® S3, an automated imaging system that quantifies cell behavior over time by 
automatically gathering and analyzing images of cell cultures. As illustrated in Figure 18, all 
CAR T cell groups showed reactivity against tumor cells, but different SSEA-4 CARs induced 
different tumor elimination kinetics. In case of MDA-MB-231 as target cell line, XS spacer CAR-
expressing T cells only controlled the tumor growth throughout the detection period, but did 
not eliminate the tumor cells. The most rapid tumor eradication was observed when target cells 
were treated with S spacer CAR-expressing T cells, while the L spacer CAR T cell group 
required longer time intervals to reach comparable MDA-MB-231 cell killing. In control groups, 
the tumor cells remained in an exponential growth phase throughout the experimental period. 
When MCF-7 were used as target tumor cells, similar functional efficacies were seen. Again, 
T cells expressing the S spacer CAR were most potent in inducing tumor cell death, followed 
by L spacer CAR T cells. In contrast to co-cultures with MDA-MB-231, however, the XS spacer 
CAR T cell group also induced MCF-7 regression although the kinetics were the slowest 
Figure 17: Degranulation of T cells after stimulation with 
MDA-MB-231 and MCF-7. SSEA-4-specific CAR T cells and 
non-transduced control T cells were co-cultured with the 
indicated breast cancer cell lines at a ratio of 1:1 and in the 
presence of fluorochrome-conjugated CD107a mAb. After a 
5 hours incubation, CD107a externalization was measured 
by flow cytometry. Analysis was performed on the CD8+ 
population for non-modified control T cells and on the 
ΔLNGFR+CD8+ subset for transgenic T cells. Data represent 
the average of 4 donors and 3 similar independent 
experiments. 
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among all receptor constructs tested. Noticeably, in the control groups the growth of MCF-7 
cells stagnated in the last third of the test period although confluency was not reached. This 
emphasizes the slow growth kinetics of this cell line upon estrogen removal (assay was 
performed in TexMACS™ medium without additives). 
 
 
Figure 18: Dynamic monitoring of CAR T cell-mediated cytotoxicity. (A) On day 11 after T cell transduction, 
MDA-MB-231 and MCF-7 cells stably expressing eGFP were co-cultured with different CAR T cell groups at a ratio 
of 1:1 and fluorescence emission was measured in the IncuCyte® imaging platform for 5 days with 2 hours interval. 
Untransduced T cells and target cells only served as negative controls. Shown is one representative experiment 
from 3 separate experiments and 5 donors in total. (B) Sequential images of co-cultured MDA-MB-231 and CAR or 
control T cells. Green fluorescence represents target cells, while immune cells are not labeled.  
 
In addition to their cytotoxic potential, tumor-activated CAR T cells were tested for their 
cytokine production and secretion ability. Using the MACSPlex technique, supernatants of 
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24 hour co-cultures were analyzed for secreted levels of GM-CSF, IFNα, IFNγ, IL-2, IL-4, IL-5, 
IL-6, IL-9, IL-10, IL-12p70, IL-17A, and TNFα. While IL-4, IL-5, IL-6, IL-9, IL-10, IL-12p70, and 
IL-17A were not detected at significant levels (data not shown), all CAR T cell groups showed 
increases in GM-CSF, IFNγ, IL-2, and TNFα in comparison to non-transduced T cells. 
Essentially, for both target cell lines a similar efficacy pattern was observed as in the kinetic 
cell lysis assay with the S spacer CAR being consistently the strongest inducer of T cell effector 
function. Cytokine levels induced by the L spacer CAR were either comparable or slightly 
higher to those induced by the S spacer CAR. 
 
 
Figure 19: Cytokine secretion by CAR transduced T cells following antigen stimulation. On day 11 following 
transduction, XS, S, and L spacer CAR expressing T cells were cocultured with the indicated cell lines at a ratio of 
1:2 for 24 hours and culture supernatants were analyzed for cytokine release using the MACSPlex technique. 
Cultures of non-modified T cells with tumor cells served to assess the specificity of CAR-mediated lymphocyte 
response. Results are a summary of 3 independently tested donors. 
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Of note, when CAR T cells were co-cultured with MCF-7 cells, higher levels of IL-2 and  
TNFα were detected than for the cohort co-incubated with MDA-MB-231. This is likely due to 
the fact that the production of these cytokines is most sensitive to PD-1 signaling (Wei et al., 
2013) and MDA-MB-231 expresses higher levels of its ligands PD-L1 and PD-L2 than MCF-7 
(Figure 20). 
 
 
It is well established, that T cells which are able to execute several effector functions at the 
single cell level, called “polyfunctional” T cells, are the key mediators contributing to the 
development of potent and durable immunity against viral infections or cancer (Almeida et al., 
2007; Baitsch et al., 2011; Seder et al., 2008). To evaluate whether the generated SSEA-4-
directed CAR variants are able to induce polyfunctionality in modified T cells, analyses on 
single cell level by intracellular cytokine staining combined with concurrent detection of 
degranulation was performed following antigen stimulation. SSEA-4-specific CAR T cells were 
co-incubated with either MDA-MB-231 or MCF-7 and gene-modified degranulating T cells were 
then analyzed for their ability to simultaneously produce the effector cytokines IFNγ and TNFα. 
The gating strategy applied for analysis is depicted in Figure 21A. As expected, the response 
of activated CAR T cells was in all groups heterogeneous. Overall, the frequency of cytokine 
producing cells within the CD107a-positive compartment ranged between 14-40% with TNFα 
being the predominant cytokine. In the context of this work, polyfunctionality was defined as 
the ability to degranulate and concurrently produce both IFNγ and TNFα. When CAR T cells 
were stimulated with MDA-MB-231, the lymphocyte group incorporating the S spacer CAR 
showed the highest frequency of polyfunctional effector cells for both the CD4+ as well as the 
CD8+ subset, while the XS spacer CAR T cell group displayed the lowest frequency. 
Stimulation with MCF-7, on the other hand, resulted in the XS spacer CAR group showing the 
highest percentage of CD107a+TNFα+IFNγ+ T cells, followed by the S spacer CAR followed by 
the L spacer CAR T cells. However, the data for the XS spacer CAR T cell group needs to be 
Figure 20: Expression of PD-L1 and PD-L2 on MDA-MB-231 and MCF-7. Surface expression was analyzed 
by flow cytometry when cells reached a confluency of 80%. APC conjugated mAbs were used for antigen 
detection. Grey line is isotype control and black line is SSEA-4 stain.  
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considered with caution, as the overall frequency of degranulating T cells was comparably low, 
in this way reducing the statistical power.  
Taken together, all 3 CAR spacer variants tested were able to induce cytotoxicity and cytokine 
production in T cells following SSEA-4 stimulation. The extent of T cell reactivity differed among 
the different receptor constructs, although no direct correlation of receptor potency and spacer 
length was observable. The following functional hierarchy from most reactive to least reactive 
was seen: S spacer CAR > L spacer CAR > XS spacer CAR.  
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Figure 21: Heterogeneity of IFNγ and TNFα production by cytolytic CAR T cells. (A) Gating strategy applied 
to analyze the cytokine production within the CD107a+ compartment of gene-modified CD4+ and CD8+ T cells. (B) 
IFNγ and TNFα production of CD107a+CD4+ and CD107a+CD8+ CAR T cells stimulated with MDA-MB-231 or  
MCF-7 at a ratio of 1:1. Analysis for non-modified control T cells was performed on the entire CD8+ and CD4+ 
subsets. Representative data for 4 donors and after 5 h of stimulation is shown.  
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3.7 Establishment of in vivo tumor xenograft models with MDA-MB-
231 and MCF-7 
Having confirmed the in vitro function of SSEA-4-directed CAR T cells, the next step was to 
evaluate the in vivo activity of these cells in a xenograft model. To determine the appropriate 
time point for CAR T cell therapeutic intervention, a tumor growth kinetic analysis was first 
performed. For this purpose, female NSG™ mice were inoculated with 5∙106 or 10∙106 cells of 
luciferase-GFP-expressing MDA-MB-231 or MCF-7 and from day 7 on, tumor progression was 
followed 2-3 times weekly for a period of 40 days. Measurements of tumor load were performed 
by both serial BLI and physical caliper measurements of which a summary is shown in Figure 
22A. In general, imaging data correlated to standard external caliper measurements of tumor 
growth, but BLI permitted earlier detection of tumor progression. This observation was most 
pronounced for MCF-7. While physical measurements did not show any tumor growth 
throughout the measurement period, BLI indicated, that in the initial phase, cell proliferation 
had taken place, but reached a plateau after approximately 28 days. Consequently, optical 
imaging was considered accurate and therefore appropriate to assess tumor burden in 
upcoming therapeutic studies. A tumor dose of 10∙106 cells was selected for tumor inoculation 
and day 14 post tumor implantation was chosen as the starting point for CAR T cell therapy, 
as from this day on the slope of the growth curve remained constant (MCF-7) or kept increasing 
(MDA-MB-231). Ex vivo analysis of two tumor samples per group on day 14 confirmed that no 
antigen loss occurred during in vivo propagation. Indeed, both cell lines retained antigen 
positivity at levels comparable to their in vitro cultured counterparts – irrespective of whether 
5∙106 or 10∙106 cells were injected (Figure 22B, data not shown for 5∙106 injected cells). 
Additionally, histological examination of these tumors for mouse CD31 expression, a marker 
for blood vessels, showed that extensive vascularization had taken pace in MDA-MB-231 but 
not in MCF-7 tumors. Indeed, while in the first xenograft model, mature blood vessels were 
already identifiable, the MCF-7 tumor model failed to induce pronounced angiogenesis as 
indicated by the relatively small puncta-like staining of CD31 in these tumors. This is likely the 
cause for the observed arrest in MCF-7 tumor growth. Since proper tumor vascularization is a 
prerequisite to allow systemically administered CAR T cells to efficiently traffic to the tumor 
sites, the MCF-7 tumor xenograft model was deselected from upcoming in vivo CAR T cell 
functionality studies. Consequently, only the MDA-MB-231 tumor model was used as a target 
for the therapeutic evaluation of SSEA-4-redirected T cells in vivo.  
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Figure 22: Characterization of MDA-MB-231 and MCF-7 tumor growth in subcutaneous xenograft models. 
(A) In vivo tumor growth curves of MDA-MB-231 and MCF-7. Female NSG™ mice were injected s.c. with either 
5∙106 or 10∙106 tumor cells stably expressing luciferase and progression of tumor growth was monitored in 2-4 day 
intervals by physical caliper measurements and BLI (n=5-6 for each MDA-MB-231 group and n=12-13 for each 
MCF-7 group). On the day of tumor inoculation, MCF-7 injected mice were additionally supplemented s.c. with 
estrogen pellets to support tumor growth. Data are presented as means ± SEM. (B) SSEA-4 expression by  
MDA-MB-231 and MCF-7 after in vivo propagation. Following 14 days of in vivo expansion, tumors were removed, 
dissociated and single cell suspensions were analyzed for SSEA-4 expression by flow cytometry. Red line points 
out SSEA-4 labeling by APC-conjugated mAb, while black line represents staining with isotype-matched control 
antibody. Data shown is from the cohorts injected with 10∙106 tumor cells and representative for two tumors 
analyzed per group. (C) Immunofluorescent analysis of tumor angiogenesis by pan endothelial marker CD31 
(green). DRAQ5 (blue) was used to visualize cell nuclei. Images are derived from tumors initiated with 10∙106 cells 
and representative for two tumors analyzed per group.  
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3.8 Functional in vivo characterization of SSEA-4 directed XS, S, 
and L spacer CAR T cells  
To assess the in vivo therapeutic potential of SSEA-4-redirected XS, S, and L spacer CAR T 
cells, NSG™ mice were implanted s.c. with 1∙107 luciferase-GFP-expressing MDA-MB-231 
tumors and 14 days later a single dose of 2∙106 of the respective CAR T cells was administered 
systemically. All T cell products had been previously enriched for ΔLNGFR as described in 
2.2.2.12. For the control group receiving untransduced immune cells, T cell doses were 
adjusted to the highest total cell number administered among the different CAR T cell cohorts. 
During the therapeutic treatment, tumor burden and CAR T cell frequency in peripheral blood 
were analyzed weekly by BLI and flow cytometry, respectively (Figure 23A). As evident in 
Figure 23B, XS and L spacer CAR T cell therapy mediated no anti-tumor effect and only mice 
that had received S spacer CAR T cells experienced a reduction in tumor growth as compared 
with the control group treated with untransduced lymphocytes (p=0.079). However, on day 16 
following therapy start, the latter cohort required euthanasia due to severe morbidity symptoms 
such as ruffled fur, hunched body posture, lack of motility, and weight loss (Figure 23C). 
Notably, the pattern of body weight loss observed in the S spacer CAR-treated group (Figure 
23C) inversely correlated with the pattern of CAR T cell infiltration in peripheral blood (Figure 
24) suggesting that proliferation of the cellular product had been occurring and further 
promoted toxicity.  
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Figure 23: In vivo activity of SSEA-4-directed CAR T cells. (A) Outline of the experimental design to study the 
therapeutic potential of XS, S, and L spacer CAR T cells in a subcutaneous xenograft model. Female NSG™ mice 
injected s.c. with MDA-MD-231 tumors on day -14 were therapeutically treated with untransduced or XS, S, or L 
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spacer CAR T cells on day 0 and subsequently subjected to blood analysis and BLI according to the schedule 
shown. Study endpoint for each group was defined by tumor reaching 1 cm in any direction, more than 20% weight 
loss, lack of motility or a combination thereof. For the S spacer CAR T cell-treated group, humane endpoint criteria 
were generally reached on day 16 and for the remaining cohorts on day 24. (B) Mean growth of s.c. MDA-MB-231 
tumors in the 4 cohorts as determined by BLI over time. Error bars represent SEM. (C) Body weight development 
of mice treated with untransduced or XS, S, or L spacer CAR T cells throughout the therapeutic period (4 mice per 
group; each line represents one mouse). Similar results were seen in mice treated with 1 107 SSEA-4 CAR T cells.  
 
By contrast, XS and L spacer CAR T cell-treated mouse cohorts did not display body weight 
reduction during therapeutic treatment (Figure 23C) and an increase of peripheral blood 
infiltration by transgenic T cells was observed only for the L spacer CAR group – although the 
proliferative capacity was less pronounced than for S spacer CAR-expressing T cells (Figure 
24). Collectively, targeting SSEA-4 in vivo by CAR T cells generally mediated weak anti-tumor 
effects at best and efficacy was associated with CAR T cell proliferation, but also with adverse 
events. 
 
Figure 24: Frequency of CAR (human CD45+ΔLNGFR+) and untransduced (human CD45+ ) control T cells in 
mouse peripheral blood over the course of therapy. Female NSG™ mice with established s.c. MDA-MB-231 
tumors were injected i.v. with 2∙106 XS, S, and L spacer CAR T cells and starting day 3 post adoptive transfer their 
frequency in peripheral blood was monitored by flow cytometry. For injection of untransduced control T cells, cell 
number was adjusted to the highest total T cell number injected in the CAR T cell groups. Each line represents one 
mouse. 
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When mice cohorts reached the humane experimental endpoint, in addition to blood, bone 
marrow, spleen, lung, and liver were subjected to flow cytometric analysis for CAR T cell 
infiltration. Initially, tumor samples were included in analysis, but the low cell viability upon 
dissociation (~25-33%) as well as the strong GFP signal spreading in all flow cytometric 
channels yielded unreliable data for interpretation (data not shown).  
As illustrated in Figure 25, a significant and large increase in transgenic cells was found in 
blood and all four organs of mice treated with S spacer CAR T cells compared to the cohort 
receiving untransduced control T cells. The pronounced bioactivity of these cells was in strong 
contrast to XS spacer CAR T cells, for which no significant in vivo proliferation was seen in any 
of the organs. Altogether, it appeared that XS spacer CAR T cells were inert to activation. 
Intriguingly, for the L spacer CAR T cell group, a significant expansion was observed only in 
the lung, indicating that the cells are either partially retained and activated for proliferation or 
retraffic to the pulmonary organ from the system.  
 
 
Figure 25: Organ infiltration by CAR-expressing or untransduced control T cells. Upon reaching humane 
endpoint criteria, blood samples were collected and mice were euthanized directly thereafter. Bone marrow, spleen, 
lung, and liver were collected, processed into single cell suspensions and stained with mAbs for enumeration of 
human T cell by flow cytometry. For analysis only viable single cells were considered. Plots indicate mean frequence 
+ SD of human CD45+ (untransduced control) or CD45+ΔLNGFR+ (CAR-expressing) T cells per million cells as 
measured by flow cytometry of each homogenized organ (n=4).  
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3.9 Characterization of the in vivo toxicities mediated by SSEA-4-
directed CAR T cells 
To understand whether the observed toxicities in the S spacer CAR T cell treated mouse cohort 
were related to an anti-tumor response or resulted from on target/off tumor recognition, tumor-
free NSG™ mice were adoptively transferred with high dose (1∙107) XS, S, or L spacer CAR-
expressing T cells or untransduced control lymphocytes and toxicity was evaluated via clinical 
symptoms. Strikingly, adverse events were observed in all cohorts receiving SSEA-4-directed 
therapy, although different CAR T cells displayed a distinct hierarchy of severity. For the S 
spacer CAR T cell-treated group, significant toxicity (ruffled fur, hunched posture, tremor, 
reduced motility) was observed already within a few hours of adoptive transfer and was further 
accompanied by body weight loss of almost 0.7 g/day. On day 6 following CAR T cell infusion, 
the mice eventually required euthanasia (Figure 26). 
The L spacer CAR-treated mouse cohort showed intermediate levels of toxicity symptoms 
which appeared several days after adoptive transfer. Initially, the decrease in body weight was 
mild, but became more pronounced between day 5 and 10. Humane endpoint criteria were 
reached by day 14 (Figure 26).  
Treatment with XS spacer CAR T cells did not display any overt clinical symptoms such as 
changes in body posture or fur. The body weight dropped only slightly in the first 2-4 days but 
stabilized thereafter. Despite the reduced severity of adverse events, SSEA-4-directed 
treatment was lethal in all animals and the mice naturally succumbed to therapy by day 16 
(Figure 26).  
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In addition to physical symptoms, all mouse cohorts receiving SSEA-4-directed CAR T cell 
therapy showed significantly elevated serum levels of human IFNγ. Moreover, the S spacer 
CAR T cell-treated group exhibited significant increases of human IL-2 and TNFα in peripheral 
blood (Figure 26). Overall, these data indicated that significant and dangerous on target/off 
tumor toxicity occurred upon targeting SSEA-4 in vivo. 
Figure 26: Body weight development in tumor-free NSG™ mice following adoptive transfer of 
SSEA-4-directed CAR T cells. Naïve NSG™ mice were treated systemically with 1∙107 XS, S, or L 
spacer CAR T cells and body weight development was monitored. For injection of untransduced control 
T cells, cell number was adjusted to the highest total T cell number injected in the CAR T cell groups. 
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To investigate the pathology elicited by SSEA-4-directed CAR T cell treatment, formalin 
preserved internal organs of S spacer CAR and untransduced control T cell-treated mice were 
subjected to an examination by a pathologist blinded to the treatment conditions. No obvious 
differences in tissue and organ structure between the groups were detected by him. In an 
alternative attempt to locate the major sites of on target/off tumor toxicity, bioinformatical 
expression analysis of the enzyme catalyzing the final step in SSEA-4 synthesis (CMP-N-
acetylneuraminate-β-galactosamide-α-2,3-sialyltransferase 2, ST3GAL2) was performed by 
using data derived from The Human Protein Atlas (https://www.proteinatlas.org). However, 
ST3GAL2 showed relatively broad tissue distribution and did not correlate with SSEA-4 
expression (data not shown). Therefore, differences in CAR T cell activity between distinct 
organs were investigated. Small intestine, colon, kidneys, ovaries and stomach were excluded 
from analysis due to no detection of human T cell infiltrates and although a presence of S 
spacer CAR T cells was identified in brain and skin, the total human lymphocyte amount in 
these organs was too low for investigative purposes. For this reason, the primary focus was 
laid on blood, liver, lung, spleen and bone marrow. Strikingly, compared to human lymphocyte 
infiltrates in blood, liver and spleen, the bone marrow- and lung-resident CAR T cells exhibited 
higher levels of ΔLNGFR expression as determined by median fluorescence intensity (FI) 
(Figure 28A). Taking into consideration that transgene transfer had occurred into actively 
proliferating T cells that had undergone CD3/CD28-stimulated chromatin rearrangement, it 
was hypothesized that gene integration was favored at genomic sites that are decondensed 
during proliferation. When T cells return to steady state, the sites are partially recondensed. 
Figure 26: Blood serum levels of human IFNγ, IL-2, and TNFα in NSG™ mice. Non-tumor-bearing NSG™ mice 
were adoptively transferred with 1∙107 XS, S, or L spacer CAR T cells or untransduced control T lymphocytes and 
6 days later, blood samples were analyzed for the presence of human cytokines as stated in the diagrams (n=3 
mice per group).  
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However, antigen recognition-triggered CAR T cell proliferation would reopen these sites thus 
inducing enhanced transgene transcription.  
To test whether lung and bone marrow were sites of active CAR T cell proliferation, S spacer 
CAR or untransduced control T cells were lentivirally engineered to express GFP-luciferase 
(transduction efficiency 82%) and 2∙106 CAR or untransduced T cells were injected i.v. into 
tumor-free NSG™ mice. Thereafter, the luciferin signal was examined regularly over a course 
of 3 days. Immediately after adoptive transfer, CAR and control T cells trafficked to the lung, 
where they were retained for several hours. With progressing observation time, however, 
control T cells left the organ and distributed throughout the mouse body resulting in the loss of 
a localized luciferin signal. Overall, no proliferation of these cells was detectable. In case of S 
spacer CAR T cells, however, a fraction of lymphocytes remained retained in the lung and the 
luciferin signal continuously increased over time indicating active proliferation of the cells was 
taking place. Moreover, a separate luciferin signal became evident in the bone marrow and 
exhibited the strongest growth rate (Figure 28B). Thus, it was concluded that lung and bone 
marrow were the primary sites of CAR T cell proliferation. Analysis of PD-1 expression by T 
cells infiltrating bone marrow, lung, spleen, and liver further confirmed that CAR T cell 
expansion was driven by antigen recognition. While in all organs analyzed, untransduced T 
cells showed only minimal PD-1 expression, CAR T cells significantly upregulated the 
activation marker and the biggest difference to baseline PD-1 expression in untransduced 
control T cells was observed in lung and bone marrow. Taken together, the data suggested 
that bone marrow and lung were the primary sites of on target/off tumor recognition by  
SSEA-4-directed CAR T cells.  
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3.9.1 Identification of SSEA-4-expressing cells in bone marrow 
The enhanced proliferation as well as PD-1 expression by CAR T cells in bone marrow 
suggested that SSEA-4-directed therapy targeted some aspect of bone. Indeed, the total cell 
number of live bone marrow cells isolated from the femurs and tibias of mice treated with 1∙107 
SSEA-4-direced (S spacer) CAR T cells was significantly diminished compared to mice treated 
Figure 28: Localization of SSEA-4-CAR T cell activity following adoptive transfer in NSG™ mice. (A) Median 
Fluorescent Intensity (FI) of ΔLNGFR expression by gene-modified T cells infiltrating different organs. Sixteen (S 
spacer CAR) or twenty-four (XS and L spacer CAR) days after intravenous CAR T cell administration into NSG™ 
mice, blood, bone marrow, spleen, lung, and liver of the animals were harvested, dissociated to single cell 
suspensions and ΔLNGFR expression was evaluated by flow cytometry. For analysis, gating was performed on 
viable human CD45+ single cells expressing ΔLNGFR (n=4 mice per group). (B) In vivo BLI of T cell trafficking and 
proliferation. Luciferase-expressing mock and CAR (S spacer) T cells were injected intravenously into NSG™ mice 
and their biodistribution was analyzed at indicated time-points post infusion. Images are representative for two mice 
analyzed per group. (C) Median Fluorescent Intensity (FI) of PD-1 expression by untransduced and S spacer CAR-
transduced T cells infiltrating different organs. Three days after adoptive transfer of T cells in NSG™ mice, bone 
marrow, spleen, lung, and liver were excised, processed into a single-cell suspension and PD-1 expression of the 
infiltrating human immune cells was analyzed by flow cytometry. For transduced cells, gating was performed on 
viable human CD45+ ΔLNGFR+ singlets; for untransduced cells, viable human CD45+ single cells were considered 
in the analysis (n=4 mice per group).  
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with equal numbers of untransduced control T cells (Figure 29A). In addition, SSEA-4-directed 
treatment led to a distortion of the mouse CD45+:CD45- ratio within the lineage-negative bone 
marrow compartment and was associated with strong decrease of mouse CD45+ cells (Figure 
29B) as well as a loss of the CD45+Sca-1bright population (Figure 29C). Given that SSEA-4 is 
not expressed by lineage-positive bone marrow cells and encompasses ~0.03% of the lineage-
negative compartment (Figure 29D), it was hypothesized that the glycolipid is restrictively 
produced by hematopoietic progenitor cells. As expected, SSEA-4-positive cells were 
markedly enriched for co-expression of CD117 and Sca-1 (Figure 29E) which is characteristic 
for undifferentiated cells (Brown et al., 2015). Besides, expression of CD34, CD48, CD135, 
and CD150 by the SSEA-4+Lin-Sca-1+CD117+ population more specifically identified the 
subset as multipotent progenitor cells (MPPs) (Figure 29F). Further evidence that SSEA-4-
directed treatment affected MPP homeostasis was provided by the observation that following 
CAR treatment, a significantly reduced frequency of low differentiated CD48high cells, the 
ultimate descendent of short-term hematopoietic stem cells (Figure 29F), was observed. While 
in mice treated with untransduced control T cells the CD48high population constituted around 
40-48% of the Lin-CD45+Sca-1+CD117+ compartment, in mice receiving SSEA-4-directed CAR 
T cell therapy this population dropped to 27-33% (Figure 29G, H).  
Importantly, expression of SSEA-4 was also assessed on human CD34+CD38+ cells derived 
from mobilized stem cell apheresis products of healthy donors (Figure 29I). Around 30 out of 
1∙106 cells were shown to be positive for the glycolipid and although this frequency is drastically 
low, the mere presence of SSEA-4-expressing hematopoietic progenitor cells poses a high risk 
that similar adverse events may be observed in SSEA-4-directed treatment modalities for 
humans as were seen in mice. 
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Figure 27: Bone marrow toxicity following SSEA-4 CAR T cell therapy and phenotypic characterization of 
bone marrow-resident SSEA-4-expressing cells. (A) Total bone marrow cell count following treatment with 
SSEA-4-directed CAR or untransduced control T cell. NSG™ mice were treated with 1∙107 S spacer CAR-
expressing T cells and 3 days later total bone marrow cell number was determined. Control group was treated with 
untransduced T cells and the administered dose was adjusted to the total cell number used in the CAR T cell group. 
Data are the average number of cells from the femurs and tibiae of one mouse (n=5 mice per group). (B) Mouse 
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CD45+:mouse CD45- ratio of lineage-negative bone marrow cells after therapy. For analysis, only viable single cells 
were considered and lineage-positive mouse cells were excluded by Ter119-, CD5-, CD11b-, Gr-1-, Ly6B-, and 
CD45R-directed mAbs, all conjugated to the same fluorochrome. Therapeutic T cells were excluded by human 
CD45-labeling. (C) Sca-1-expression in the CD45+Lin- bone marrow compartment after therapy. Viable single cells 
were preselected for analysis. The black line represents isotype control and the red line Sca-1 staining. Histograms 
are representative for 5 samples per group. (D) SSEA-4-expression by lineage-negative and lineage-positive bone 
marrow cells of untreated NSG™ mice. Data are representative for 3 bone marrow samples analyzed. (E) Analysis 
of Sca-1 and CD117 expression by lineage-negative, SSEA-4-positive bone marrow cells. Numbers in quadrants 
next to the dot plot represent percentages of positive cells within the respective dot plot quadrant. (F) 
Subcharacterization of SSEA-4-expressing Lin-Sca-1+CD117+ (LSK) cells based on CD34, CD48, CD135, and 
CD150 expression. Isotype staining is represented by the black line and antigen staining by the red line. (G) 
Proportion of CD48high versus CD48neg/low population within the LSK compartment after treatment (n=4 mice per 
group). (H) Representative histograms for CD48 expression by the LSK compartment after S spacer CAR or 
untransduced control T cell treatment. (I) Expression of SSEA-4 by human CD34+CD38+ progenitor cells mobilized 
into peripheral blood. Data is representative for two donors analyzed. 
 
 
3.9.2 Identification of SSEA-4-expressing cells in lung 
A novel study has recently described the lung as a second site of hematopoietic activities and 
a niche for hematopoietic progenitor cells (Lefrançais et al., 2017). Therefore, it was 
hypothesized that the target population of SSEA-4-directed CAR T cells in the lung may also 
consist of MPPs – as in bone marrow. To address this, lungs of untreated NSG™ mice were 
processed into single cell suspensions and SSEA-4 expression was analyzed on the CD45-
positive and CD45-negative cell subset. Consistent with the findings for bone marrow, the 
overall frequency of cells expressing the glycolipid was very low, ranging typically between 
0.3-0.6%. However, contrary to the expectations, the major antigen signal was located within 
the CD45-negative compartment (Figure 30A) indicating that the main target population in the 
lung differed and was not made up of MPPs. To identify the SSEA-4-expressing subset, an 
antibody screening based on a library of 29 antibodies comprising phenotypic cell surface 
markers was performed. For this purpose, lung tissue derived from untreated NSG™ mice was 
dissociated into single-cell suspensions and the SSEA-4-positive cell population was 
characterized for the expression of the selected markers. According to the labeling pattern, 
each antigen was classified into either no staining (<10% of cells positive), partial staining with 
two discrete populations, partial staining with a smear of positive cells, and full staining (>90% 
of cells positive) (Figure 30B). Intriguingly, only 3 markers showed an expression in less than 
10% of cells (CD45, CD138, Gr-1) and a partial staining pattern was observed for 22 antigens 
indicating cellular heterogeneity within the SSEA-4-positive subset. Positivity for CD98 and 
CD81 in 75% and >90% of cells, respectively, was not indicative as these molecules show a 
broad cellular distribution and functional versatility (Cantor and Ginsberg, 2012; Levy, 2014; 
Vences-Catalán et al., 2017). However, co-expression of CD44 by >90% of SSEA-4-positive 
cells revealed an epithelial origin and co-staining for Prominin-1 (>90% of cells) suggested a 
low differentiation status. Thus, it was concluded that SSEA-4 expression in lung tissue is 
mainly restricted to epithelial progenitor cells.  
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Figure 30: Phenotypic characterization of SSEA-4-expressing cells in lung tissue. (A) Expression of SSEA-4 
on lung CD45+ and CD45- cells. Lugs of untreated NSG mice were dissociated and the thus obtained single cell 
suspensions were subjected to flow cytometric analysis for correlated CD45 and SSEA-4 expression. Isotype 
control was used to assess background staining for SSEA-4. Dead cells and cell aggregates were excluded for 
analysis. (B) Phenotyping of SSEA-4-expressing lung cells. A library of 29 antibodies was used to identify cell 
surface markers co-expressed by SSEA-4-positive cells. According to the frequency of antigen-positive cells within 
the SSEA-4-expressing compartment, markers were categorized into no staining, partial staining with discrete 
populations, partial staining with smeared population, and full staining. A total of 5 lungs of untreated NSG mice 
were analyzed. (C) Expression of CD44, CD81, CD98, and Prominin-1 on SSEA-4-positive lung cells as determined 
by flow cytometry. Gating was performed on viable SSEA-4-positive single cells. Histograms are representative for 
5 lungs analyzed. 
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4 Discussion 
Due to its poor prognosis and few available treatment options, TNBC represents a significant 
clinical challenge which is associated with higher mortality compared to other breast cancer 
subtypes. Several novel therapeutic approaches against TNBC have been explored, including 
small molecule inhibitors, vaccination, monoclonal antibodies, and adoptive TIL therapies, with 
only modest benefit thus far (Lee and Djamgoz, 2018). In light of the recent breakthrough in 
the treatment of hematological malignancies in terminally ill patients using CAR T cell therapy, 
this study attempted to transfer the CAR technology to the treatment of TNBC. In this context, 
SSEA-4 was selected as a candidate target antigen for several reasons. First, it is expressed 
by various TNBCs (Aloia et al., 2015) and other cancers (Saito et al., 1997; Gottschling et al., 
2013; Ye et al., 2010; Noto et al., 2013; Lou et al., 2014; Sivasubramaniyan et al., 2015) thus 
not only representing an attractive target for a breast cancer subtype that up to now lacks 
known targetable antigens, but also offering the possibility for a therapy that can be extended 
to other malignancies. Second, the glycolipid was reported to be expressed by chemoresistant 
TNBC subpopulations (Aloia et al., 2015) and targeting SSEA-4 offered a complementary 
treatment approach to chemotherapy, so that a combination of both therapeutic modalities was 
likely to increase the overall survival rate of cancer patients. Third, the antigen has been 
suggested to play a critical role in metastatic processes (Sivasubramaniyan et al., 2015) and 
elimination of SSEA-4-positive tumor cells held promise to diminish the metastatic potential of 
cancers. Fourth, although SSEA-4 is strongly expressed by embryonic and mesenchymal stem 
cells (Breimer et al., 2017; Gang et al., 2007; Pittenger, 1999; Riekstina et al., 2009; Shinohara 
et al., 2015), we have identified its expression in adult non-malignant tissue to be limited to cell 
subpopulations in placenta, testis, skin and small intestine (unpublished observation). As 
placenta and testis are immune privileged organs, potential on target/off tumor toxicities were 
expected to be restricted to skin and small intestine. In addition, one preclinical study had 
previously demonstrated that systemic SSEA-4-directed mAb treatment exhibited anti-tumor 
efficacy against glioblastoma without any reported in vivo toxicities (Lou et al., 2014). Against 
this background, the present study addressed the development and evaluation of several 
SSEA-4-directed CAR T cell therapies and investigated the CAR structure-to-function 
relationship with an emphasis on the spacer domain of the synthetic molecules. Besides, it 
evaluated the suitability and the pitfalls of commonly used flow cytometric methods for the 
detection of the artificial receptors. The following chapters discuss the findings of this research 
in the context of current scientific development in the CAR T cell field.  
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4.1 Comparison of different CAR T cell detection methods  
The modular design of CARs allows for their building blocks to be easily exchanges, thereby 
providing the possibility of unlimited receptor versatility. An accompanying challenge of such a 
receptor changeability is a universal and reliable detection method for the synthetic molecules. 
While the majority of clinical trials applies quantitative polymerase chain reaction (qPCR) 
methodology to detect the presence and frequency of gene-modifiedT cells (Kochenderfer et 
al., 2010; Morgan et al., 2006; Porter et al., 2011; Maude et al., 2014), in the developmental 
phase this technique is unwiedly as it provides no information about the expression of the 
transgene. Therefore, standard laboratory technique is to detect CAR expression by flow 
cytometry using recombinant antigen-Fc fusion proteins (De Oliveira et al., 2013) or antibodies 
directed against either an epitope tag (Liu et al., 2016) or the extracellular structure of the 
receptor such as the spacer region (using an anti-IgG Fc antibody) (Kowolik et al., 2006) or 
the receptor’s scFv domain (using anti-mouse or anti-human F(ab)-specific antibody) (Kunkele 
et al., 2015). More recently, also the use of Protein L (Zheng et al., 2012) and monoclonal anti-
idiotype antibodies (Jena et al., 2013) has been proposed for CAR expression detection. While 
all are valid methods, each of them has a disadvantage. The use of recombinant antigens or 
monoclonal anti-idiotype antibodies for instance requires the development of a new reagent 
for each CAR specificity. On the other hand, the introduction of a tag may have a strong impact 
on the receptors’ expression, functionality and potentially immunity, and necessitates an 
extensive testing beforehand. Consequently, for reasons of convenience, Protein L and anti-
mouse/human F(ab) specific antibodies are currently the most widely used reagents to analyze 
CAR expression. However, an extensive comparison of these agents has not yet been 
performed and every research center’s choice on which one to use is based on an idiosyncratic 
decision.  
Due to the unavailability of a synthetic fluorochrome-conjugated SSEA-4 molecule – which 
would have been unarguably the best detection agent – an alternative approach for the 
analysis of SSEA-4-directed CARs had to be applied. In initial expression analyses using 
HEK293T cells, a Protein L-conjugate was applied, however, the labelling reactions regularly 
suffered from significant background and limited discrimination of populations with low 
transfection efficiencies. Subsequent thorough analysis and staining protocol optimization 
revealed that published work on Protein L for CAR detection used T cell populations where the 
majority of cells (>70%) expressed the transgene and contained high transgene copy numbers, 
which in turn helped improving the specific staining index. To ensure appropriate determination 
of CAR expression on T cells, a comparative analysis of the Protein L- and anti-mouse F(ab)-
based staining methods was conducted and set in relation to the expression of the transduction 
marker ΔLNGFR. Strikingly, CAR stainings with Protein L exhibited a spacer-dependent effect: 
while a complete congruency of L spacer CAR and ΔLNGFR expression was detectable, the 
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frequency of CAR-positive cells within the transgenic population declined with decreasing 
spacer length – despite equivalent ΔLNGFR expression. It is not clear, whether the observed 
trend is due to a decreased expression of the synthetic receptors on the cell surface or due to 
an impaired accessibility of the labeling protein to its epitope. In fact, the more proximal the 
scFv is located to the cell membrane, the more the binding interactions can be affected by the 
dense glycocalyx. In support of this hypothesis, detection of XS spacer CAR-expressing 
populations with the polyclonal anti-mouse F(ab)-directed antibody exhibited a reduction in the 
median FI of the transgene-positive cells compared to ΔLNGFR expression. Nevertheless, the 
overall frequency of the positive population remained comparable to the marker protein, 
indicating that the glycocalyx may impair but not completely abrogate the binding interactions. 
In light of the staining data obtained with Protein L, it is debatable whether labeling with the 
polyclonal anti-mouse F(ab)-directed antibody recognized exclusively functional CARs or may 
have also resulted in the recognition of improperly folded receptors on the cell surface which 
escaped Protein L-based detection. To better understand the underlying mechanisms, an 
extended study analyzing the expression pattern of various CARs incorporating different scFvs 
is necessary. Although the restriction to SSEA-4-directed CARs is a limitation of the present 
study, the work clearly illustrates that the detection of functional CARs is not a trivial task and 
susceptible to artefacts. Thus, the different detection methods employed by different 
laboratories may lead to discrepant findings and lead to contradictory results in the literature.  
 
 
4.2 Impact of the spacer region on CAR function 
Traditionally, the spacer region between the targeting moiety and the transmembrane domain 
of a CAR molecule has been regarded as an inert structural element that facilitates the 
positioning of the antigen binding unit outside the T cell glycocalyx (Moritz & Groner, 1995). 
Accumulating evidence, however, suggests that it can have a significant effect on T cell effector 
function so that the design of receptors for novel targets needs to consider the localization of 
the target epitope and based on this customize the spacer length for optimal CAR signaling 
(Guest et al., 2005; Haso et al., 2013; Hudecek et al., 2016). To determine systematically the 
optimal spacer length for a SSEA-4-directed CAR, five receptor variants were generated with 
identical ligand binding and signaling domains, but with alternative spacer regions. Upon 
transient introduction into HEK293T cells and comparative expression analysis, the three best 
expressed candidates were selected to progress to the next series of experiments, in which 
they were investigated for their ability to induce T cell-mediated cytotoxicity and cytokine 
production. Although all CARs mediated detectable antigen-specific target cell lysis and 
cytokine release in vitro, a clear functional hierarchy was observed. The S spacer CAR was 
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functionally the most dominant of all SSEA-4-directed CARs examined, followed by the L 
spacer CAR and subsequently by the XS spacer CAR. In vivo, when low CAR T cell doses 
(2∙106) were administered, bioactivity was detected only within the S spacer CAR T cell injected 
cohort, while high CAR T cell dose infusions (10∙106) resulted in reactivity of all CAR variants 
– with the same hierarchical profile as seen in vitro. These data clearly demonstrate a dose-
dependent effect of CAR T cell functionality – a phenomenon that has already been described 
by various investigators (Stemberger et al., 2012; van der Waart et al., 2014; Kagoya et al., 
2016; Sabatino et al., 2016). Nevertheless, it cannot be excluded that toxic effects may have 
appeared at a later time point when low dose XS and L spacer CAR T cells were administered, 
although this could not be observed in the given experimental setting due to the later 
development of xenotoxicity.  
It is surprising that no obvious correlation between spacer length and CAR potency was 
observed within this study. As SSEA-4 is a relatively small antigen and the REA101-targeted 
epitope of the glycolipid is comprised of the three saccharide moieties distal to ceramide 
(NeuAcα2-3Galβ1-3GalNac; Figure 3B) – that is half of the extracellular hexasaccharide unit 
– it was anticipated that a long to intermediate spacer would be required to reach the epitope. 
Thus, the low reactivity of the XS spacer CAR (spacer 12 amino acids in length) was expected 
and attributed to an inefficient accessibility of the membrane-proximal scFv to its antigenic 
determinant. Additionally, as described in 4.1, the possibility of impaired surface expression of 
this receptor variant remains.  
The superior reactivity of the S spacer CAR (spacer 45 amino acids in length) rather than the 
L spacer CAR (spacer 228 amino acids in length) is less clear. One possible explanation is 
that the L spacer receptor is too long and therefore hampers efficient downstream signaling 
upon antigen engagement, while the S spacer CAR may have the optimal length. However, it 
is important to note that various internal work investigating additional CAR specificities report 
predominantly a better functional performance of S spacer-incorporating CARs compared to 
other spacer receptors. Moreover, although a direct comparison of results from CD19-directed 
CAR T cell clinical trials is difficult due to the various differences in protocols, co-stimulatory 
signaling, patient groups and disease state, the rough trend can be observed that CAR T cell 
therapies that demonstrated potent activity in the clinic contained the S spacer sequence 
(derived from CD8α) (Porter et al., 2011; Kalos et al., 2011). By contrast, a clinical trial that 
utilized the spacer region derived from IgG1 Fc domain demonstrated less impressive anti-
tumor efficacy (Savoldo et al., 2011). These observations indicate that not only the length but 
also the nature of the spacer region affects the receptor’s bioactivity. Although the causative 
reasons have not been entirely elucidated, preliminary work within the scope of this study 
indicates that the reduced efficacy of IgG Fc spacer-harboring CARs may be due to lower 
surface stability compared to CD8α-derived spacer CARs. This is significant as previous 
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studies analyzing the impact of the spacer region were performed within the framework of Ig-
derived sequences and have not been compared to CD8α-derived spacers (Guest et al., 2005; 
Hudecek et al., 2016; Künkele et al., 2015). Thus, this study provides evidence that not only 
structural and spatial elements in CAR T cell:target cell interaction seem to influence a chimeric 
receptor’s potency, but also additional factors which are not entirely understood yet. 
Presumably, receptor surface stability and spacer flexibility, which can impair ligand affinity, 
play a role as well. Thus, it is to be appreciated that in their basic form, CARs represent 
complex molecules and additional work is needed to understand and harness their full potential. 
 
 
4.3 Choice of animal model for testing in vivo toxicity of SSEA-4-
directed CAR T cells 
Mouse xenograft models are currently the standard testing approach to assess the efficacy of 
novel CAR T cell therapies. In the majority of studies, however, the human antigen-specific 
CAR T cells do not cross-react with the cognate murine antigen, in this way failing to provide 
significant information about potential CAR T cell-mediated autoimmune reactivity. 
Exceptionally, in the present study, the NSG™ mouse-based tumor xenograft model served 
as a suitable platform to study SSEA-4-directed CAR T cell therapies in the context of both 
therapeutic efficacy and on target/off tumor toxicity. The highly immunodeficient animal strain 
allowed a potent engraftment of the human therapeutic cells and the carbohydrate-reactive 
scFv of the CAR, which is able to cross-recognize its cognate epitope on both human and 
murine cells, enabled to address and investigate possible on target/off tumor reactivity towards 
healthy cells. As previous histochemical analysis by ourselves has shown a correlated 
expression of SSEA-4 between mice and humans, we thus had a clinically relevant xenograft 
model with predictive value for potential on target/off tumor reactivity in human patients. It was 
found that adoptive transfer of SSEA-4-directed T cells in mice resulted in only a modest anti-
tumor efficacy, but severe on target/off tumor toxicities – a scenario that has often observed 
with other CAR T cell therapies in the clinical setting (Morgan et al., 2010; Lamers et al., 2006, 
2007, 2013). Thus, this study once more emphasizes the need for elaborated toxicity 
evaluation models in the preclinical setting. Due to the inadequacy of current preclinical models, 
the majority of clinical trials testing CAR T cell therapies are being initiated “blindly” without 
knowledgeable preparation for potential adverse events. However, blind translation of a  
SSEA-4-directed CAR T cell therapy to the clinical setting could have led to catastrophic 
consequences in patients. Care has to be taken that no further life-threatening therapies enter 
the clinic. Therefore, it is encouraging that the scientific community has started to appreciate 
the insufficiency of current animal models and more sophisticated toxicity testing approaches 
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are now being developed (Berger et al., 2015; Siegler and Wang, 2018). Although this is one 
step in the right direction, one major missing parameter is the analysis of these toxicities in an 
immunocompetent host, which would allow the interplay of other components of the immune 
system in these complex interactions to be studied. To assess e.g. the extent of CRS a 
humanized NSG™ mouse model with an engrafted human immune system would have been 
necessary. Nonetheless, such a model would have likely provided only limited information 
about cytokine-driven adverse events as several human cytokines secreted by activated 
immune cells mostly do not cross-react with the respective murine receptors. A fully murine 
model may have equally restricted predictive power due to mouse-human divergence and – in 
worst case – may underestimate the toxicity associated with CAR T cells. Indeed, a previous 
study analyzing NKG2DL-directed CARs in various mouse models has demonstrated that 
while marked adverse events can be observed in BALB/c mice upon treatment, these CAR T 
cells manifest little toxicity in C57BL/6 mice (VanSeggelen et al., 2015) suggesting that the 
functionality of CARs may be strain-dependent in murine T cells.  
In an attempt to better understand the mechanisms and full spectrum of CRS-based adverse 
events, Taraseviciute et al. have recently developed a non-human primate model which 
recapitulates the most significant toxicities of CAR T cell therapy, including CRS and 
neurotoxicity (Taraseviciute et al., 2018). It is to be expected that this model will soon provide 
novel insights that may help overcoming the most serious side effects associated with CAR T 
cell therapy, although, it is likely that the model will find only limited use in the future due to 
economic and ethical reasons.  
 
 
4.4 Characterization of SSEA-4-expressing subpopulations 
targeted by CAR T cells 
Ever since its original description as an embryonic antigen in 1983 (Kannagi et al., 1983), 
SSEA-4 has been widely used as a marker for stemness and pluripotency. Beyond 
regenerative medicine research, however, the glycolipid has remained largely unexplored in 
the last 35 years and knowledge about its function as well as its distribution in normal adult 
tissue is still limited. Prior to the inception of this project, internal histochemical and flow 
cytometric screening approaches identified SSEA-4 to be expressed by cell subpopulations in 
the placenta, testis, skin, and small intestine, indicating a restricted distribution in post-natal 
tissue. Thus, in the present study, which aimed to evaluate the in vivo targeting of SSEA-4 by 
CAR T cells, potential injury of healthy tissue was expected to be limited to skin and small 
intestine. Contrary to this supposition, adoptive transfer of SSEA-4-directed CAR T cells into 
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NSG™ mice resulted in severe toxicities dominated by on target/off tumor recognition in lung 
and bone marrow with the latter demonstrating hypocellularity and a strong decrease of the  
CD45+Sca-1bright population. Subsequent analysis in non-treated mice identified hematopoietic 
MPPs in the bone marrow and epithelial progenitor cells in the lung to be expressing SSEA-4, 
providing evidence that the glycolipid is not a restricted embryonic marker, but is also 
expressed by adult progenitor cells.  
Taking into consideration that in oncology, SSEA-4 expression has been described to occur in 
a variety of tumors, e.g. breast cancer (Aloia et al., 2015; Huang et al., 2013), basaloid lung 
cancer (Gottschling et al., 2013), ovarian carcinoma (Ye et al., 2010), gliobastoma (Lou et al., 
2014) and oral cancer (Noto et al., 2013), our findings described here further support the 
cancer stem cell theory, which proposes that cancer originates from normal stem or progenitor 
cells. Indeed, in the lung, SSEA-4 expression highly correlates with Prominin-1 (CD133), a 
marker for hematopoietic, neuronal and endothelial progenitor cells in both humans and mice 
(Fargeas et al., 2006). In a colon carcinoma study conducted by Zhu et al. in 2008, Prominin-
1-positive cells were shown to expand disproportionately during malignant transformation and 
that cells within the neoplastic lesions were progeny of Prominin-1 cells. Upon tumor 
progression, only a fraction of cells retained the Prominin-1-positive phenotype and only a 
fraction of these cells were proliferating (Zhu et al., 2009). Based on the co-expression of 
SSEA-4 and Prominin-1 in lung-resident progenitor cells observed in this study, it is tempting 
to speculate that similar findings may be observed for SSEA-4-expressing cells. 
As the approach for the identification of SSEA-4-positive cells conducted within the scope of 
this study was restrictive, it cannot be certain that all SSEA-4 expressing cells were identified. 
It is likely that – similar to Prominin-1 – progenitor cells in other tissues express the glycolipid 
and any potential anti-tumor benefit gained by therapeutic targeting of SSEA-4 would have to 
be carefully weighed against the ensuing destruction of various progenitor cells. In this context, 
it is intriguing that a previous study on mAb-based targeting of SSEA-4 demonstrated 
therapeutic efficacy against glioblastoma without reported in vivo toxicities (Lou et al., 2014). 
Taking into consideration that Lou et al. targeted the same epitope on SSEA-4 as the present 
work (unpublished data) it is surprising that severe on target/off tumor adverse events were 
observed only in this study. A possible explanation for this discrepant observation may be the 
different nature of the therapeutics used. The immune response triggered by T cells is more 
pronounced than that of antibodies and it is possible that potential adverse events were 
delayed and may have appeared at a later timepoint in the mAb therapy setting (Lou et al. 
analyzed the therapeutic efficacy only for 31 days). Furthermore, CAR T cells exhibit a several 
magnitude higher overall avidity to their antigen than the cognate antibody (Morgan et al., 2010; 
Watanabe et al., 2015; Turatti et al., 2007; Stone et al., 2012) which in turn decreases the 
sensitivity threshold. Consequently, mAb may preferentially recognize SSEA-4high cells while 
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CAR T cells may also recognize cells that express the antigen at levels that are hard-to-detect 
for antibodies. In the present study, it cannot be excluded that SSEA-4-directed CAR T cells 
might have engaged with antigen-positive cells that were not detected by antibody screening. 
One observation favoring this hypothesis is the finding that SSEA-4 stainings always gave a 
slight shift (~1-2%) of the “negative” population towards the positive axis while isotype controls 
did not (examples in Figure 27D, E). As this shift was observed ubiquitously, it was initially 
considered unspecific. Alternatively, it is possible that the introduction of the (G4S) linker 
between the VL and VH regions of the cognate antibody to generate the scFv may have 
modified the epitope specificity, permitting structurally similar epitopes present on non-target 
antigens to be cross-recognized by the CAR T cells. Additional work is needed to understand 
whether these potential mechanisms indeed occurred. 
Another aspect to consider between both studies is the administration route of the therapeutics. 
Lou et al. applied the mAb intraperitoneally which leads to a rapid and convective distribution 
in the body, while the present study used the intravenous application option. In the latter case, 
the cells first travel to the lung where they reside for several hours. As this is also the first site 
of antigen exposure, toxicity appears inevitably before or in parallel to tumor control. In the 
case of mAb application, the fast distribution kinetics may have enabled that a high amount of 
the injected dose reaches the tumor site prior to binding to on target/off tumor tissues. 
Nevertheless, these variables could have only lead to a delay in the toxic effects, but not 
completely abolished them. It is, therefore, realistic to presume that a combination of the 
factors discussed above led to the conflicting findings.  
 
 
4.5 Conclusions 
The extreme potency of CAR T cells and the severe side effects observed within the scope of 
this study highlight the essentiality of judicious target antigen selection. Rather than focusing 
on potential clinical benefit and oncogenic function of a candidate antigen, tumor selectivity 
needs to be prioritized to ensure an acceptable safety profile for this novel treatment modality. 
In fact, already in the past, a widespread application of CAR T cell therapy in the solid tumor 
setting has been impeded by the lack of truly tumor-specific antigens. In an endeavor to 
circumvent this obstacle, standard practice has become to target antigens that are 
overexpressed in solid cancers but show minimal expression on normal tissue. However, 
several clinical trials using this approach have described abundant on target/off tumor toxicities 
and at the same time only a limited anti-tumor activity – even in settings in which the target 
antigen is expressed at close to undetectable levels on healthy tissue (Morgan et al., 2010; 
Lamers et al., 2006, 2007, 2013). With this in mind, investigators need to verify in future 
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endeavours that sufficient information is known about the expression pattern of a potential 
target antigen on healthy tissue including the clinical relevance of antigen-expressing 
subpopulations. Expression by vital cell types – no matter how infrequent their presence in the 
human body is – has to weigh heavily against a candidate antigen. In this context, it is also 
imperative to reconsider the restrictedness of embryonic antigens. As exemplified in present 
work, antigens that are currently described to be specific to embryonic development may 
indeed be additionally expressed by certain adult tissues. If this tissue is vital to maintain life, 
therapeutic targeting may have a detrimental outcome. In a similar example, carcinoembryonic 
antigen (CEA), the expression of which is postulated to decrease after birth is – strictly taken 
– not a fetal antigen as it is also expressed by cell populations throughout the digestive tract 
in adults (Hammarström, 1999; Uhlen et al., 2010).  
Given that it is difficult to exclude the possibility that a tumor target may be co-expressed on 
essential healthy tissue, the use of safety mechanisms in CAR therapy can offer an alternative 
approach to maximize tumor specificity. Indeed, diverse strategies are currently being 
developed to help overcome the detrimental autoreactivity of CAR T cells, including dual CAR 
approaches that require the recognition of two different antigens on the tumor cells to 
effectively activate the engineered T cells or various suicide mechanisms for the ablation of 
the therapeutic cells upon manifestation of severe on target/off tumor toxicity (Fesnak et al., 
2016). However, an accurate evaluation of these different approaches in a clinically relevant 
model is missing. In this context, SSEA-4 may serve as a model antigen that can not only 
provide a better understanding of the strengths and shortcomings of the different safety 
strategies, but also supply a platform for comparative efficacy analyses of these mechanisms. 
The essentiality of SSEA-4-expressing cells in a mouse model will easily identify “leaky” 
technologies and eliminate them before they can enter the clinical trial setting, in this way 
accelerating the translation of the most promising technologies into clinical benefit.  
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